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ABSTRACT
The unintentional presence of peanut in food products through allergen crosscontact is a considerable safety concern for peanut-allergic individuals. The food industry
monitors for this contamination using immunoassays; however, these detection methods
demonstrate issues with recovery and accurate quantification of allergenic protein when
analyzing processed, complex food matrices. Of particular concern is the deficit in
immunoassay-based detection and quantification of peanut in cookie and dark chocolate
matrices, as the unintentional presence of peanut has been observed in these food
products. A liquid chromatography with tandem mass spectrometry (LC-MS/MS) method
for the detection and quantification of peanut protein in cookie and dark chocolate was
developed to overcome the issues plaguing immunoassays in analysis of peanut in these
matrices.
Peanut-incurred cookie and dark chocolate matrices were generated at various
concentrations of peanut. Untargeted MS analysis of incurred matrices identified and
quantified peanut peptides. Peptides were subjected to selection criteria, based on
abundance and robustness in matrix, to determine 32 (cookie) and 67 (dark chocolate)
candidate target peptides for the method. Candidate peptides were filtered to determine

robust and sensitive target peptides in each matrix using iterative rounds of targeted MS.
Six (cookie) and seven (dark chocolate) final peptides were determined. This resulted in
nine unique peanut peptides for the method.
A quantitative strategy was developed based on stable isotope labeled (SIL)
peptides and an external calibration to peanut flour (PF). Quantification was reported in
parts per million (ppm) peanut protein. Optimization of various aspects of the method,
including instrument parameters, LC, and sample preparation, improved the method’s
sensitivity and variability. The LC-MS/MS method was evaluated with incurred matrices
and demonstrated highly sensitive and reliable detection, even at low concentrations of
peanut protein (1.24 ppm peanut protein in cookie and 2 ppm peanut protein in dark
chocolate). This sensitivity is sufficient to detect peanut concentrations relevant for the
most sensitive peanut-allergic individuals.
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CHAPTER I: A REVIEW OF THE LITERATURE
I. INTRODUCTION
Food, though essential to human life, can elicit a number of adverse reactions
following its consumption. There are a wide variety of such negative reactions, however
one of the most prominent examples is food allergy. A food allergy is an individualistic
hypersensitivity reaction to food proteins, which can result in a range of symptoms, from
mild to life threatening1, 2. One important allergenic food source is peanut, which effects
approximately 2% of US individuals and elicits particularly severe reactions3-5. In order
to protect allergic consumers in the United States (US), there are regulatory requirements
for the food industry in their labeling of allergens on food products and in their
management of food allergens throughout food processing6, 7. To comply with the US
governance of allergens, the food industry has adopted several detection methods for the
purposes of identifying and quantifying the presence of food allergens in products.
Detection methods face a wide variety of issues in detecting and accurately quantifying
peanut protein in certain food matrices. One approach to the detection and quantification
of food allergens that shows promise for overcoming some of the issues plaguing current
detection methods is mass spectrometry (MS).
II. FOOD ALLERGY
Adverse reactions to food can be mediated by an individual’s immune system or
non-immune mediated. Reactions which are not facilitated by the immune system can
have a metabolic, pharmacologic, toxic, or undefined mechanism8. Metabolic reactions
include intolerances, such as the malabsorption of lactose due to the enzymatic deficiency
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implicated in lactose intolerance9. Pharmacologic reactions result from a biochemical or
physiological effect of food ingredients, for example the effect of caffeine10. When food
is contaminated with a particular dose of chemical compounds, like fertilizers, or natural
compounds, like mycotoxins, toxic reactions to food can occur11. There are also reactions
to food additives, like sulfites, which have an undefined or poorly understood
mechanism8. These adverse reactions to food are not considered food allergies.
Immune-mediated mechanisms include a wide variety of reactions which can be
further classified as immunoglobulin E (IgE)-mediated, non-IgE-mediated, cell-mediated,
or mixed and non-IgE mediated reactions10. Food allergy is an immune-mediated reaction
of particular importance and is considered a global health concern due to its prevalence
and implications for individuals affected12.
Food allergy is defined as an individualistic hypersensitivity reaction to a food
protein facilitated by the immune system1. A hallmark characteristic of food allergy is the
reproducibility of the reaction in allergic individuals each time the implicated food is
consumed13. Food allergy can elicit an extensive array of symptoms and can be caused
by, in theory, any protein found in food. There are two important types of allergic
reactions to food proteins including non-IgE-mediated food allergy and IgE-mediated
food allergy.
i.

Non-IgE-Mediated Food Allergy
Non-IgE-mediated food allergies are adverse reactions to a food protein which are

characterized by the absence of IgE antibodies in the induction of this allergic reaction,
rather cell components cause the clinical allergenic response14. Though mechanisms of
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non-IgE-mediated food allergy are variable by disorder and not fully understood, there is
evidence that immune cells, like T cells, B cells, macrophages, and eosinophils, plus their
resulting cytokines are involved in the inflammatory response to the food protein15, 16. T
cells may play a particularly important role in these reactions as food-specific T cells
have been isolated and identified in individuals with non-IgE-mediated food allergies17.
Non-IgE-mediated food allergies are known as delayed hypersensitivity reactions,
meaning symptoms present a number of hours after the food has been ingested18. This
onset time of symptoms can vary from six hours to over 48 hours following the
consumption of the implicated food1. The most prominent disorders which are classified
as non-IgE-mediated food allergies are food protein-induced enterocolitis, food proteininduced proctitis, food-protein induced enteropathy, and celiac disease19. The
gastrointestinal tract or the skin is the primary location of symptoms resulting from these
reactions. In fact, the type of T cell implicated in the reaction varies based on this
location, T helper 1 (Th 1) cells are involved in gastrointestinal reactions and cutaneous
lymphocyte antigen (CTA+) cells in skin-based reactions17. As a result, some of the most
common symptoms associated with non-IgE-mediated food allergy are vomiting, atopic
eczema, nausea, and diarrhea13, 15. Individuals diagnosed with a non-IgE-mediated allergy
typically adopt a diet which avoids any consumption of the allergenic food20. Though
non-IgE-mediated food allergies are important, much of the focus for the food industry,
in the literature, and for research is on IgE-mediated food allergies, as these are the more
common cause of food allergy15.
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ii.

IgE-Mediated Food Allergy

IgE-mediated food allergies are designated as such based on the involvement of
food-specific IgE antibodies in the allergic reaction14. These hypersensitivity reactions
are the food allergy reactions which are most common, best characterized, and most wellknown15, 21. Though IgE plays a beneficial role in host defense against parasites and
venoms, it is an antibody type that is deleterious to humans in the case of food allergy22.
IgE antibodies play a crucial role in both steps of a food allergy – sensitization and
elicitation.
The development of an IgE-mediated food allergy begins with sensitization, a
mechanism in which the exposure to allergenic food proteins initiates the production of
allergen-specific IgE antibodies which bind to mast cells or basophils23. B cells are
responsible for the production of these specific IgE antibodies24. The binding of an IgE
antibody to these effector cells is facilitated by the high-affinity IgE receptor (FcεRI) or
the low-affinity IgE receptor (FcεRII)25. After specific IgE antibodies are bound to mast
cells or basophils, the individual is considered primed for an allergic reaction and
sensitized to the allergenic protein. It is important to clarify that sensitization alone does
not equate to allergy as the presence of specific IgE in a patient’s serum does not confirm
the individual will react to the implicated food13.
Upon subsequent exposure to an allergenic protein in a sensitized individual,
elicitation of an allergic reaction occurs. The allergenic protein crosslinks the IgE
antibodies bound to sensitized cells, which triggers the release of mediators, like
histamine, from the cells into the bloodstream to initiate a wide variety of physiological
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responses1. The release of mediators from mast cells or basophils is known as
degranulation. In addition to histamine, other mediating molecules can be released,
including heparin, tryptase, chymase, prostaglandins, leukotrienes, and other cytokines25.
These released molecules then mediate the hypersensitivity reaction by inducing
vasodilation, increasing vascular permeability, stimulating nerves and muscles, and
activating the complement system23. This results in the immediate onset of the symptoms
typically manifested in an IgE- mediated allergic reaction.
Food allergy is thought to be caused by a variety of factors, including genetic
influences such as loss of function mutations or polymorphisms in tolerance-associated
genes, and environmental factors like reduced microbial exposure or vitamin D
deficiency26. Additionally, the dual allergen hypothesis suggests that early oral exposure
to food allergens is more likely to induce tolerance, whereas epicutaneous exposure from
the environment is more likely to result in sensitization to the allergen27.
a. Prevalence of Food Allergy
The prevalence of IgE-mediated food allergy in children and adults has been
continually increasing in recent decades and is now deemed a major health concern for
many westernized nations2, 28. In the US, it is estimated that around 32 million individuals
have food allergies, including 5% of children and 3-4% of the adult population26, 28, 29.
Over 90% of all food allergic reactions in the US are due to the presence of eight
allergenic foods which are known as the “Big Eight”30. These eight allergenic foods are
wheat, peanuts, tree nuts, eggs, soy, crustacean shellfish, fish, and milk. In children, the
most common food allergy is peanut (2.2%), followed by milk (1.9%), shellfish (1.3%),

6
and tree nut (1.2%)3. Among adults, shellfish (2.9%), milk (1.9%), peanut (1.8%), and
tree nut (1.2%) are the most common allergenic foods31. Of individuals with food allergy,
including children and adults, approximately 40-45% report having multiple food
allergies3, 31. Of the US population, 1.3% of individuals are allergic to more than one
food32. In children, 2.4-3.4% have multiple food allergies32, 33. The prevalence of
individuals who are allergic to more than one food follows a clear trend of decreasing as
the individual ages32. For children 1-5 years old, 3.4% have multiple food allergies, for
individuals over 60 years old the prevalence decreases to 0.6%32. Individuals with
multiple food allergies are required to avoid multiple foods in an elimination diet and this
may affect growth in children and nutrition in adults34. One phenomenon associated with
food allergy prevalence data is that in studies which require individuals to self-report
their food allergy, the prevalence is commonly over-estimated compared to the true
prevalence of food allergy which emphasizes the importance of objective diagnostic
methods and criteria8. Additionally, the prevalence of food allergy has been correlated
with certain factors of individuals including age, race, income, and geographic region33.
b. General Food Allergy Symptoms
As these reactions are IgE-mediated, symptoms are immediate and typically
present within minutes to one or two hours after ingestion13. Symptoms of allergic
reactions can present in multiple different organ systems and can range in severity from
mild to life-threatening2. The cutaneous, gastrointestinal, respiratory, cardiovascular, and
neurological system can all exhibit symptoms following elicitation13. Some of the most
common symptoms include nausea, urticaria, pruritis, abdominal cramping, rhinitis, and
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swelling35. The most severe symptom is anaphylaxis, a potentially fatal reaction which
can include a drop in blood pressure, difficulty breathing, or shock36. Symptoms of food
allergy and their severity may vary based on the allergen, form of the allergen, amount of
allergen ingested, and sensitivity of the individual1.
c. Diagnosis of Food Allergy
An accurate diagnosis of food allergy is critical, not only for the safety of the
individual, but also because a diagnosis comes with economic, social, and emotional
costs to the diagnosed. The first step in diagnosis of a food allergy is evaluation of the
medical history of the patient37. After food allergy is suspected as the condition affecting
the patient, the next step is typically a skin prick test (SPT). In an SPT, extracts from
allergenic foods are injected into the epidermis to bind and detect IgE to the allergenic
proteins38. Wheal size resulting from SPT is used to confirm sensitization but does not
confirm allergy5. Food-specific serum IgE (sIgE) testing is also used to diagnosis food
allergy, as an increase in sIgE is associated with increased probability of allergic
reaction5. The most preferred method for diagnosis of food allergy is the oral food
challenge (OFC). OFCs require the patient to consume incremental amounts of the
suspected allergenic food and any symptoms are recorded and used for diagnosis37. A
double-blind, placebo-controlled, food challenge (DBPCFC) is the gold standard for the
diagnosis of allergy, but due to the cost, time required, and potential for severe reactions,
many clinicians rely on skin SPT, sIgE testing, and convincing patient reaction history39.
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d. Food Allergy Treatment
Currently there is no cure for food allergy, instead individuals must simply
manage their hypersensitivity. To manage a food allergy, individuals adopt an avoidance
diet in which they eliminate any consumption of the implicated allergenic food from their
dietary intake. However, an avoidance diet is not entirely effective as approximately 10%
of allergic individuals experience an allergic reaction each year though attempting to
avoid their allergen40. In the case that a severe allergic reaction does occur, the
recommended treatment is administration of epinephrine injected intramuscularly to
reduce and reverse the symptoms of allergy41. One treatment option, growing in
popularity over recent years, is immunotherapy. Immunotherapy attempts to induce
desensitization in an allergic individual by repeatedly and incrementally exposing the
individual to a dose of their allergen. This is thought to cause the individual to be less
reactive to the allergen and increase their tolerance through elevated interleukin-10 and
IgG4 production, which suppress the allergic response42. While currently viewed as a
valid treatment option for some allergic individuals, the long-term efficacy of
immunotherapy is uncertain43.
e. Resolution of Food Allergy
As opposed to the desensitization induced by immunotherapy, some individuals
will spontaneously outgrow their food allergy through what is termed as resolution42.
Though the exact mechanism is unknown, those with resolved food allergy have shown
increased populations of T regulatory cells in individuals and an increase in secretion of
interleukin-1044. Rates of food allergy are typically consistent throughout early
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childhood, but the prevalence decreases by approximately 2.3% by age 10 due to the
resolution of allergies in this time frame45. There are certain food allergies which are
more likely to resolve compared to other food allergies. For example, allergies to milk or
egg are more likely to resolve, while peanut or tree nut allergies are more likely to
persist46. Persistence of a food allergy has been associated with a number of factors,
including more severe symptomology, low threshold dose, and the presence of other
atopic diseases46.
f. Cost of Food Allergy to Stakeholders
Food allergy comes at a significant cost to many stakeholders, including the
individual diagnosed, family members, food manufacturers, and other members of the
food industry. In fact, the overall economic cost of food allergy in children alone is
estimated to be over $24 billion annually47. The cost of food allergy is not only
economic, but also has social and emotional effects on allergic individuals and their
families. Food allergy can cause anxiety for a number of reasons, including uncertainty
surrounding diagnosis and fear of reaction48. Parents of children with food allergy report
an emotional impact of having a child with food allergy, as well as a restriction in
activities the family or individual participates in49. Food allergy has also been linked to
growth impairment in children with food allergy and nutritional deficits in allergic
individuals50.
III. PEANUT AND PEANUT PROTEINS
Peanut, Arachis hypogaea, is a tetraploid organism belonging to the Fabaceae
family, which is commonly referred to as the legume family51. Peanut or “groundnut” is a
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legume and oilseed by classification, not a nut, and produces its seeds underground, yet
flowers above the soil52. Peanut seeds, which are round or oblong, develop within the
plant’s underground pods in two-seeded or three-seeded varieties53. A. hypogea is divided
into two subspecies hypogea and fastigiata, each having several varieties52. Peanuts have
a long history of evolution, cultivation, and use as a food product. Due to their
macromolecular composition, peanuts are considered a valuable crop, ingredient, and
food product.
i.

Origin of Peanut
Domesticated peanut, which is widely cultivated and used today, is the result of

an ancient evolutionary hybridization event followed by selection and cultivation of the
species by man54. The exact date of hybridization is not known, but this cross is estimated
to have occurred over 4,500 years ago55. The origin of A. hypogea occurred in South
America, specifically in the regions of southern Bolivia and northern Argentina56. In the
hybridization event, two diploid progenitors crossed and formed the tetraploid organism,
an organism containing four copies of each chromosome. The crossing organisms have
been determined by cytogenetic analysis to be A. duranensis and A. ipaensis56. Because
this hybridization and ensuing polyploidy occurred between two different species within
the Arachis genus, A. hypogea is an allotetraploid52. Following hybridization, ancient
peoples began cultivation and the early stages of domestication.
ii.

Peanut Cultivation

Human cultivation of tetraploid peanut is suggested to have occurred as early as
1200-1500 B.C. in Peru, according to palaeobotanical artifacts56. Over time, the
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cultivation of peanuts expanded across Central and South America57. By the time of
Spanish exploration of the region, peanut agricultural activity had spread to many areas,
including Mexico, Brazil, Argentina, Paraguay, and Bolivia, as documented by early
explorers58. After European discovery of peanut, the plant was spread across the globe
and was grown in Europe, Africa, Asia, and the US58.
A. hypogea is now widely cultivated in the modern world. The US produces over
3.1 million tons of peanuts each year59. Peanuts are typically grown in tropical, subtropical, or temperate climates52. Peanuts are harvested around 120-140 days after
planting, and the seeds are allowed to dry before storage or further processing53. In the
US there are three primary growing regions for peanut; Southeast (Alabama, Florida,
Georgia), Southwest (New Mexico, Oklahoma, Texas), and Virginia-Carolina (North
Carolina, South Carolina, and Virginia60. There are four market types of peanuts which
are produced in the US, including Runner, Virginia, Spanish, and Valencia. The
predominant market types grown in the country are Runner and Virginia, and Runner
types account for approximately 80% of all peanuts in US60, 61. These market types are
characterized by different physical features, including kernel size and skin color.
iii.

Peanut Consumption

Peanut seeds are widely consumed in the US. Per capita consumption for the US
is estimated at approximately 7.1 pounds of shelled peanut annually62. Peanut products
can take a variety of forms, some of the most common include peanut oil, peanut butter,
roasted snack nuts and mixes, and peanut flour63. In the US, the most popular
consumption of peanuts is through peanut butter products, which account for 50% of the
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peanuts consumed in the country53, 64. Peanut oil is produced by extracting oil from
shelled and crushed peanuts and is often used for cooking or frying65. Peanut butter
production begins with roasting and grinding the peanut seeds, followed by the addition
of additives such as sugar and salt66. Roasted peanut snacks are typically produced by
frying the nut and coating the outside with sweet or salty flavor components63. Peanut
flour is obtained by processing raw or roasted peanuts with a heat treatment, removal of
oil, and drying65. Peanut flour is commonly used in confections, nutritional bars, and
baked goods and is often added for its protein content as it is approximately 50%
protein65.
iv.

Composition of Peanut
Peanuts are recognized as a nutritionally dense food due to their macromolecular

composition. Raw peanuts are comprised of 49.2% lipids, 25.8% protein, and 16.1%
carbohydrates, as well as low amounts of water and ash67. The lipid fraction of peanuts,
predominantly triacylglycerols, is high in unsaturated fatty acids and is often extracted
for peanut oil products53, 67. The lipid content of a peanut seed can vary from 36-54%
depending on peanut type and cultivar68. Peanuts have comparable protein contents to
other legumes, including chickpea, cowpea, lentil, and green pea which are
approximately 24-26% protein69. When compared to nuts, including almond, cashew nut,
hazelnut, walnut and others, peanut has a greater protein content than all the edible nut
seeds70. Peanut protein content is known to vary by market type and cultivar67. The major
carbohydrates in peanut seed are oligosaccharides, including sucrose and stachyose, and
starch71. Peanuts also include micronutrients such as vitamins and minerals71.
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v.

Peanut Protein
As plant seeds, peanuts contain numerous types of proteins that have varying

biological functions for the organism. Proteins in plant seeds serve different roles
including metabolic, structural, nutrient storage, or defense roles51, 72. The primary
protein types in peanuts are cupins, prolamins, oleosins, defensins, profilins, and
pathogenesis-related proteins51. Cupins function as seed storage proteins and the main
two types of cupins in peanuts include vicilins and legumins73. A seed storage protein is a
protein which serves as a deposit of amino acids for later use by the plant during
germination and growth72. Prolamins can also be divided into two types, 2S albumins and
nonspecific lipid transfer proteins (nsLTP)51. 2S albumins are seed storage proteins and
also act as trypsin inhibitors51, 74. Cell wall organization, membrane stability, and signal
transduction are roles of nsLTPs75. Oleosins function to bind to and cover oil bodies
within peanuts for the purpose of stabilization and integrity during seed rehydration73.
Defensin proteins’ primary function is to protect the plant through an innate immune
response, mainly against plant pathogens and fungi76. Profilins are responsible for
binding actin and regulating polymerization77. Plant pathogenesis-related proteins have
varying enzymatic activities, depending on the protein, that are induced under stress or
infection73.
Peanuts contain all nine essential amino acids, though at low levels compared to
the recommendations for intake78. The major amino acids in peanuts, based on
abundance, are aspartic acid, glutamic acid, and arginine, while the limiting amino acid is
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methionine79. The amino acids found in peanut protein have been determined to be
approximately 39% hydrophobic, 10.5% hydrophilic, 33% acidic, and 17.5% basic70.
vi.

Peanut Allergens
Due to the proteinaceous nature of peanuts and their high consumption, the

potential for allergenic proteins is evident. The World Health Organization and
International Union of Immunological Studies (WHO/IUIS) has classified 17 peanut
proteins as allergenic proteins80. Of the 17 peanut allergens, nine show more prominent
clinical relevance in the allergic population81. Nomenclature for these allergens follows
the typical allergen naming in which the first three letters from the genus (Ara), the first
letter from the species (h), and a number is used to designate allergens80. For example,
one allergenic protein from peanut is designated as Ara h 1. Of the 17 identified peanut
allergens, four are considered major allergens. These four allergens include two cupins,
Ara h 1 and Ara h 3, as well as two prolamins, Ara h 2 and Ara h 651, 82. Ara h 2 and Ara
h 6 are specifically 2S albumins, which have been demonstrated as allergenic proteins
with high risk for severe reactions83. Depending on market type, Ara h 1, 2, 3, and 6
comprise approximately 17.1%, 6.2%, 70.6%, and 5.8% of the total protein in peanut,
respectively84. Minor allergens include Ara h 7 (2S albumin), Ara h 9, Ara h 16, and Ara
h 17 (nsLTPs), Ara h 10, Ara h 11, Ara h 14, and Ara h 15 (oleosins), Ara h 12 and Ara h
13 (defensins), Ara h 5 (profilin), and Ara h 8 (pathogenesis-related protein)51. Ara h 4
was once considered to be a separate allergen but is now deemed an isoform of Ara h 3
due to its sequence and amino acid homologies85. A protein isoform is a different form of
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a protein which can originate from multiple genes or a singular gene which has been
alternatively spliced86.
Several factors are thought to contribute to the allergenicity of these peanut
proteins, namely abundance, multiple IgE-binding epitopes, resistance to digestion and
processing, and the structure of the allergen87. The four major peanut allergens are known
to be the most abundant proteins in peanuts84. Additionally, Ara h 2 and Ara h 6 have
been found to be considerably resistant to digestion by pepsin, a major stomach
enzyme88. Furthermore, linear epitopes have been well mapped for the major peanut
allergens; 21 epitopes have been identified for Ara h 1, 8-10 for Ara h 2, 4 per Ara h 3
monomer, and 7 for Ara h 674, 89.
IV. PEANUT ALLERGY
Due to the proteinaceous nature of peanut and its widespread consumption, the
potential for allergy to peanut is evident. In the US, peanut allergies are one of the most
common food allergies and have been increasing in prevalence over recent decades31, 90.
Allergy to peanut is characterized by its reaction severity, low threshold doses, and low
resolution rates28, 91, 92.
i.

Prevalence of Peanut Allergy
Current estimates of peanut allergy prevalence for individuals in the US are

approximately 2.2% for children and 1.8-2.0% in adults3, 4. The type of prevalence study
and requirements for diagnosis impacts the estimated prevalence of peanut allergy. In a
study that used peanut-specific IgE testing and corresponding clinical criteria, peanut
allergy prevalence was determined to be 1.3% overall, with age group determinations of
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1.8% for ages 1-5, 2.7% for ages 6-19, 0.9% for ages 20-59, and 0.3% ages 60 and
above32. Using self-reported symptoms and surveyor determinations of probable allergy,
another study found peanut allergy prevalence to be 1.4% in children and 0.8% overall93.
Prevalence enumeration based on peanut allergy diagnosis codes and healthcare
databases was used in one study which found prevalence to be 2.2% for children94.
Among children with food allergy, peanut allergy is the most common as 25.2% of
children with food allergy are allergic to peanut33. For adults, peanut allergy is the third
most common allergenic food, only shellfish and milk allergies have higher prevalence31.
With respect to multiple food allergies, 25-50% of peanut allergic individuals are also
allergic to tree nuts9. Both peanut allergy prevalence and incidence is known to be
increasing in recent decades94. For children, the self-reported prevalence of peanut
allergy increased from 0.4% in 1997 to 0.8% in 200293. With current estimates of peanut
allergy near 2% for children, there is sufficient evidence that peanut allergy is increasing
in prevalence.
ii.

Peanut Allergy Symptoms

Peanuts are one of the allergenic foods that are known for severe
symptomology91. Because a peanut allergy is an IgE-mediated reaction, its symptoms are
characterized by acute onset after consumption of peanut protein, typically within
seconds or minutes15, 95. In fact, the median time elapsed between exposure to peanut and
elicitation of symptoms in peanut allergic individuals is three minutes96. Exposure to
peanut can occur through one of three different routes, ingestion, skin contact, or
inhalation, but reactions predominantly occur through ingestion97. A majority of peanut-
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allergic individuals begin to experience symptoms of allergy within the first two years of
life and symptoms are observed after the first known consumption of peanut in 72% of
children9, 96.
Reactions to peanut are particularly severe when compared to allergic reactions
elicited by other food sources. For reactions in children with any food allergy, 38.7% of
reactions in children are considered severe, however for peanut-allergic and tree nutallergic individuals, more than 50% have histories of severe reactions33. In adults with
food allergy, peanut allergy has the greatest proportion of individuals with histories of
severe reactions, 67.8%, compared to other food allergies31. In a study of allergic
reactions to peanut, 54% of reactions involved one organ system, while two organ
systems were involved in 32% of reactions, three for 13% of reactions, and four organ
systems were implicated in only 1% of reactions to peanut49. Symptoms relating to the
skin are the most prominent for peanut allergy and are found in 89% of reactions to
peanut49. These include rashes, urticaria, and angioedema95. Respiratory symptoms, such
as laryngeal edema, coughing, and asthma, are found in 42% of peanut reactions and 26%
of reactions include gastrointestinal symptoms like abdominal pain, diarrhea, and
vomiting49, 95. Additionally, cardiovascular symptoms, like hypotension and arrhythmias,
are present in 4% of peanut reactions49, 95. The most severe symptoms involved in a
peanut allergic reaction are anaphylaxis and anaphylactic shock. Approximately 5% of all
allergic reactions to peanut involve anaphylaxis97. Anaphylactic reactions to peanut can
result in a wide variety of symptoms, including cardiovascular collapse, severe
abdominal pain, trouble swallowing, difficulty breathing, wheezing, hypotension, and
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systemic shock98. In the US, fatal food-induced anaphylaxis rates are estimated at 0.04
deaths per million individuals each year, and over half of these deaths are attributed to
peanut-induced anaphylaxis99, 100. In fact, peanuts and tree nuts are the allergenic food
sources with the highest fatal anaphylaxis rates, resulting in 55-87% of food-triggered
anaphylactic deaths101. The mortality of peanut allergy is estimated at 2.13 per million
person years, which is higher than any other food allergy102.
One factor that contributes to the severity of peanut allergy is its characteristically
low threshold doses for many individuals. The amount of peanut needed to elicit a
reaction in peanut-allergic individuals may be as little as 0.2 mg of peanut protein92.
Considering a single peanut contains approximately 300 mg of peanut protein, the most
sensitive allergic individuals can react severely to trace amounts of peanut103.
iii.

Diagnosis of Peanut Allergy

The diagnosis of peanut allergy is analogous to the diagnosis of other food
allergies. With regard to diagnosis, it is important to consider the onset of peanut allergy.
Peanut allergy can present at any life stage, including in adulthood; however, the average
age of presentation is 14-18 months46, 49. Diagnosis, as with other food allergy, is highly
reliant on a convincing patient history. In fact, a history of reaction to peanut is often
considered the most important “test”104. In addition to patient history, SPT, sIgE,
component-resolved diagnostics (CRD), and OFC are the most prominently used
diagnostic methods for peanut allergy. SPT can be used in early stages of diagnosis of
peanut allergy, but only indicates sensitivity and does not directly correlate with clinical
reactivity81. In SPT, the size of the wheal can be used to predict reactivity. A wheal size
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larger than 8 mm is over 95% predictive of clinical reactivity to peanut105. Like SPT,
sIgE testing only indicates sensitivity to the allergenic food, not clinical reactivity and
certain sIgE results may indicate different degrees of reaction severity81.
CRD is another diagnostic method that is commercially available and is used for
peanut allergy diagnosis106. This approach is a type of sIgE testing; however, it tests for
specific food proteins or epitopes of food proteins106. In theory, this differentiates IgE
binding which is clinically relevant from binding that would not elicit a reaction106. When
sIgE testing is used for peanut components, 70-90% of individuals with confirmed peanut
allergy have sIgE to Ara h 1 and Ara h 2103, 107. Between 45-95% of allergic individuals
have sIgE to Ara h 3108. However, sIgE to Ara h 2 and Ara h 6 is known to have the
highest diagnostic ability for peanut allergy, and it can give insight into reaction
severity106, 109. Sensitization to Ara h 8 alone is a phenomenon observed in some tested
individuals and this usually indicates tolerance for peanut, not reactivity110.
Though the aforementioned tests are commonly used in diagnosing peanut
allergy, the gold standard is DBPCFC, as for other food allergies. When physiciansupervised, an OFC is considered the most preferred and definitive test for peanut
allergy104. However, DBPCFCs are expensive, require significant challenge time, and
have the potential to cause dangerous reactions104.
iv.

Peanut Allergy Treatment
The treatment of peanut allergy, much like that of other food allergies, consists

primarily of adoption of an avoidance diet. Though individuals seek to avoid exposure to
peanut through elimination diets, about 10% of peanut-allergic individuals report an
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allergic reaction each year due to an accidental exposure40. Because individuals still
experience allergic reactions, additional treatment is needed. One principal component of
peanut allergy treatment is the use of epinephrine upon accidental exposure to the
allergen. Due to the severity of allergic reactions to peanut, the administration of
epinephrine, antihistamines, and bronchodilators are recommended to treat allergic
individuals who have been exposed to peanut111. The use of these treatment medications
is typically based on reaction severity. For severe reactions and anaphylaxis,
intramuscular injection of epinephrine is administered and for less severe reactions
antihistamines and bronchodilators are recommended111. Epinephrine is critical in
controlling a severe reaction to peanut and potential anaphylaxis because it can reverse
any symptom of the allergic reaction, while antihistamines are not as effective for
respiratory and cardiovascular symptoms112. The actions of epinephrine include
decreasing mast cell and basophil release of mediators, vasoconstriction, bronchodilation,
and overall increased blood flow to counter an allergic reaction113. There are risks in
using epinephrine to treat anaphylaxis and those primarily stem from recognition of a
reaction and improper use of epinephrine injectors112. Unfortunately, it is common for
epinephrine administration to be too late, at the incorrect or insufficient dose, or simply
erroneous due to lack of knowledge regarding administration114.
Another option to manage peanut allergy is oral immunotherapy (OIT), which has
been increasing in interest from both patient and research perspectives. The goal of
peanut OIT is to increase an individual’s threshold of tolerance to peanut in order to
reduce their reaction risk upon an accidental or trace exposure. In a peanut OIT sequence,
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the initial phase of immunotherapy involves rapidly increasing doses of peanut, followed
by the build up phase with a more gradual increase of peanut protein111. Next, the
immunotherapy transitions to a maintenance phase, which consists of a therapeutic dose
of peanut for an extended period111. One study of peanut OIT in children found 71% of
children receiving immunotherapy achieved desensitization115. However, another study
found OIT to be effective in children, but non-statistically significant desensitization rates
were observed between adults in OIT-treated groups (41.5%) and placebo groups
(14.3%)116. While there is some evidence of OIT promoting desensitization for peanutallergic individuals, specifically for children, long term studies and follow up is needed to
assess real tolerance117. OIT may be a promising management option for peanut-allergic
individuals, but immunotherapy-induced dosing reactions occur which may deter certain
individuals111. There is one peanut OIT product, Palforzia, that was approved by the US
Food and Drug Administration for use in peanut-allergic children in 2020118.
v.

Resolution of Peanut Allergy
In contrast to desensitization promoted through OIT, a subset of peanut allergic

individuals will naturally outgrow their peanut allergy through a process known as
resolution. Resolution is typically marked by an increase in T regulatory (TREG) cells, a
decrease in peanut-specific IgE, and the absence of clinical reactivity when exposed to
peanut117. Unlike other food allergies, including allergy to egg and milk, peanut allergies
are much less likely to resolve as an individual develops28. In fact, approximately 20% of
peanut allergic children will outgrow their allergy by adulthood117. Resolution is more
likely before the age of six years old and occurs at a lower rate after the individual is 10
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years of age119. Wheal sizes resulting from SPT analysis are thought to be a predictor of
tolerance or persistence. Decreasing wheal size indicates a higher probability that the
individual will resolve their peanut allergy, while larger and increasing wheal sizes are
more indicative of persistence of peanut allergy120.
vi.

Cost of Peanut Allergy to Stakeholders
Peanut allergy is accompanied by a wide variety of costs, including financial and

psychological, to many stakeholders, such as patients, caregivers, clinicians, and the food
industry. Financial costs associated with peanut allergy include both direct and indirect
costs91. Peanut allergy increases annual medical costs for the allergic individual or the
family of the individual. Direct costs include general physician visits, allergist visits,
emergency department (ED) visits, antihistamine medication, epinephrine autoinjectors,
and more47. In fact, peanut is the most common allergenic food to cause ED visits and
23% of peanut-allergic children and 20% of peanut-allergic adults report a visit to the ED
each year3, 31, 121. Lifetime costs associated with anaphylaxis treatment and epinephrine
autoinjectors for peanut-allergic individuals are estimated at $25,228122. Furthermore,
there are indirect costs associated with peanut allergy, including special diets for allergic
individuals, allergen-free foods, changes in childcare, lost wages due to doctor
appointments, and more91. The financial burden of all childhood food allergy in the US is
approximately $24.8 billion47.
In addition to the financial costs, there are substantial psychological and
emotional costs associated with peanut allergy91. The severity of allergic reactions to
peanut and the fear of accidental exposures leads to the observed psychological impact of
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peanut allergy, which most commonly manifests as sadness, depression, embarrassment,
nervousness, and anxiety91. For peanut-allergic children, bullying from peers contributes
negatively to social and emotional health112. Additionally, it is well understood that
peanut allergy reduces the overall quality of life (QoL) for patients, family members, and
caregivers91, 123. The restrictions on daily life and activities, especially with school,
restaurants, and travel, have a negative impact on QoL91. Modifications to diet, avoidance
diets, and restrictive eating can also have a negative effect on peanut-allergic individuals
health-related QoL124.
V. ALLERGEN REGULATION
Due to the danger associated with IgE-mediated allergic reactions, the need to
regulate allergenic foods is imperative in order to increase the safety of food products for
consumers. In the US, regulation of the presence of allergenic foods occurs for packaged
foods through labeling requirements and mandated allergen control plans to ensure good
manufacturing practices and preventive controls for cross-contact prevention. There are
two primary legislative acts that govern food allergen regulation in the US, the Food
Allergen Labeling and Consumer and Protection Act and the Food Safety Modernization
Act. In addition to regulated allergen labeling, precautionary allergen labeling is a
voluntary allergen statement used to communicate the potential risk of allergen presence
in a food product, although it is recognized by stakeholders as misleading or confusing to
consumers. The purpose of these regulations, both mandated and voluntary, is to protect
allergic individuals from consuming products which certainly or may contain an
allergenic food, so that an avoidance diet can be followed.
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i.

Food Allergen Labeling and Consumer Protection Act
As allergic individuals must adopt an elimination diet to avoid any consumption

of the allergenic food, consumers must be able to discern whether or not their allergen is
present in packaged food products. In 2004, the US Congress enacted the Food Allergen
Labeling and Consumer Protection Act (FALCPA)6. FALCPA requires plain-language
labeling of the allergenic foods which have been intentionally added to a food product6.
The act requires “major allergens” to be declared, and this list is what is known as the
“Big Eight” allergenic foods (milk, eggs, fish, shellfish, tree nuts, peanuts, wheat, and
soy)6, 30. Plain-language labeling requires ingredients to be listed by their common name,
even if a derivative of the allergenic food source has been used in the food product125. For
example, if casein is used in a formulation the label must declare the presence of “milk”
in the food product 126. The declaration of the presence of allergens can be listed within
the ingredients statement or recorded in a separate, typically adjacent, statement which
lists any and all allergenic foods present in the food127. FALCPA does not include
labeling requirements for highly refined oils because protein residues, if present, should
be at trace levels which may not cause allergic reactions in most allergic individuals125.
Additionally, FALCPA does not apply to made-to-order food products or food prepared
in restaurants112.
ii.

Food Safety Modernization Act

Because allergic consumers adopt avoidance diets to minimize the potential for
reactions, the unintentional addition of food allergens to food products is also a concern.
This unintentional presence of allergen residues in foods is known as cross-contact and is
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a hazard which may pose a risk to allergic consumers. In fact, the leading cause of food
recalls in the US is the presence of undeclared food allergens in food products126. In
attempt to mitigate this risk and protect allergic consumers, the Food Safety
Modernization Act (FSMA) was passed by the US Congress in 20117. FSMA requires
food manufacturers to develop and implement a food allergen control plan (ACP) to
prevent allergen cross-contact during food production and processing. This aspect of
FSMA’s guidance, requires a food hazard analysis in which allergens are classified as a
chemical hazard128. The motivation behind ACPs is to mandate the diligence of food
manufacturers in preventing allergen cross-contact within their production and packaging
processes129. ACPs and current good manufacturing practices (cGMPs) for allergen
management typically include dedicated equipment, cleaning and sanitation protocols,
supplier ingredient controls, product sequencing, and labeling controls127.
iii.

Precautionary Allergen Labeling for Allergens

Precautionary allergen labeling (PAL) is a voluntary statement which can be used
by food companies to communicate to consumers the possible presence of an allergen in
a food product as a result of cross-contact92, 130. PAL statements are intended to denote
the risk of the unintended presence of an allergen in a food product, however they are
only slightly regulated in the US. PAL statements must be truthful and not misleading,
plus cannot be used as a substitute for cGMPs131, 132.
This results in inconsistencies of PAL statement phrasing and consumer confusion
about the actual risk associated with these labels133. Phrases which are considered PAL
include, but are not limited to, “may contain (allergenic food),” “may contain traces of
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(allergenic food),” “processed in a facility that manufactures (allergenic food),”
“packaged in a shared facility,” and others40, 106.
The issue with inconsistencies of PAL statements is that consumers interpret PAL
statements differently based on wording; however, these phrases do not denote varying
degrees of risk. For example, one study found that consumers with peanut allergy were
more likely to purchase products with PAL statements containing “shared facility” rather
than a “may contain peanuts” statement134. Consumers may even ignore PAL statements,
especially if previous consumption of a product did not result in an allergic reaction135.
Because PAL is not regulated, food companies may use these labels in order to avoid
liability, regardless of the risk136. Non-risk-based and widespread use of PAL statements
can be advantageous to food manufacturers because consumers who have allergic
reactions to foods with PAL may be unable to litigate regarding these reactions136.
The primary consideration for PAL statements is whether the warning label is effectively
communicating a risk of allergic reaction to consumers. For peanut contamination
specifically, one study investigated allergen contamination in products with and without
PAL statements. Peanut was found in 4.5% of products with peanut PAL statements and
in 0% (of 120 analyzed products) with no declaration of peanut presence137. Another
study found detectable levels of peanut in 7% of products containing a peanut PAL
statement134. Company size may play a role in the likelihood that a product with a peanut
PAL statement tests positive for peanut contamination137. Products from small companies
had 7.7% of PAL statement products contain peanut, while large companies tested
positive for peanut only 1.7% of the time137. While the frequency of peanut detected in
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products labeled with PAL statements may be low as determined by some studies, these
results do reflect the expected sporadic nature of allergen cross-contact138.
iv.

Other Voluntary Labeling
In addition to PAL, there are other unregulated voluntary allergen labels that have

been observed on packaged food products. This subcategory of voluntary allergen claims
is referred to as “free-from” claims. Examples of these claims include, “allergen-free” or
naming a specific allergen that is supposedly absent from the product, such as “peanutfree”139, 140. These types of claims are currently not regulated in the US by FALCPA or
FSMA and have no quantitative basis6, 7, 141. There is one exception for these unregulated
claims and that is a “gluten-free” claim which is indeed regulated and has a quantitative
limit of 20 ppm gluten142.
v.

Food Allergen Risk Assessment
A critical component of allergen control and food allergen labeling considerations

is risk assessment. Food allergens are unique in the risk that they pose to allergic
consumers and therefore require a specific risk assessment strategy143. There are four
components of a food allergen risk assessment, hazard identification, hazard
characterization, exposure assessment, and risk characterization143. In the first step of
food allergen risk assessment, the hazard identified is generally the potential of causing
an allergic reaction in allergic individuals143. Hazard characterization, the second step of
risk assessment, consists of a determination of the possibility of an adverse effect
following exposure to the hazard144. This characterization is primarily based on a
minimum dose or threshold concentration below which reactions are less likely to
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occur144. For food allergens, reference doses can be used. The Voluntary Incidental Trace
Allergen Labeling (VITAL) program established reference doses for several allergenic
foods92. These were calculated using distribution models of no-observed adverse effect
levels (NOAELs) and lowest-observed adverse effect levels (LOAELs) from clinical
challenge data to deduce an eliciting dose for the most sensitive 5% (ED05) or 1% (ED01)
of allergic individuals92. EDs, eliciting doses, refer to the dose that would elicit an
allergic response in x% of the allergic population145. The VITAL reference dose for
peanut is 0.2 milligrams (mg) of peanut protein and was established based on the ED0192.
In short, an eating occasion that contains a total of 0.2 mg of peanut protein would be
expected to elicit an allergic reaction in the most sensitive 1% of peanut-allergic
individuals. The third step of a risk assessment for a food allergen hazard is an exposure
assessment. In an exposure assessment, the concentration of the food allergen in the food
and the intake amount of food are multiplied to deduce the total exposure to the
allergenic protein in a single eating occasion144. The fourth and final step of food allergen
risk assessment is risk characterization, in which all previous steps are considered to
calculate the probability or frequency of an adverse allergic reaction to the presence of
allergens in the food at certain population levels146.
vi.

Food Allergen Recalls
One important aspect of food allergen regulation in the US is the recall of

products found to contain undeclared allergens. FALCPA requires declaration of the
major allergenic foods on a food label; therefore, products containing a major allergenic
food without appropriate labeling are considered “misbranded”147. Upon inspection or
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detection of undeclared allergens in a food product, firms and the Food and Drug
Administration (FDA) or USDA Food Safety and Inspection Service (FSIS) work to
recall products and inform consumers148. In the US, the most common cause of food
recalls by the FDA is related to food allergen labeling147. The products recalled at the
highest frequency include bakery products, followed by snacks and candies147.
Additionally, the most common allergenic foods which prompt a recall are milk, wheat,
and soy147.
VI. ALLERGEN DETECTION METHODS
As a result of regulatory measures and for the purpose of risk reduction, the
ability to detect and quantify the presence of protein from allergenic food sources in food
products is of significant value to the food industry. Current analytical allergen detection
methods for food products include enzyme-linked immunosorbent assays (ELISA),
lateral flow devices (LFD), polymerase chain reaction (PCR), and liquid chromatography
tandem mass spectrometry (LC-MS/MS)149. ELISA and LFD detection methods have an
immunological basis, while PCR and LC-MS/MS are non-immunologic and detect
nucleic acids or proteins, respectively.
i.

Immunoassay Overview
ELISA and LFD are both immunoassays that are commonly used as food allergen

detection methods in the food industry. ELISA and LFD are immunological assays that,
at the most basic level, function through binding of an antigen to antibodies, typically
immunoglobulin G (IgG) antibodies, which have been raised against the target antigen150.
With respect to antibodies for immunoassays, there are two types that are utilized by kits.
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Polyclonal antibodies are generated from different B cell clones, while monoclonal
antibodies originate from a single B cell150. The result of raising antibodies from different
B cell clones compared to a single B cell is that polyclonal antibodies will bind different
epitopes, while monoclonal antibodies will recognize a single epitope150.
ii.

Enzyme-Linked Immunosorbent Assays (ELISA)
a. Principles of ELISA

ELISA detection methods are the most commonly used food allergen detection
methods in the food industry primarily due to their reasonable sensitivity and simplicity
for routine monitoring of food allergens35, 150, 151. There are both commercial and
noncommercial ELISA assays. Companies may manufacture a kit to be sold
commercially or laboratories may develop their own assays for use in house. Because it is
an immunoassay, the fundamental concept of an ELISA is the binding of kit antibodies to
a target antigen, the allergenic protein in the food35. There are multiple types of ELISA
kits, including sandwich ELISA assays and competitive ELISA assays. The most
common ELISA format used for food allergen detection is the sandwich ELISA152.
Furthermore, kits can be crafted in order to detect a specific allergenic protein, and some
can detect multiple proteins152. In a sandwich ELISA, capture antibodies are coated in the
sample wells to bind any antigen present in the sample150. Second, a detection antibody
binds to any antigen which has been retained by the capture antibody. The detection
antibody is often conjugated with an enzyme to create a detectable signal150.
Quantification of the allergen or allergenic food in the sample is then based on the
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interpolation of sample absorbance to a standard curve. For a sandwich ELISA, the
absorbance is directly proportional to the concentration of the target analyte153.
b. Advantages of ELISA Methods
Overall, food allergen detection by ELISA is considered an effective and valuable
tool for use in the food industry for multiple reasons. It is widely accepted that these kits
have sensitives or detection limits at ranges which would generally ensure safety for
food-allergic consumers149. Commonly, kits have detection limits in the low parts per
million (ppm) range. Reagents and materials used in the kits are also conducive to food
processing facilities149. Another advantage of food allergen detection by ELISA is that
these analyses are generally quick and do not require great expertise for completion of the
analysis or expensive, specialized laboratory equipment150. Instrumentation for
colorimetric measurements, such as a plate reader, is a necessary, but is considered a
reasonable expense for most laboratories or facilities152.
c. Limitations of ELISA
There are several limitations that exist for ELISA methods when used for food
allergen detection. One prominent issue with ELISA detection methods is the ability of
the extraction process to effectively extract the target protein from the food that is being
analyzed150. For food allergen detection, one issue contributing to an inefficient
extraction is the food matrix and its interference with the target protein150. To overcome
this issue, many extractions for ELISA may utilize an extraction additive to assist in
protein extraction154.
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ELISA detection methods can be limited in their ability to detect allergens after
the food has been processed due to changes in proteins’ structures and properties, which
may impact binding155. Various processing effects of the food matrix may change the
accessibility or structure of conformational epitopes for detection by kit antibodies156.
There are a wide range of changes to target proteins that can occur during food
processing, which may impact the ability of ELISA kits to detect the analyte. Examples
of these changes include aggregation, denaturation, hydrolysis, degradation, reduction,
and oligomerization of proteins151. Furthermore, food matrix components can interact
with proteins and impact their solubility and thus, their extractability by the kit buffer151.
On the other hand, these assays may be cross-reactive with components of a food matrix,
prompting over-recovery and inaccurate quantification by over-estimation of the
allergen155. These sorts of changes may impact the ability of the kit antibody to capture
the intended target protein in the food matrix and thus impact the kit’s efficacy to detect
food allergens precisely and accurately in food matrices. Another limitation of ELISAs is
that because the assay hinges on antibody binding, there are varying epitopes that will be
recognized and to different extents, thus there is the possibility of variable quantification
due to binding affinities157. Due to uncertainties with ELISA kits’ ability to effectively
detect and quantify food allergens in specific matrices, it may be necessary to confirm the
results of an ELISA analysis with a non-immunological detection method.
d. Peanut ELISA Methods
There are a large number of ELISA methods that have been developed
commercially for the detection of peanut, which target different proteins and result in
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different sensitivities in certain food matrices. Some of these commonly used assays
include the Veratox® for peanut allergen (Neogen®) with a range of quantitation of 2.525 ppm peanut, the BioKits Peanut Assay Kit (Neogen) with a range of quantitation of 120 ppm peanut, the AgraQuant® Peanut Kit (Romer Labs®) with a range of quantitation
from 1-40 ppm peanut, the Ridascreen® Peanut Kit (R-Biopharm®) with a quantitation
limit of 0.75 ppm peanut, and the Peanut Protein ELISA Kit II (Morinaga Inc.) with a
quantitation range of 0.31-20 ppm peanut protein according to each respective
manufacturer. However, a factor in an ELISA kit’s recovery and quantification is often
the food matrix which is analyzed.
One study of six commonly used assays determined that all kits reported
reasonable recoveries of peanut protein158. The same study characterized the antibodies of
the ELISA kits, reporting which peanut proteins are predominately recognized by the kit
antibodies158. Five of the six kits predominately recognized Ara h 3, the most abundant
peanut protein, and the other, the Morinaga kit, recognized primarily Ara h 2 and Ara h 6.
In a study comparing the recovery of peanut protein in processed pastry samples by the
Morinaga Peanut ELISA kit and the Veratox for peanut allergen (Neogen) using different
extraction buffers, the Morinaga kit outperformed the Veratox kit in recovery of peanut in
samples that were extensively processed159. However, with minimally processed pastry
samples or in the pastry dough, peanut detection was greater with the Veratox kit159. This
suggested an effect of the protein targeted by the kits’ antibodies because Veratox kits
target mainly Ara h 3159. Though Ara h 3 is abundant, it was more susceptible to heat
processing and therefore, recovered to a greater extent with less thermal processing159.
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In another study of ELISA recovery of peanut protein, food matrices were treated
with moist heat and dry heat and then analyzed by the Veratox kit and the BioKits
assay160. The results indicated a lower level of peanut recoveries for all heat-treated
samples for both kits, though to different extents160. Overall, the study concluded that
certain ELISA kits may not be suitable for analysis or result in accurate quantitation of
food matrices that have been thermally processed, due to the induced structural and
conformation changes of the proteins160. In a study comparing the peanut recoveries of
two ELISA kits (BioKits from Neogen and Peanut Residue ELISA kit from ELISA
Systems) from peanut-incurred cookies, the results showed a dominant effect of thermal
processing, as all four samples were detected in the 10 ppm peanut cookie that was baked
for 11 min but in only one 10 ppm peanut cookie sample after 16 minutes of baking161. In
a study of spiked dark chocolate and incurred cookies, five commercially available
ELISA kits were used to detect peanut in various levels of the food matrices162. In the
cookie, the average recovery ranged from 72.9-190.9% and for the dark chocolate, 43.7151.8%162. The study concluded that all five kits performed well in the 5-10 ppm peanut
range but struggled in the lower concentration ranges and had variations of 44-191%
across all kits162. There is an observed issue with the detection of trace levels of peanut
protein when using ELISA detection methods to analyze cookie and dark chocolate
matrices.
There are also noncommercial assays for peanut detection in food products which
have demonstrated some efficacy in a number of food matrices. One polyclonal antibody
assay evaluated different matrices (oil, ice cream, cookies, chips, chocolate candy, pasta
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sauces) and reported recoveries of peanut protein ranging from 45-100%163. Another
noncommercial ELISA was developed and used to analyze various spiked matrices (milk,
chocolate candies, cereals) and found recoveries of peanut protein ranging from 99126%, with an overall LOD of 2 ppm peanut protein in matrix164. An ELISA assay,
developed with a calculated LOD of 0.07 ppm peanut protein and LOQ of 0.15 ppm
peanut protein, was used to analyze spiked chocolate and effectively detected the 10 ppm
peanut chocolate165. Another noncommercial ELISA was developed and detected peanut
in ice cream at approximately 40 ppm peanut protein166. A common acknowledgement of
ELISA method developers is that a greater understanding of the impact that the food
matrix imparts on target proteins and their detection, if solved, would improve the
sensitivity of ELISA assays166. One sandwich ELISA was developed to detect peanut in
complex food matrices (spiked dark chocolate and ice cream) and reported LODs ranging
from 0.2-1.2 ppm peanut167. One important consideration for peanut ELISAs, whether
commercial or noncommercial, is that many underestimate (approximately 3.5-fold)
peanut when the peanut material has been roasted or thermally processed168. On the other
hand, these ELISA methods can overestimate raw peanut by a factor of 3.9168.
iii.

Lateral Flow Devices (LFD)
a. Principles of LFD

LFDs are another common immunoassay used in the food industry for food
allergen detection. LFDs are also referred to as dipsticks, strip tests, or lateral flow
assays169. An LFD functions like an ELISA detection kit in that it relies on antibodyantigen binding to indicate the presence of a food allergen, however an LFD yields only a
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qualitative or a semi-quantitative result152. Most LFDs are designed with four main parts,
sample pad, conjugate pad, membrane, and absorbent pad170. The sample is added to the
sample zone with a membrane containing specific antibodies raised for the target
analyte150, 169. These antibodies are not bound to the membrane, but bind to target protein,
if present. The antigen-antibody complex then progresses through the LFD to the test
zone169. The test zone contains a second target-specific antibody that will bind the
antigen-antibody complex to form the test line, indicating a positive result169. The visual
indicators of the LFD tests are created using colored particles coated with antibody171.
These devices also use a control line that will display a band, whether or not any analyte
was detected, to confirm the test was run properly171.
b. Advantages for LFD Use
The primary advantages of LFDs are their speed and ease-of-use for routine
analysis in food processing facilities150. LFDs are fast, relatively inexpensive, and do not
require any additional instrumentation or equipment157. It is widely accepted that LFDs
are valuable food allergen detection methods for verifying the efficacy of sanitation and
cleaning protocols for the food industry149.
c. Limitations of LFD
The most prominent limitation of LFDs for use as a food allergen detection
method is that they are not capable of accurate quantification of the detected analyze.
LFDs commonly have limits of detection (LOD) near 0.5-5 ppm but have limited efficacy
in quantifying detected analyte171. For risk assessment purposes, it is much more valuable
to obtain a quantitative amount for the food allergen present in order to calculate
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exposure dose143. LFDs typically determine the presence or absence of a food allergen in
a sample and, at best, can only be considered semi-quantitative or qualitative152. The
semi-quantitative consideration comes from the fact that the intensity of the test band is
correlated to the amount of the target antigen in the sample35.
Because LFDs function fundamentally similar to an ELISA, they face many of the
same matrix-based issues in their detection of food allergens. As a result of food
processing, the target proteins of LFDs may have endured conformational or solubility
changes which may negatively affect their detection by the strip test169. As with ELISA
methods, potential cross-reactivity of the test’s antibody with matrix and other proteins is
considered a drawback for LFD172. Another issue with LFDs is the possibility for falsenegative reactions which is called the prozone phenomenon or hook effect173. This effect
occurs when there are high amounts of the allergenic protein present in the test sample, so
much so that it is greater than the antibody binding capacity of the test and the result is no
band formation at the test line174. This is an overloading effect that results in a falsenegative test result. This is a significant limitation of this detection method with respect
to the protection of allergic consumers and food safety. Some LFD manufacturers utilize
an overload line to address the issue of false negative results due to the hook effect169.
d. Peanut LFD Methods
There are several LFDs that have been developed for the detection of peanut, both
for uses in sanitation and cleaning validation or analysis of food materials. Some
developed LFDs have shown comparable sensitivity to ELISA methods. One lateral flow
immunoassay developed using Ara h 1 monoclonal antibodies accomplished sensitive
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detection of peanut in peanut meal (0.5 ppm peanut)175. Another LFD analyzed peanut in
food matrices (chocolate milk, cereal bar, chocolate candy, and others) and reported
LODs near 1 ppm peanut protein in food sample176. However, like ELISA methods,
LFDs struggle when analyzing peanut in complex or processed food matrices. For
example, in a study of two commercially available LFDs, peanut-containing cookies were
analyzed, and several false-negative results were reported in this matrix at concentrations
less than 21 ppm peanut in cookie177. Additionally, three commercially available peanut
LFDs were used to evaluate spiked cookie dough and chocolates, and two LFDs detected
at 1 ppm peanut in both matrices, while the other LFD detected only at 14.2 ppm peanut
in the chocolate and 4 ppm peanut in the cookie dough178. These LODs in cookie and
chocolate matrices are not necessarily sensitive enough to ensure food safety for allergic
consumers.
iv.

Polymerase Chain Reaction (PCR)
a. Principles of PCR
PCR is a deoxyribonucleic acid (DNA)-based method that can be used to detect

DNA from an allergenic food source. PCR methods function by targeting and amplifying
specific DNA sequences that are unique to the species from which the allergen
originates179. Generally, PCR methods can be divided into three steps. First, DNA is
extracted and purified from the food matrix that is to be analyzed for allergenic
material180. Next, the specific DNA target sequence is amplified150. The amplification
process is completed by a thermostable DNA polymerase and begins with melting or
denaturation of the DNA strands179. Next, DNA primers, which are oligonucleotides
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flanking the target DNA, bind to the denatured DNA strand174. Lastly, DNA polymerase
extends the primer DNA and synthesizes a new strand or copy of the target DNA
sequence181. These three steps of amplification are controlled by temperature and are
usually completed in multiple (25-45) thermal cycles until a detectable amount of copy
DNA has been generated179. Following amplification, the third step of PCR is that the
amplified DNA is detected which can be done via several methods180.
There are several types of PCR, but most of the PCR methods that are commonly
used for indirect food allergen detection are general PCR or real-time PCR150. Though
there are multiple different types of PCR methodologies, real-time PCR is considered
especially beneficial as an allergen detection method because it can quantify the initial
amount of DNA present in the sample prior to amplification180. For real-time PCR,
quantification can be completed using the number of thermal cycles needed to produce
detectable product DNA to determine initial target DNA concentration182. On the other
hand, end-point PCR is considered only qualitative179.
b. Advantages of PCR Use
The target DNA for the PCR method can originate from a gene for an allergenic
protein or simply originate from the allergenic food183. The key to target DNA selection
is the specificity of the target sequence to the source of the allergenic material. In theory,
a target DNA sequence for a PCR method may be more specific than an amino acid
sequence for a peptide or protein-based detection method183. This is because there are
three nucleotides to encode each codon for a specific amino acid and for most amino
acids there are multiple codons180. Therefore, one advantage of PCR is that a DNA
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sequence is, in theory, more specific than an amino acid sequence that might be used in a
peptide or protein-based detection method180. Additionally, nucleic acids are more stable
than proteins so PCR methods can, theoretically, utilize harsher extractions to analyze
food that has been extensively processed150.
c. Limitations of PCR Methods
One limitation of using a DNA-based method to indicate the presence of food
allergens is that the quantitative correlation between DNA and a specific protein amount
is not well understood184. The allergen-encoding DNA is not always linearly related to
the presence of an allergen in the sample157. However, the amount of DNA in an
organism is considered more stable than the protein amounts, since proteins can vary
across individual organisms, species, and varieties150. Even so, many allergenic food
sources have much less DNA by composition compared to protein149. Another limitation
of DNA-based detection methods is the effect of the food matrix and processing on target
DNA. First, processing of the food matrix has the potential to alter the DNA and its
structure, which will decrease its detection157. Further, DNA can be degraded during food
processing, which can significantly decrease its detection by a PCR method185.
Additionally, food matrix components like salt, lipids, and proteins, are known to
interfere with DNA amplification and result in a decrease in the amplification efficiency
and result in lower sensitivity or false negative results179. PCR also requires more
expensive instrumentation compared to immunoassays150.
The main limitation of using PCR to indicate the presence of food allergens is
based on the principle of the detection method, in that it is not detecting proteins from the
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allergen source or surrogates of allergenic proteins. The issue is that PCR detects a class
of molecules, nucleic acids, which are not the causative agent of food allergy186. In short,
PCR an indirect detection method. Additionally, the processing of food differently
impacts nucleic acids and proteins because they are two separate types of molecules, plus
DNA and protein can be separated during food processing techniques like protein
concentration152, 186. Therefore, detection of DNA to indicate the presence of allergenic
food proteins is flawed in its principle as a detection method.
d. Peanut PCR Methods
There are many real-time PCR methods which have been developed to detect
peanut. Several qualitative methods for the detection of peanut in foods by PCR have
been developed and appear to be generally robust and relatively sensitive in their
detection, with LODs less than 10 ppm peanut165, 187, 188. Semi-quantitative and
quantitative PCR methods for peanut have also been established, though they recognize
their deficit in being able to accurately quantify allergens in some food matrices165. One
PCR method developed with an Ara h 1 primer target with an absolute LOD of 5
picograms (pg) of peanut was used to analyze chocolate material with peanuts and
reported a positive detection, even in a complex matrix189. One study used real-time PCR
of a mat K chloroplast marker to detect peanut protein at 1 ppm peanut, with an absolute
LOD of 2.5 pg of DNA and to detect peanut in commercial matrices (cereal bar and
chocolate bar) with a broad quantification range of 1-105 ppm peanut190. A comparative
study of ELISA and real-time PCR in their detection and quantification of peanutcontaining food matrices indicated that heat treatments resulted in a decrease in recovery
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in both detection methods, in a similar manner161. It is often observed that peanut PCR
methods demonstrate high variation between replicates due to the exponential component
of amplification191.
v.

Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
a. Principles of MS
MS-based allergen detection methods have been developed for an extensive list of

allergenic foods. The principle of these detection methods is that MS is used for the
detection of specific mass-to-charge (m/z) ratios corresponding to specific peptide
sequences to indicate the presence of protein in a sample192. These methods can also be
developed to be quantitative using internal or external calibration techniques192.
A critical component of understanding food allergen detection and quantification by MS
is the basic principles of MS. There are three basic components of an MS instrument, the
ion source, mass analyzer, and detector. The ion source is responsible for ionizing and
volatilizing the particles to be analyzed193. Ion sources for protein or peptide methods are
usually matrix-assisted laser desorption ionization (MALDI) or electrospray ionization
(ESI)194.For ESI, the ionization is completed using electric voltage, and this ion source is
compatible with an upstream LC system193.
The next part of MS instrumentation is the mass analyzer. The role of the mass
analyzer is to determine the m/z of the ions195. There are five commonly used mass
analyzer types. These are quadrupoles (Q), ion traps (IT), time-of-flight (TOF) analyzers,
Fourier transform ion cyclotron resonance (FTICR) analyzers, and Orbitraps193. Each of
these mass analyzers, have varying sensitivities, as well as differences in mass range,
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resolution, and accuracy155. A quadrupole allows ions of certain m/z values to pass based
on radio frequency and voltage potentials193. Quadrupoles have limited resolution and
mass accuracy193. Orbitraps are able to separate ions using an oscillating electric field and
are known for their accuracy and resolution193.
Instruments can have a single mass analyzer or can have two mass analyzers in
sequence, which is known as tandem MS (MS/MS). The coupling of mass analyzers in
tandem for MS increases the sensitivity of detection, as well as allows for higher
resolution and mass accuracy149. Before the second mass analyzer, fragmentation of
precursor ions is completed to generate product ions196. Product ions are important for the
identification of the target analyte or target peptide because product ions increase
specificity or confidence in detection196. Most commonly, fragmentation is completed by
collision gas, which breaks up the molecular bonds that are the most labile193. In peptide
analysis, this is most commonly the cleavage of the CO-NH bond of the peptide
backbone193. This results in y and b ions193.
The next step within in MS is the detection of ions. There are several types of ion
detectors, including electron multipliers, Faraday cups, photographic plates, scintillation
counters, and others197. The ion detector does not measure mass, but instead generates a
signal any time an ion is detected. Results of the detector are shown as spectra of relative
ion abundance as a function of the m/z 197. MS spectra are then used to discern sequence
information using software to compare with protein sequence databases to identify the
amino acid sequences of detected m/z values193, 198.
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MS analysis benefits from the use of analyte separation and this often occurs in
the form of liquid chromatography (LC). A common MS set up for the detection of food
allergens or other analytes consists of an LC coupled to an MS instrument containing two
mass analyzers (tandem MS), abbreviated as LC-MS/MS. High pressure LC (HPLC) is
the most commonly used separation technique in the field of proteomics, specifically
reverse phase HPLC (RPLC)199, 200. It is also the superior method for separation, as it is
markedly reproducible and has a large dynamic range193. The theory behind using RPLC
is after an ion-pairing agent is added to sample peptides, they become positively charged
and can be separated using the mobile phase, typically acetonitirile201. This method
separates peptide based on their hydrophobicity interaction with the column material, or
stationary phase200. An important aspect of RPLC for a quantitative MS method is that
the retention time (RT) of a peptide, the time it elutes from the column into the
instrument, is consistent across similar chromatographic conditions because the elution is
based on the peptide’s composition and physiochemical properties202, 203. One benefit to
using LC is that it has a very high dynamic range, which helps when analyzing analytes
that may be in low abundance, like food allergens150.
There are two broad categories for types of MS methods, untargeted and targeted
analyses, which each have several varieties within them. In untargeted proteomics
strategies, also referred to as discovery proteomics, the signal intensity of precursor ions
determines their selection for fragmentation for MS2204. There is no user determination of
which precursor ions to select. In contrast, targeted proteomics workflows allow for the
user to predetermine precursor ions for isolation in MS1 and fragmentation for MS2205.
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There are multiple kinds of targeted MS methods, including selected reaction monitoring
(SRM, also referred to as multiple reaction monitoring or MRM), and parallel reaction
monitoring (PRM). In SRM, both precursor and product ions are selected, whereas in
PRM methods only the precursor is predetermined, and all product ions are measured205.
PRM is a valuable approach on a high-resolution MS (HRMS) instrument, specifically
with a hybrid quadruple Orbitrap mass analyzer and has been shown to have superior
quantification performance compared to SRM methods157.
In addition to untargeted and targeted MS strategies, there are also two different
approaches to using MS for proteomics. These include top down proteomics and bottom
up proteomics193. Top down proteomics is the measurement and fragmentation of intact
proteins by MS, without prior enzymatic digestion. These methods may involve
separation strategies for proteins and specific fragmentation techniques193. Bottom up
proteomics involves enzymatic digestion of proteins in a sample extract, which are then
separated by chromatography and evaluated by MS193.
Of particular value for MS-based allergen detection methods is their quantitative
potential. Targeted MS methods can be designed for absolute quantification methods in
which the goal is quantification of protein or peptide present in the analyzed sample206.
Quantification of allergenic protein in food samples assumes a proportional relationship
between the signal from the MS and the amount of the target analyte in the sample193.
Targeted MS-based detection methods, when appropriately developed and applied, are
considered to be accurate and reproducible157. One common approach to quantification is
to include a known amount of an internal standard, typically isotopically labeled versions
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of target peptides193. These internal standards will behave similarly to the peptide
analytes as they are molecularly identical except for the mass difference due to the
isotopic nuclei (C, N, H)207. This strategy guarantees nearly identical behavior of the two
versions of the peptide through LC and MS-MS methodologies and instrumentation193.
The ratio between the “light” peptide (the analyte) and the “heavy” peptide (the isotope
labeled peptide) can be used for quantitation through a light-to-heavy ratio since a molar
amount for the heavy peptide is known207.
There are also strategies for quantifying allergenic protein via external calibration
using calibration curves. In this approach, absolute quantification of proteins and peptides
can be determined using a correlation of the target analyte signal and the measured
standard curve of samples with known concentrations193. MS-based methods boast LOQs
that may be as low as in the femtomole or attomole range151. Additionally, it is important
to consider the reporting units generated by the quantification for these methods so that
they can be used for comparison with reference doses for risk assessment149. Thus, it is
advisable to create methods with reporting units of total protein from the allergenic food
source.
One key to appropriate quantitation for these targeted methods is target selection,
which is a very important component of method development205. Target selection should
consider a number of factors, but primarily target peptides should be sensitive,
reproducible, and specific193. Furthermore, target peptides must be present and detectable
in the native food matrix and in the processed food matrix193.
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b. Advantage of MS-Based Methods
There are several advantages to using MS as a food allergen detection method.
First, the advantage over DNA based detection methods is that MS is directly detecting
the protein responsible for food allergy, whereas DNA-based methods only indirectly
indicate the presence of allergenic protein. MS-based detection methods also have the
ability to overcome the effects of a food matrix, an issue demonstrated in immunoassay
detection methods. This is because MS only relies on m/z values of selected peptides
instead of antibody recognition of an epitope151. LC-MS/MS methods have an advantage
over ELISA in processed food products because the conformation of the protein does not
need to be maintained for detection of peptide sequences by MS208. LODs and LOQs for
MS-based methods can be in the femtomole or attomole range for peptide on column,
which is a comparable level to immunoassays151. With targeted MS methods, sensitivities
for the detection of food allergens can be achieved with respect to consumer safety157.
MS methods can also be multiplexed, in which target peptides for multiple allergens can
be included in a single analysis149. This results in the possibility of a more time and
resource efficient allergen analysis method.
c. Limitations of MS
Though MS-based allergen detection methods have advantages over most current
detection methods, there are still some limitations to using MS for food allergen detection
and quantification. The first is that peptide identifications are highly dependent on the
availability of protein sequence databases209. Furthermore, the quality of the MS data and
resulting quantitation is dependent on the accuracy of protein sequence databases used, as

48
well as the search algorithms and software utilized for the identifications150. Second,
while MS may be advantageous for food matrix analyses as it does not need to preserve
protein conformation, processing or matrix-induced modifications change the m/z of the
target peptide and therefore may impact detection and quantification. Another limitation
of MS is that quantification of allergens by MS relies heavily on the initial extractability
of proteins containing the target peptides. Food processing can improve or diminish the
extractability of proteins which can greatly altern the allergen concentration of extracts
compared to the starting material151, 152. This increases the importance of accurate
calibration, either internal or external, for MS methods. Another broadly recognized
limitation of MS-based detection methods is the cost and expertise required for these
analyses. Equipment, materials, and instrumentation for these detection methods are
expensive and require costly maintenance150. Additionally, MS workflows and data
analysis often require personnel with great expertise150. Because of cost and expertise
requirements, MS methods are typically not used for routine analysis but have value as
confirmatory methods upon unexpected results with other detection methods, like
ELISA149.
d. Peanut MS Methods
There are numerous LC-MS/MS methods that have been developed for the
detection and quantification of peanut protein. Methods may target different peptides
from different proteins, approach quantification in various ways, and be established for
detection in a wide range of matrices. Some work has been completed for the selection of
target peptides that perform well in a wide variety of matrices (fermented, thermally
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processed, complex, and fatty matrices), and one study identified 16 quality target
peptides that are sensitive and robust across the aforementioned matrix types210. These
targets selected also considered the isoforms of major allergens, which promotes accurate
quantitation of peanut210. In some methods, peptide markers from more than one protein
are used to encompass different expression levels of proteins across different varieties of
peanut and peanut products211.
An LC-MS/MS method for analysis of peanut in a complex mixture of nuts
(hazelnuts, pistachios, almonds, and walnuts) achieved an LOD of 26 ppm peanut in
matrix (6.5 ppm peanut protein)212. Methods have been developed for the detection and
quantification of peanut in complex matrices, like chocolate dessert and chocolate bars
but struggled to robustly detect below 10 or 50 ppm peanut protein, depending on target
peptide213. One MS method was able to detect incurred dark chocolate material at levels
as low as 2 ppm peanut protein using two tryptic peptides from Ara h 1214. An LCMS/MS method used to analyze rice crispy and chocolate snacks obtained LODs of 5
ppm peanut protein in matrix for Ara h 2 and 1 ppm peanut protein in matrix for Ara h
3211. An SRM method targeting two tryptic peptides from Ara h 3 was developed and was
successful in its detection of peanut at levels as low as 10 ppm peanut (2.5 ppm peanut
protein) in enriched cookies215. Detections as low as 2.5 ppm peanut protein were
achieved in an MRM method analyzing contaminated chocolate, cookie, ice cream, and
tomato sauce216. For the four peptide markers included in that method, the LOQs ranged
from 2.5-50 ppm peanut protein in matrix216.
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Though MS methods may overcome several matrix and processing issues
observed by ELISA, target peptides for MS methods from Ara h 1 and Ara h 3 (cupins)
appear to be more susceptible to processing effects than Ara h 2, Ara h 6, and Ara h 7 (2S
albumins)217. Even so, an MRM method to detect peanut peptides in thermally processed
samples (boiling, roasting, frying) utilized peptides that achieved sensitivities of 0.1-30
attomoles on-column217. Furthermore, an MRM method developed to detect peanut in
raw and cooked wheat matrices using two Ara h 1 peptides showed greater quantitative
accuracy than five analyzed ELISA kits, as the ELISAs reported overestimations of
peanut in the wheat matrix218.
VII.

SUMMARY
Food allergy is an important food safety consideration for both the food industry

and allergic consumers. Peanut allergy is of particular concern due to its prevalence,
reaction severity, low threshold dose, and common presence in a variety of food products
in the US. Because of regulatory measures, the food industry must have the ability to
detect peanut protein in processed foods for the purposes of consumer protection and
government compliance in the US. Current peanut allergen detection methods,
specifically ELISA, PCR, and LFD struggle in their detection and accurate quantification
of peanut protein in certain processed food matrices. MS-based peanut detection methods
may have potential for effective quantification of peanut protein, even in complex and
processed food matrices.
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CHAPTER II: THE SELECTION AND FILTRATION OF TARGET PEPTIDES
USING UNTARGETED AND TARGETED MS ANALYSES OF INCURRED
COOKIE AND DARK CHOCOLATE MATRICES
I. ABSTRACT
Peanut allergy has prevalence rates near 2% for individuals in the United States
(US) and is associated with particularly severe reactions1-3. The US requires ingredient
labeling of peanut to protect peanut-allergic consumers4. Thus, the detection of peanut
protein in food matrices is a critical component of food safety for the food industry and is
used to monitor allergen cross-contact. Immunochemical detection methods for peanut
have demonstrated deficits in accurate quantitation in processed and complex matrices,
including cookie and dark chocolate5, 6. Mass spectrometry (MS)-based detection
methods may provide an alternative approach. In this work, target peptides were
identified for an MS method that detects and quantifies peanut in cookie and dark
chocolate matrices.
A discovery-based approach to target selection was utilized. Incurred cookie and
dark chocolate matrices were generated at various concentrations of peanut protein.
Incurred matrices and peanut flour (PF) samples were analyzed using untargeted MS
proteomic techniques. Peptide identification was completed using a peptide sequence
database search through a proteomics software for peanut (Arachis hypogea) and for
respective matrix components. Selection criteria, designed to identify abundant peptides
which are the least affected by the matrix, were applied to identified peanut peptides to
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classify a subset of peptides as candidate target peptides. In the matrices, 32 (cookie) and
67 (dark chocolate) candidate target peptides were determined.
Following identification of candidates, iterative rounds of targeted MS were
completed to empirically discern underperforming target peptides. Six (cookie) and seven
(dark chocolate) target peptides persisted through all targeted MS rounds. Combining the
filtered target peptides for both matrices, resulted in a list of nine unique peanut peptides.
The nine final target peptides demonstrated promising sensitivity, between 10-50 ppm PF
prior to any method optimization. Many of the nine final target peptides have been
included in other published quantitative MS methods for peanut.
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II. INTRODUCTION
Peanut is considered one of the “Big Eight” allergenic foods and allergy to peanut
affects approximately 2% of individuals in the US1, 2. The Food Allergen Labeling and
Consumer Protection Act (FALCPA) requires a plain-language declaration of peanut and
peanut-derived ingredients in food products in order to protect allergic consumers4. To
comply with US regulation and increase consumer safety, the food industry has adopted
various detection methods for peanut, of which ELISA-based methods are most
prominently used. A food matrix, which can be defined as the assembly of, and complex
interactions between, physical and chemical components of a food, often complicates the
detection of peanut contamination by immunoassay detection methods5, 7. Undeclared
peanut has been detected in commercially available cookie and dark chocolate products
and ELISA methods have demonstrated issues in accurately quantifying this
contamination due to changes in target analytes in the matrix or after processing5, 6, 8. In
an interlaboratory study that investigated five commercially available ELISA kits, peanut
in cookie was consistently overestimated by the kits with average percent recoveries
greater than 100% for four of the five kits6. For dark chocolate, recoveries ranged from
43.7-151.8%, depending on the kit used6. Other studies have reported concerning low
recoveries of peanut in chocolate, such as 13-42% recovery of peanut9.
Therefore, this work sought to develop an MS method for the detection and
quantification of peanut protein in processed food matrices, specifically cookie and dark
chocolate, as their complexity has resulted in inaccurate quantitation of peanut protein by
commonly used detection methods. Both selected matrices are considered complex in
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nature. Cookies may contain a gluten network, which is rubbery and viscoelastic in
dough and after extensive thermal processing, proteins may be structurally or irreversibly
changed10. Dark chocolate is complex due to its high fat content and phenolic
compounds11. MS-based methods may be more advantageous for thermally processed
matrices compared to immunological assays because the structure of the target protein
need not be conserved as MS targets peptides, instead of proteins, which also allows for a
more rigorous protein extraction12.
For the method, it is necessary to detect low levels of peanut protein in a final
food product. Thus, one consideration for matrix generation is whether the allergen
source material is added prior to (incurred matrices) or following processing of the food
matrix (spiked matrices)13, 14. The use of incurred matrices allows for the discernment of
two primary effects on analyte recovery, the first being the interactions of the allergenic
proteins with matrix components (matrix effect) and the effect of processing the material
on the proteins targeted by the method (processing effect). Spiked matrices may allow for
only limited determination of the effect of the food matrix and does not account for any
processing-induced changes of the protein analyte with respect to their interaction with
matrix proteins13, 15. A wide variety of protein modifications can occur during the
processing of a food matrix, including protein denaturation, protein aggregation, as well
as chemical modifications such as results of the Maillard reaction, matrix lipid oxidation,
or enzymatic modification16. These changes may impact the solubility and extractability
of allergenic proteins and therefore affect their recovery in detection methods15. Spiked
matrices also fail to accurately mimic real-world contamination of food products during

71
production because cross contact may occur before the final product stage, for example
by shared manufacturing equipment17. Therefore, utilizing incurred matrices, instead of
spiked matrices, for the development of allergen detection methods is advantageous as it
inherently encapsulates both the effects of a food matrix and its processing.
Other MS-based peanut allergen detection methods have been developed
previously for cookie and dark chocolate matrices from only spiked materials or pseudoincurred materials18-20. Because of the nature of the food materials used to develop the
method, the final method may not effectively account for the comprehensive matrix
effect. MS-methods for incurred cookies and chocolate have been developed, but some
have limits of detection and quantitation insufficient compared to the needed method
performance determined for this work21-23.
One of the most critical components of an MS method is the target peptides on
which the method is based. In MS-based allergen detection methods, detection of selected
target peptides from the allergen source is used to indicate and quantify the presence of
the allergenic food in the sample analyzed24. There are two primary approaches to target
peptide selection for an MS method, which are bioinformatic or in silico-based target
selection and discovery-based target selection25. In the first approach, protein sequences
are digested in silico with a protease, typically trypsin, to generate a list of peptide
sequences to consider as targets. Selected peptides also must be unique to the species of
the allergenic source and therefore, should be analyzed using Basic Local Alignment
Search Tool (BLAST) to determine their specificity to the intended species24. If a target
peptide is not unique, it is not fit for a quantitative MS detection method26. One limitation
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for this selection approach is the availability of protein sequence information, as this
strategy may not be feasible unless sequence data is accessible27. Secondly and arguably
more important, is the limitation that a bioinformatic-based selection approach may not
consider the effect of the food matrix or its processing on proteins and respective
peptides25. The method that overcomes this deficit and considers the food matrix effect is
discovery-based target selection. In a discovery-based approach to target selection, the
food sample containing the allergenic food is analyzed using discovery MS and detected
mass events are searched against a protein sequence database to identify detected
peptides25. These peptides are then evaluated considering further criteria to select a
number of target peptides that show greatest promise as quality targets for an MS
method. Limitations of this approach to target selection include reliance on protein
sequence availability for peptide identification, the requirement of high-resolution MS
instrumentation, and a certain expertise in analysis of discovery MS data25. These target
peptides should also be analyzed for their specificity to the intended species, as with
bioinformatically generated target peptides, and only specific peptides are fit for
quantitative MS methods24, 26.
For the method developed in this work, a discovery-based approach to target
selection was utilized, and screening of identified target peptides for sensitivity and
robustness was completed. Following the identification of candidate peanut peptides in
matrix, an empirical filtration of peptides was completed using targeted MS, specifically
parallel reaction monitoring (PRM), to determine the best performing peptides for each
matrix to consider as target peptides for a quantitative MS method.
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III. MATERIALS AND METHODS
i.

Analysis of Cookie Matrix Ingredients
Ingredients for the cookie matrix, including unsalted butter, granulated sugar,

table salt, baking soda, and all-purpose wheat flour were obtained from a local market in
Lincoln, Nebraska. Prior to the generation of the peanut-incurred cookie matrix,
ingredients to be used in the cookie formulation were evaluated for the presence of
peanut using a commercially available ELISA kit (Veratox® for Peanut ELISA kit,
Product no. 8430 Neogen® Lansing, Michigan). The ingredients analyzed for the
presence of peanut were wheat flour, butter, and sugar. Ingredients at low risk for peanut
cross-contact, such as salt, baking soda, and dextrose (Spectrum® Chemical MFG
Corporation, New Brunswick, New Jersey) were not evaluated. For the wheat flour,
butter, and sugar, three samples (5.00 grams each) were taken randomly from ingredient
packages. ELISA analysis was conducted according to the protocol provided by the kit
manufacturer. Extractions from the samples for each ingredient were evaluated in
duplicate wells.
ii.

Incurring Strategy and Homogeneity Evaluation for Cookie Matrix

Light roast Old Virginia Byrd Mill peanut flour (PF) (12% fat) was sourced from
the Golden Peanut and Tree Nuts Company (Alpharetta, Georgia). The PF was
determined to be 52.12% protein according to Dumas analysis. PF was incurred into the
cookie matrix prior to processing by incorporation in the sugar to be used subsequently in
the cookie formulation. The peanut-incurred sugar was prepared initially at a high
concentration and serially diluted to all needed incurred levels using blank sugar. A
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KitchenAid® Stand Mixer (4.5 quart) was used to prepare peanut-incurred sugar levels.
To create the highest incurred sugar level (36,359.33 ppm PF in sugar), 651.46 g of sugar
was added to a mixing bowl, followed by the addition of 24.58 g of PF. To ensure a
homogenous mixture of the PF into the sugar, the mixture was thoroughly mixed for five
minutes.
To create subsequent levels of peanut-incurred sugar, the previously formulated
incurred sugar was serially diluted with blank sugar to achieve the desired concentration.
This dilution of was completed with masses according to Table 2.1. Six levels of peanutincurred sugar were prepared, including 3,636.15, 363.63, 36.36, 7.27, and 3.64 ppm PF
in sugar, to prepare six levels of incurred cookie dough.
Table 2.1: Masses Used to Generate Peanut-Incurred Sugar and Subsequent Dilutions
Designed
Cookie
Matrix
Level
Matrix
(ppm PF)
10000

Designed Actual
Blank
Mass of
Total
Cookie Cookie
Sugar
Previous
Mass of
Mass
Matrix Matrix Concentration
Mixed
Incurred
Incurred Removed for
Level
Level
in Sugar
with
Level
Mix (PF + Formulation
(ppm
(ppm
(ppm PF)
Previous
Added
Sugar)
(g)
peanut peanut
Level
(g)
(g)
protein) protein)
(g)
5,000
5,212
36359.33
24.58*
651.46
676.03
550.15

1000

500

521.20

3636.15

66.89

601.98

668.86

550.15

100

50

52.12

363.63

68.72

618.45

687.17

550.15

10

5

5.21

36.36

78.02

702.17

780.19

550.15

2

1

1.04

7.27

180.04

720.18

900.22

550.15

1

0.5

0.52

3.64

300.07

300.07

600.15

550.15

*PF

After mixing, two levels (36,359.33 and 363.63 ppm PF) of the peanut-incurred
sugar were transferred to separate baking trays and spread to even thickness. Nine
samples (1.00 g each) were taken from each tray. Locations for sampling were
equidistant from one another and evenly distributed to provide a holistic view of the
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distribution of PF in the sugar. The samples were analyzed using ELISA to ensure
homogeneity of the sample. For ELISA analysis, the manufacturer’s protocol was
followed with minor modifications. The procedure was adjusted for analysis of a 1.00 g
sample and sample extractions were diluted using the kit’s extraction buffer to ensure a
level of peanut protein within the kit’s quantification range of 2.5-25 ppm peanut and
evaluated in single wells.
iii.

Generation of Cookie Matrix

Following determination that the wheat flour, butter, and sugar did not contain
detectable levels of peanut and confirmation of the homogeneity of peanut-incurred sugar
mixes, the cookie matrix was generated. The method and formulation used for the cookie
matrix was based on the American Association of Cereal Chemists (AACC) International
method 10-50-0.5, with modifications. All equipment and utensils were washed prior to
matrix generation and in between each level produced to prevent cross-contact. The
generation of the matrices began with the 0 ppm peanut protein cookie, followed by
generation of the 0.52, 1.04, 5.21, 52.10, 521.20, 5,212 ppm peanut protein cookies. This
order of increasing peanut protein concentration was selected in order to minimize the
potential for allergen cross contact. Ingredient masses used to generate the cookie
matrices are summarized in Table 2.2.
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Table 2.2: Cookie Formulation for Peanut-Incurred Cookie Matrices
Ingredient

Mass in Formulation
Blank Matrix
(g)

Mass in Formulation
Incurred Matrices
(g)

Unsalted Butter

270.84

270.84

Granulated Sugar

550.15

550.15*

Salt

8.89

8.89

Baking Soda

10.58

10.58

Dextrose Solution

139.65

150.00

Distilled Water

67.71

67.71

All-Purpose Flour

952.18

952.18

Total:
*At appropriate PF concentration

2000.00

2010.35

To prepare the cookie matrices, the butter and sugar (blank or incurred at the
appropriate PF concentration) were added to a Hobart© Commercial mixer (Model A200,
20 quart) and mixed for two and a half minutes. For all breaks between mixes, any
ingredients that had adhered to the sides of the mixing bowl or the beater attachment
were scraped with a spatula. Distilled water and dextrose solution were added second,
followed by additional mixing for two and a half minutes. Half of the wheat flour, salt,
and baking soda mix were added to a KitchenAid mixer and thoroughly mixed for 30
seconds. This mixture was incorporated into the Hobart mixer to be combined with the
previously added ingredients. As this mixing continued, the second half of the wheat
flour, salt, and baking soda mix was added to the Hobart mixer until mixed for four
minutes and fully incorporated.
The dough was removed, and a portion was rolled to an approximate thickness of
one quarter inch. Next, cookies were cut using a square cookie cutter with sides that were
4.2 centimeters in length. Cookies were transferred to a baking tray lined with parchment
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paper and appropriately spaced to ensure separation after spreading during baking. The
cookies were baked for 20 minutes in Reed Revolving Reel Oven at 176.67 °C. Mass
determinations of reserved dough and the cookies after baking allowed for a calculation
of the percent water lost during baking. Using water loss, experimental peanut protein
concentrations were calculated for each cookie level (0, 0.63, 1.24, 6.21, 62.08, and
6,206.93 ppm peanut protein). After weighing, baked cookies were stored at room
temperature in an unsealed container for 12 hours to ensure proper drying. Following
drying, cookies were stored at 4 °C.
iv.

Dark Chocolate Matrix Manufacture
The dark chocolate matrix was manufactured in the pilot plant of a prominent

chocolate manufacturer under the supervision of University of Nebraska staff. A common
formulation used by the manufacturer for dark chocolate was used for the peanut-incurred
dark chocolate, which included sugar, chocolate liquor, cocoa butter, soy lecithin, and
vanillin. The materials used for the dark chocolate were well characterized by the
manufacturer. The dark chocolate formulated was approximately 45.95% cocoa. The PF
used in preparation of the dark chocolate was light roasted, 12% fat PF obtained from the
Golden Peanut Company, which was determined to be 55.7% protein by Dumas analysis.
The PF was added at the refining step to ensure consistent particle size and prior to the
conching step to ensure homogeneity. Therefore, the dark chocolate is appropriately
deemed an incurred matrix. Two levels of peanut-incurred dark chocolate were generated
(100 and 5,000 ppm peanut protein) and used to obtain desired levels of incurred dark
chocolate by mixing and tempering with a 0 ppm peanut protein dark chocolate.

78
v.

Untargeted MS Analysis of Incurred Matrices
a. Grinding
Blank cookie and dark chocolate samples (0 ppm peanut protein) and the highest

concentration of peanut-incurred cookie and dark chocolate (6,206.93 ppm peanut protein
cookie and 5,000 ppm peanut protein dark chocolate), as well PF, were ground into finer
particles prior to analysis by discovery proteomics techniques. To grind the baked cookie
samples, approximately 100 g of the cookies were ground in a Cuisinart® Mini-Prep®
Plus food processor (24 oz). For cookie dough samples, partitioning into finer particles
was completed manually with a spatula. The dark chocolate was ground manually with a
razor blade. The PF had a fine particle size and thus, was not ground prior to protein
extraction.
b. Extraction
Protein extraction of the incurred matrix samples was completed in triplicate
using a chaotropic buffer containing 6M Urea (Bio-Rad Laboratories©), 2M Thiourea
(Sigma-Aldrich®), 20 mM DL-1,4-Dithiothreitol (DTT) (Acros Organics, Thermo
Scientific™), and 50 mM Tris-hydrochloride (Tris-HCl) (pH 8.8) (Trizma® HCl, SigmaAldrich). For all matrix samples, this extraction was completed at a 1:20 w/v ratio. This
equated to 0.500 g of matrix extracted in 10 mL buffer. PF samples were extracted at a
concentration equivalent to a 5,000 ppm peanut protein matrix. For PF samples, the
extraction concentration was selected based on the amount of PF that would theoretically
be present in 0.5 g of the 5,000 ppm peanut protein cookie dough. For weighing
accuracy, this amount of PF and corresponding buffer was scaled up by a factor of three.

79
This equated to 0.015 g (15 mg) of PF extracted in 30 mL buffer. This extraction is
referred to as a 5,000 ppm peanut protein matrix equivalence.
To begin extractions, sample tubes were vortexed to promote suspension of the
solid sample in buffer. Sample tubes were transferred to a shaking water bath (200 rpm)
at 60 °C for 10 minutes (Julabo SW22 Water Bath). This was followed by a one minute
vortex of each sample. Following this, samples were transferred to a water bath sonicator
(Bransonic® S800 Ultrasonic Bath) and sonicated for 10 minutes at room temperature
(RT). Next, samples were vortexed briefly to resuspend sample solids in buffer. Samples
were returned to the 60 °C shaking water bath and incubated for 10 minutes, followed by
a centrifugation at 3,000 x g for 10 minutes at 4 °C for clarification (Centra® MP4R
Refrigerated Tabletop Centrifuge). Next, two samples (1 mL each) of each extract
supernatant were transferred to 1.5 mL microcentrifuge tubes and further centrifuged at
17,000 x g for 10 minutes at RT (Sorvall Legend Micro 17 Centrifuge). Then, 800 µL of
supernatant from each duplicate sample was combined in a 1.5 mL microcentrifuge tube
and stored at -20 °C.
Next, an SDS-PAGE gel was completed using NuPAGE™ 4-12% Bis-Tris Gels
(1.00 mm x 12 well) (Invitrogen™, Thermo Scientific™) to ensure extraction of protein
from samples analyzed. Sample extract (20 µL) was combined with 7.5 µL 4X NuPAGE
LDS Buffer and 1.5 µL water and reduced using 1 mL of ß-mercaptoethanol (BME)
(Sigma-Aldrich) at 70 °C for 10 minutes. NuPAGE SDS Running Buffer was used in a
Mini-Cell Electrophoresis Chamber (Invitrogen, Thermo Scientific). From the 30 µL of
prepared sample, 20 µL of each sample was loaded into each well. The gel was run for 35
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minutes at a constant voltage of 200V. Alongside samples, Precision Plus Protein™ Dual
Xtra Standards were run (Bio-Rad Laboratories). Protein bands were fixed in a 50%
methanol and 10% acetic acid solution for 15 minutes (Fisher Chemical™, Thermo
Scientific). Gels were stained with Coomassie Brilliant Blue R-250 Staining Solution for
1 hour and destained using Coomassie Brilliant Blue R-250 Destaining Solution for 3
hours (Bio-Rad Laboratories). The gel was rinsed with water and imaged under bright
light. Identification of protein bands in extract samples informed the determination of the
efficacy of the extraction protocol.
Following confirmation of extraction, protein quantification of sample extracts
was completed using the Cytiva 2-D Quant Kit, according to the manufacturer’s
instructions. Each extraction replicate was analyzed in duplicate. The volume of the
extract analyzed varied by sample and protein content to accommodate the kit standard
curve. Using the theoretical protein content of each matrix and sample type, an extraction
efficiency was determined.
c. PF Extraction Optimization
To address the variability observed with PF extractions prepared at 15 mg PF in
30 mL buffer, improvement of the PF extraction was pursued. To optimize this
extraction, extractions were conducted as previously described, but at four different
concentrations. The four samples analyzed were 15 mg PF/30 mL buffer, 60 mg PF/30
mL buffer, 250 mg PF/10 mL buffer, and 500 mg PF/10 mL buffer. Triplicate extracts
were completed for each of the levels. Extract samples were analyzed in duplicate by 2D-
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Quantification, and extraction efficiencies were calculated to determine an optimal PF
extraction concentration to minimize variability in weighing and quantification.
d. Digestion
Samples were prepared for tryptic digestion with reduction and alkylation.
Methods were based on the manufacturer’s recommendation for In-Solution Tryptic
Digestion for Pierce™ Trypsin Protease, MS Grade (Thermo Scientific), with minor
modifications. In the first untargeted experiment, 21 µL of cookie and PF sample extracts
were buffered with 30 µL of 50 mM ammonium bicarbonate (ABC) (Fluka® Analytical,
Sigma-Aldrich) and reduced with 3 µL of 100 mM DTT. For the dark chocolate
untargeted analysis, 10.5 µL of dark chocolate matrix and PF sample extracts were
prepared for digestion with 30 µL of 50 mM ABC and reduced with 3 µL of 100 mM
DTT. Reduction was conducted at 95 °C for five minutes. Following reduction, samples
were cooled. Next, samples were alkylated with 6 µL of 100 mM iodoacetamide (IAA)
(BioUltra, Sigma-Aldrich) and incubated in the dark for 20 minutes. Trypsin protease (2
µL, 100 ng/uL) was added to each sample and incubated for one hour at 37 °C. Next, an
additional 2 µL of trypsin was added to samples. Digestion continued overnight, for a
period not to exceed 16 hours, at 30 °C. Digestion was halted by transfer of digested
samples to a 20 °C freezer. An SDS-PAGE gel was completed in the manner described
previously to confirm trypsin digestion.
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e. Desalting
Sample digests were desalted to remove non-peptide components from the
samples using PierceTM C18 Spin Columns (Thermo Scientific). The manufacturer’s
protocol was followed with minor modifications. Formic acid (FA) was used instead of
the recommended trifluoroacetic acid (TFA). All solvents used in desalting were
Optima™ LC/MS Grade including FA, acetonitrile (ACN), methanol, and water (Fisher
Chemical, Thermo Scientific).
f. Lyophilization and Resuspension
Desalted samples were lyophilized using a Savant SpeedVac SPD120 Vacuum
Concentrator and a Savant RVT105 Refrigerated Vapor Trap to lyophilize peptide
samples. Prior to injection for liquid chromatography and tandem mass spectrometry
(LC-MS/MS), cookie matrix samples and the accompanying PF samples (5,000 ppm
peanut protein matrix equivalence) were resuspended in 60 µL of a 5% ACN and 0.1%
FA buffer (Optima Grade, Thermo Scientific). For the dark chocolate samples, as only
10.5 µL of extract was digested, the resuspension volume was halved with respect to the
cookie samples. Thus, dark chocolate samples were resuspended in 30 µL of 5% ACN
and 0.1% FA prior to MS analysis. The optimized version of the PF samples (5,000 ppm
peanut protein matrix equivalence) was run alongside dark chocolate samples.
g. LC-MS/MS
Peptide separation was completed using a Dionex UltiMate 3000 UHPLC+
system for liquid chromatography and a Hypersil GOLD™ Dim. (mm) 11x1 (Part No
25002-101030) column at 35 °C (Thermo Scientific). Triplicate injections (9 µL) were
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analyzed for each sample. The LC method began with a six minute equilibration at 2%
ACN (0.060 mL/min flow rate). An ACN gradient from 2% ACN to 40% ACN (0.060
mL/min) over 70 minutes was used to elute peptides. The LC method continued for six
minutes at 40% ACN (0.060 mL/min). Next, was a five minute wash at 98% ACN (0.060
mL/min) followed by a six minute wash using 100% methanol (0.150 mL/min). Reequilibration at 2% ACN was completed for 17 minutes (0.150 mL/min) and then for four
minutes at a 0.060 mL/min flow rate. All solvents, including ACN, FA, methanol, and
water were of Optima LC/MS Grade (Fisher Chemical, Thermo Scientific).
A Thermo Scientific™ Q Exactive™ Plus hybrid quadrupole-Orbitrap™ mass
spectrometer was used for this analysis and was set in data dependent acquisition (DDA)
mode. The full scan MS method was run in positive ion mode at 70,000 resolution with a
scan range of 400 to 1,400 m/z. Settings for MS1 scans included the automatic gain
control (AGC) target set at 3e6 and the maximum injection time (IT) at 100 milliseconds
(ms). The top 20 precursor ions were selected for fragmentation. Precursors with
unassigned charges, a charge of +1 or greater than 5+ were excluded. For MS2 scans, a
scan range of 200 to 2,000 m/z was used, and analysis was completed at a resolution of
70,000. The AGC target was set at 1e5, and the maximum IT was set at 240 ms. The
normalized collision energy (NCE) used was 27. Dynamic exclusion for 20 seconds (s)
was also used.
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h. Peptide Identification and Semi-Quantitation
Data analysis, including peptide identification and semi-quantitation of identified
peptides, for untargeted MS runs was conducted using PEAKS® Studio 8.5 Software
(Bioinformatics Solutions). To accommodate the PEAKS project workflow, identification
began with a de novo search. The de novo search was completed using a parent mass
error tolerance of 5.0 ppm and a fragment mass error tolerance of 0.05 Daltons (Da). A
fixed modification of carbamidomethylation (+57.02 Da) was included due to the
alkylation of reduced sulfide bonds by IAA. Variable modifications included in the
search were the oxidation of methionine (+15.99 Da) and hydroxyprolination (+15.99
Da). Data from the de novo search was not utilized but completed to comply with the
software workflow required prior to PEAKS database searches.
Next, PEAKS database searches were used to identify peptides detected in the
discovery MS analysis of the incurred matrices. Databases searches for peanut peptides
utilized a genome-derived peanut protein sequence database, as used by Marsh, et
al.(2020)28. This protein sequence database was focused on proteins of the peanut seed as
opposed to a comprehensive peanut plant proteome. Nomenclature for protein isoforms,
as defined by Marsh et al. (2020), were used for this work28. Protein sequence databases
for the wheat proteome (Triticum aestivum) and cacao (Theobroma cacao) were
downloaded from UniProt Proteomes. For the cookie samples, the MS spectra were
analyzed against the peanut protein database and the Triticum aestivum proteome
separately. In the same way for the dark chocolate samples, the spectra were analyzed
against the peanut protein database and the Theobroma cacao proteome separately.
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PEAKS database searches were conducted with a 5.0 ppm parent mass error
tolerance and a 0.05 Da fragment mass error tolerance. Carbamidomethylation (+57.02
Da) was included as a fixed modification, as well as oxidation of methionine (+15.99 Da)
and hydroxyprolination (+15.99 Da) as variable modifications. Enzyme settings were
used for trypsin, and the maximum number of missed cleavages was set at zero, and no
non-specific cleavages were included. Three maximum variable post-translational
modifications (PTM) were allowed per peptide. A contaminant database was also
included in these searches. A comparative analysis between the peanut protein database
search and the matrix proteome search was completed within PEAKS in order to exclude
peptides which were detected in both the peanut and the respective matrix proteome.
Following identification of peptides, semi-quantitation of detected peanut
peptides was completed using Label Free Quantification (LFQ) in PEAKS. LFQ settings
included a 5.0 ppm mass error tolerance and a 6.0 minute retention time shift tolerance. A
false discovery rate (FDR) threshold of 1% was used. LFQ data, which was normalized to
the total ion current (TIC) for identified peptides, was exported to Microsoft® Excel®
(Microsoft 365) and the “protein-peptides” export file was used for further data analysis.
The average peak area (MS1) for each peptide in each sample were determined by
averaging the three injection replicates and the three extraction replicates for each
sample. This value was noted as the abundance for each peptide. Next, peptide peak areas
were used to determine the relative allergen abundance in the incurred cookie, incurred
dark chocolate, and PF samples. To complete this relative quantitation of allergenic
proteins using the LFQ data, the top three peptides from each protein detected were
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averaged to deduce an overall peak area value per peptide. Peanut proteins were only
relatively quantified in this way if there three peptides were detected from the protein in
the untargeted analysis. Isoforms of peanut proteins were considered in this analysis, as
some detected peptides are present in one, multiple, or all isoforms of a protein. Graphs
and figures were created GraphPad Prism, Version 9.3.0 (463).
vi.

Selection of Candidate Target Peptides in Incurred Matrices
From all identified and quantified peanut peptides in LFQ, a smaller list was

generated of peptides that demonstrated promise as quality targets. series of three
exclusion steps were conducted, followed by application of two selection criteria to
determine candidate target peptides.
First, any peptide found to be in common between the peanut PEAKS database
search and the matrix proteome PEAKS database search through the comparative
analysis was excluded. Next, any peptide that had a detection in more than one injection
in the blank matrix was removed from the potential peptide list for specificity purposes.
Any peptide which contained variable PTMs of hydroxyprolination or oxidation of
methionine were eliminated.
Peptides that were not removed by the three exclusion steps were then subjected
to two predetermined selection criteria, designed to select the best performing target
peptides in the analyzed matrix. The first selection criterion was abundance and was
applied through the selection of only the top 60% most abundant peptides in the sample
set based on the MS1 peak areas of peptides. The second selection criterion evaluated the
detection of the peptide in matrix against its detection in PF as a measure of robustness or
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matrix performance. For this, the selection criterion was established to select only
peptides with a recovery ratio of 0.1 or greater in the matrix compared to PF alone. The
ratio was calculated by dividing the average peak area of the peptide in matrix by the
average peak area of the peptide in PF. Only peptides that met both selection criteria were
deemed candidate target peptides.
vii.

Large-Scale Sample Preparation for Targeted MS
Sample preparation that was used to prepare samples for targeted MS was similar

to that of the sample preparation for untargeted MS, and any deviations from the original
protocol were for the purpose of achieving a greater amount of protein in samples prior to
analysis by MS. Extraction was completed at the same 1:20 w/v ratio described for the
untargeted MS sample preparation, except the PF extraction used was the optimized
concentration for its extraction efficiency and reduced variability (60 mg PF/30 mL
buffer). In the large-scale digestion, 105 µL of sample extracts were buffered with 150
µL of 50 mM ABC and reduced with 15 µL of 100 mM DTT. For alkylation, a volume of
30 µL of 100 mM IAA was used. Digestion was initiated using 10 µL of trypsin with a
one hour incubation at 37 °C. Next, an additional 10 µL of trypsin was added for
digestion. The total digestion volume was 320 µL.
For desalting, a larger capacity column was used (Strata™-X 33 um Polymeric
Reversed Phase (10 mg/1 mL)(Phenomenex®), and the manufacturer’s protocol was
followed with minor modifications. Samples were lyophilized as mentioned previously
and were resuspended in 300 µL of 5% ACN/0.1% FA. For filtration experiments,
samples were diluted to various concentrations using resuspension buffer (5% ACN/0.1%
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FA) and injected (15 µL) for LC-MS/MS analysis. For these samples, LC was completed
using a larger capacity column, a Hypersil GOLD aQ Dim. (mm) 20 x 2.1 (Part No
80000-506) at 35 °C. Chromatographic adjustments were made for the column. The
chromatography used for the subsequent filtration experiments begins with a six minute
equilibration at 2% ACN (0.300 mL/min). Next, a 19-minute ACN gradient from 2% to
40% ACN (0.300 mL/min) was used for peptide elution. This was followed by a five
minute wash using 98% ACN (0.300 mL/min). Re-equilibration at 2% ACN (0.300
mL/min) was completed for five minutes.
The large-scale samples were used for targeted MS analysis (PRM) to filter
candidate target peptides down to a list of the most sensitive and robust targets for each
matrix. Candidate peptide precursor m/z values were added to a scheduled PRM
inclusion list. The MS was run in positive mode at a resolution of 35,000. The AGC
target was set at 1e6, and the maximum IT was set at 500 ms. A loop count of 1 was used
for compatibility with an inclusion list. An isolation window of 0.8 m/z was used for
precursors and no isolation offset was utilized. The NCE for this method was 27.
Analysis of targeted MS data was completed using Skyline Software from the University
of Washington, MacCoss Lab29.
viii.

Targeted MS Filtration of Candidate Target Peptides in Cookie

Based on the number of candidate target peptides selected after untargeted MS
analysis, it was necessary to filter these targets down to a reasonable number for
inclusion in a targeted MS method. To accomplish this filtration, iterative rounds of PRM
were completed to experimentally determine the best performing target peptides for the
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analyzed matrix using the large-scale samples. Overall, six rounds of PRM filtration were
completed for determination of the most sensitive and robust target peptides for the
incurred cookie matrix. For PRM filtration analyses, samples are referred to by their
peanut concentration in ppm PF. A summary of the methods used for each of the six
rounds of iterative PRM for the cookie matrix are shown in Table 2.3.
Table 2.3: Method Description for PRM Filtration Rounds for the Cookie Matrix
Round of
Description of Method
Data Analysis Approach
PRM
For precursors that had multiple
Samples: PF
charge states in the inclusion, the
Levels: 10,000 ppm PF
most abundant charge state was
Injections: 2 µL, single
selected, and the least was removed,
Inclusion list: all candidate target
if could be determined. The two
peptides in two batches
Round 1
inclusion lists were combined into
All candidate target peptides, as selected
one and run again with the PF sample
based on untargeted MS analysis, were
with a scheduled inclusion list. A
added to one of two inclusion lists and
scheduling window of 2 minutes was
each was analyzed against the PF
created based off peptide retention
sample.
time (RT) from the initial run.
Samples: Incurred cookie dough and
The lowest concentration of PF that
incurred baked cookie
had at least three product ions
Levels evaluated: 10,000 5,000, 500,
detected was recorded for each
100, 50, and 10 ppm PF
sample type, cookie dough and baked
Injections: 15 µL, duplicate
cookie. Target peptides were
Inclusion list: remaining precursors after eliminated from the method inclusion
Round 2
Round 1 removal of least abundant
list if the peptide was not detected, if
charge states for some target peptides.
the lowest detected concentration
Remaining peptides included in
level was greater than 5,000 ppm PF,
scheduled inclusion list and evaluated
or if visual inspection of the
against various concentrations of
chromatogram indicated inappropriate
incurred samples.
or incomplete peak shape.
The sum of the peak area of the top
Samples evaluated: Incurred baked
three product ions was calculated, and
cookie and PF
dilution curves were created for each
Levels evaluated: 10,000, 5,000, 2,500,
peptide and matrix. The sensitivity of
1,000, 500, 100, 50, and 10 ppm PF
potential target peptides was
Injections: 15 µL, duplicate
Round 3
evaluated and peptides which were
Inclusion list: remaining precursors after
not detected below 1,000 ppm PF in
Round 1 and Round 2 eliminations.
either sample type were eliminated.
Peptides included in scheduled inclusion
The linearity of the dilution curves
list and evaluated against various
was considered and peptides with
concentrations of incurred samples.
non-linear curves were eliminated.
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Round 4

Samples evaluated: Incurred baked
cookie and PF
Levels evaluated: 1,000, 750, 500, 250,
100, 50, 10, and 1 ppm PF
Injections: 15 µL, duplicate
Inclusion list: remaining targets after
Round 1-3 eliminations.
Peptides included in scheduled inclusion
list and evaluated against various
concentrations of incurred samples.

Round 5

Samples: Incurred baked cookie and PF
Levels evaluated: 500, 100, 50, 10, and 1
ppm PF
Injections: 15 µL, duplicate
Inclusion list: remaining targets after
Round 1-4 eliminations.
Peptides included in scheduled inclusion
list and evaluated against various
concentrations of incurred samples.

Round 6

Samples: Incurred baked cookie, blank
cookie dough, blank baked cookie, and
PF
Levels evaluated: 100, 50, 25, 10, and 1
ppm PF
Injections: 15 µL, duplicate
Inclusion list: remaining targets after
Round 1-5 eliminations.
Peptides included in scheduled inclusion
list and evaluated against various
concentrations of incurred samples.
Additionally blank cookie matrix
samples analyzed to evaluate sensitivity
of remaining peptides and product ions.

ix.

Using the top three product ions and
sum of peak area as described for
Round 3, dilution curves were
created, and their linearity was
evaluated. Peptides with nonlinear
curves were eliminated. The lowest
concentration of detection was
considered and peptides which did
not have detections at or below 500
ppm PF were removed.
Using the top three product ions and
sum of peak area as described for
previous rounds, dilution curves were
created, and their linearity was
evaluated. Peptides with nonlinear
curves were eliminated. The lowest
concentration of detection was
considered and peptides which did
not have detections at or below 50
ppm PF in both sample types were
removed.
Using the top three product ions and
sum of peak area as described for
previous rounds, dilution curves were
created, and their linearity was
evaluated. Peptides with nonlinear
curves were eliminated. The lowest
concentration of detection was
considered. Relative performance in
sensitivity was compared across
remaining peptides in both sample
types to eliminate any peptides which
appeared to be underperforming.

Targeted MS Filtration of Candidate Target Peptides in Dark Chocolate
The number of candidate target peptides selected based on the two outlined

selection criteria for the dark chocolate matrix required further filtration of targets. An
empirical approach to the reduction of candidate target peptides to a reasonable number
of robust and sensitive target peptides was completed using iterative rounds of PRM
analysis of dark chocolate samples. Overall, five rounds of PRM were completed in order
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to determine the final list of sensitive and robust target peptides for the dark chocolate
matrix. A summary of the methods used for each of the five rounds of iterative PRM for
the dark chocolate matrix are shown in Table 2.4.
Table 2.4: Method Description for PRM Filtration Rounds for the Dark Chocolate Matrix
Round of
Description of Method
Data Analysis Approach
PRM
Samples: PF
For precursors that had multiple
Levels: 10,000 ppm PF
charge states in the inclusion, the
Injections: 15 µL, single
most abundant charge state was
Inclusion list: all candidate target
selected, and the least was
peptides in four batches
Round 1
removed, if could be determined.
All candidate target peptides, as selected
A scheduling window of 4
based on untargeted MS analysis, were
minutes was created based off
added to one of four inclusion lists and
peptide RT from this run to be
each was analyzed against the PF
used in subsequent analyses.
sample.
For peptides that still had two
Samples: Incurred dark chocolate and PF charge states included, the least
Levels: 10,000, 5,000, and 1,000 ppm PF abundant was removed. The
Injections: 15 µL, duplicate
sensitivity of detection of
Inclusion list: remaining target peptides
analyzed peptides was
Round 2
after Round 1, one inclusion list.
considered. Peptides which did
Peptides included in scheduled inclusion not have three product ions
list and evaluated against various
detected at 5,000 ppm PF or
concentrations of incurred samples.
lower were removed from the
method.
The sum of the peak area of the
Samples: Incurred dark chocolate and PF top three product ions for each
Levels: 2,500, 1,000, 500, 100, 50, and
peptide was determined and
10 ppm PF
dilution curves were created. The
Injections: 15 µL, duplicate
linearity of the peptide’s
Inclusion list: remaining target peptides
response in accordance with the
Round 3
after Round 1-2, two inclusion lists.
concentration of peanut. Peptides
Peptides included in two scheduled
with nonlinear curves were
inclusion lists, and each was evaluated
eliminated. The sensitivity of
against various concentrations of
each peptide was also evaluated,
incurred samples.
and peptides not detected below
1,000 ppm PF were removed.
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Round 4

Round 5

Samples: Incurred dark chocolate and PF
Levels: 500, 250, 100, 50, 10, and 1 ppm
PF
Injections: 15 µL, duplicate
Inclusion list: remaining target peptides
after Round 1-3, two inclusion lists.
Peptides included in two scheduled
inclusion lists, and each was evaluated
against various concentrations of
incurred samples.
Samples: Blank dark chocolate, incurred
dark chocolate, and PF
Levels:
Injections: 15 µL, duplicate
Inclusion list: remaining target peptides
after Round 1-4, one inclusion list.
Peptides included in scheduled inclusion
list and evaluated against various
concentrations of incurred samples.
Additionally blank dark chocolate matrix
samples analyzed to evaluate sensitivity
of remaining peptides and product ions.

Dilution curves were created for
each peptide, as described for
Round 3. Any peptides with
nonlinear dilution curves were
removed. The sensitivity
parameters allowed for the
elimination of any peptides not
detected at levels below 250 ppm
PF in the dark chocolate or
below 500 ppm PF in the PF.
Dilution curves were created for
each peptide, as described and
peptides with nonlinear
calibration curves were removed
from the method. Peptides
without a detection at a
concentration below 100 ppm PF
in PF or dark chocolate were
eliminated from the list of target
peptides.
.

IV. RESULTS AND DISCUSSION
i.

Analysis of Cookie Ingredients
The purpose of this evaluation was to verify ingredients used in the cookie matrix

did not contain detectable traces of peanut. All samples analyzed by ELISA were below
the limit of quantification (LOQ = 2.5 ppm peanut) for peanut (n=6).
ii.

Cookie Matrix: Incurring Strategy and Homogeneity Evaluation

The strategy of incurring PF into the sugar prior to the generation of the cookie
matrix was selected in order to promote homogeneity of the PF in the final matrix and
increase the accuracy of PF amounts at lower levels by eliminating the need to weigh
small masses of PF. Sugar was selected as the vehicle to be incurred with the PF
primarily due to its particle size and its ability to equitably mix with the PF.
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Samples from two peanut-incurred sugar levels (36,359.33 and 363.63 ppm PF)
were determined to be sufficiently homogeneous based on their analysis by ELISA.
Based on the average measured peanut concentration, the coefficient of variation (%CV)
was determined for each level as a measure of homogeneity, shown in Table 2.5. The
%CV values for both incurred sugar levels were less than 20%, thus these levels were
determined to be sufficiently homogenous. Furthermore, because the two evaluated
peanut-incurred sugar levels were deemed homogenous, it was assumed that all peanutincurred sugar mixes were amply homogenous for use in the generation of the cookie
matrix.
Table 2.5: ELISA Results for Homogeneity Analysis of Peanut-Incurred Sugar
36,359.33 ppm PF 363.63 ppm PF in
in sugar
sugar
Theoretical Concentration of Peanut in Sugar (ppm
peanut)
Average Measured Result ± Standard Deviation
(ppm peanut)

72,718.66

727.26

26,017.78 ± 3468

382.29 ± 21

13.33

5.73

Coefficient of Variation (%)
(N=9).

iii.

Cookie Matrix Generation

Generation of the PF-incurred cookie matrices was completed according to
formulations shown in Table 2.1. Water loss calculations were completed for each level
of the cookie matrix (Table 2.6). The average water loss for the batches of cookies was
16.6%. The %CV for the water loss measure was 3.84%.
The actual concentration of peanut protein in the cookies after baking was
calculated with consideration for the protein content of the peanut flour, as well as for

94
water loss and its effect on the total mass of the cookie batches. The actual concentrations
of peanut protein in the cookies after baking are shown in Table 2.6.
Table 2.6: Adjusted Peanut Protein Concentrations Considering Water Loss
Designed Level Concentration of Cookie
Concentration of Baked
Water Loss
(ppm peanut
Dough
Cookie
(%)
protein)
(ppm peanut protein)
(ppm peanut protein)
0

0

16.25

0

0.5

0.52

17.98

0.63

1

1.04

16.56

1.24

5

5.19

16.33

6.21

50

51.86

16.05

62.08

5,000

5,185.96

16.45

6,206.93

The designed levels of peanut protein concentration were selected for this work
according to the needed method performance for this detection method. This was
determined using risk management principles. For determination of the lowest
concentration of peanut protein per mass of food material (mg/kg) that should be detected
by the method, there are two values which must be considered. The first is the relevant
reference dose for peanut which, for the purposes of this study, is 0.2 mg peanut
protein30. This is the amount of peanut in one eating occasion that would elicit a reaction
for the most sensitive 1% of peanut-allergic individuals if consumed. This is the
Voluntary Incidental Trace Allergen Labeling (VITAL) reference dose for peanut30. The
second factor in determining risk of an allergic reaction is the typical amount of food
matrix consumed by individuals. However, to maximize safety, an overestimate of the
serving size much greater than the average consumption was used. A 100 g serving size
for the cookie was used, though the median food intake for cookies in the US is only 36.0
g31. For an individual to receive a total of 0.2 mg of peanut protein while consuming 100
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g of cookie, the concentration of peanut protein would equate to 2 ppm peanut protein in
the cookie.
iv.

Dark Chocolate Matrix Manufacture
The dark chocolate matrix was manufactured at various levels of incurred peanut

and the levels used for this work were 0, 2, 20, 100, 5,000 ppm peanut protein. In the US,
the median intake for dark chocolate in one eating occasion is 31.2 g, but a serving size
of 50 g was used to calculate the needed method performance for this project to
maximize safety for allergic consumers31. For an individual to consume the reference
dose for peanut (0.2 mg peanut protein) through the consumption of 50 g of dark
chocolate, the concentration of peanut protein would have to be 4 ppm peanut protein in
matrix30.
v.

Untargeted MS Analysis of Incurred Matrices
a. Extraction Confirmation by SDS-PAGE
SDS-PAGE gels qualitatively confirmed protein extraction from samples to be

analyzed in untargeted MS experiments. Triplicate extracts were run, including PF (5,000
ppm peanut protein matrix equivalence), blank cookie dough (0 ppm peanut protein),
blank baked cookie (0 ppm peanut protein), incurred cookie dough (5,185.96 ppm peanut
protein), and incurred baked cookie (6,206.93 ppm peanut protein), which are shown in
Figure 2.1.
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Figure 2.1: SDS-PAGE for Confirmation of Protein Extraction in the Cookie Matrix.
A) Blank cookie dough and baked cookie samples. B) Peanut-incurred cookie dough and
baked cookie samples. M: Molecular weight markers; lanes 1-3: replicate extracts of a) 0 or
b) 5,185.96 ppm peanut protein in cookie dough; lanes 4-6: replicate extracts of a) 0 or b)
6,206.93 ppm peanut protein in baked cookies; lanes 7-8: replicate extracts of PF (5,000
ppm peanut protein matrix equivalence).

Gels for all extracted samples indicated successful protein extraction. Congruent
protein banding patterns between triplicate extracts suggested similar extraction results
across replicates. With the blank cookie dough and blank baked cookie samples, wheat
protein was the primary protein source extracted and a different protein profile was
observed for wheat proteins prior to versus after baking. This finding is consistent with
the idea that thermal processing may impact the general extractability of proteins due to
changes in structure and aggregation induced by heat during baking32. The PF-incurred
cookie dough and PF-incurred baked cookie mirrored this result.
All PF extract samples have identical banding patterns and characteristic protein
bands from peanut seeds can be observed on the gels. The protein band at approximately
65 kDa is likely the monomeric form of Ara h 1, which has an expected molecular weight
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(MW) of 64 kDa when in its monomer form33. Prior to denaturation, Ara h 1 would be a
tetramer with an estimated MW near 180 kDa33. The typical Ara h 3 acidic subunit
protein bands can be observed near 37 kDa34. This protein band doublet represents
different isoforms of the Ara h 3 acidic subunit35. The band near 20 kDa can be attributed
the basic subunit of the Ara h 3 protein34. At 15 kDa, a band that may be Ara h 6 can be
observed34.
The protein bands observed for the incurred cookie dough and baked cookie
samples indicated the presence of peanut in the extract material. This can be observed by
the 20 kDa basic subunit of Ara h 3, which is noticeably present in the incurred samples
and noticeably absent from the blank samples. This provided confidence in the extraction
of peanut protein from the incurred cookie samples.
Blank dark chocolate (0 ppm peanut protein), incurred dark chocolate (5,000 ppm
peanut protein), and PF (5,000 ppm peanut protein matrix equivalence) triplicate extracts
are shown in Figure 2.2. The blank dark chocolate extract samples indicated little protein
in the observable range for the gel. There is a faint protein band near 21 kDa, which has
been attributed to a subunit of an albumin protein in cacao36. The extract samples of the
5,000 ppm peanut protein dark chocolate and the PF extract were nearly identical in their
banding patterns which indicated probable extraction of peanut proteins from the incurred
dark chocolate material.
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Figure 2.2: SDS-PAGE for Confirmation of Protein Extraction in the Dark Chocolate
Matrix.
Blank and peanut-incurred dak chocolate samples. M: Molecular weight markers; lanes 1-3:
replicate extracts of 0 ppm peanut protein in dark chocolate; lanes 4-6: replicate extracts of
5,000 ppm peanut protein in dark chocolate; lanes 7-0: replicate extracts of PF (5,000 ppm
peanut protein matrix equivalence).

b. Extraction: PF Extraction Optimization
An optimization of the PF extraction was completed in order to evaluate the
extraction efficiency and variability of four different extraction concentrations. An
overestimation of protein by 2D-Quantification for the PF extraction (15 mg PF/30 mL
buffer) which equated to an extraction efficiency of 119.00% prompted this optimization
analysis.
The average extraction efficiency was calculated for each of the four extraction
types: 15 mg/ 30 mL (136.45%), 60 mg/30 mL (63.96%), 250 mg/10 mL (66.22%), and
500 mg/10 mL (64.34%). The 15 mg PF/30 mL buffer extraction was again found to have
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overestimated protein with a 136.45% extraction efficiency. In evaluating the variation
between extracts for these sample types, the standard deviation (SD) of the extraction
efficiency was 20.78% (15 mg PF/30 mL buffer), 2.77% (60 mg PF/30 mL buffer),
4.17% (250 mg PF/10 mL buffer), and 2.80% (500 mg/10 mL buffer). As the extraction
increased from 15 mg PF/30 mL buffer to 60 mg PF/30 mL buffer, the variability
decreased. A further increase of the extraction concentration, as with 250 mg PF/10 mL
buffer to 500 mg PF/10 mL did not appear to decrease the variability any less than that
observed with the 60 mg PF/30 mL buffer samples. The larger sample size for PF may
have overcome issues with the heterogeneity of the flour sample or resulted in an
improved accuracy in weighing of the material.
The untargeted MS experiment for the cookie matrix was completed prior to this
optimization and therefore has a PF extraction of 15 mg PF/30 mL buffer, whereas the
dark chocolate untargeted MS experiment was completed following this optimization and
utilized the 60 mg PF/30 mL buffer extraction concentration with a proportionately
scaled up resuspension volume to account for the final concentration prior to injection for
MS.
c. Extraction: 2D-Quantification
Quantification of the soluble protein in sample extracts was completed to
determine the protein concentration of extracts to evaluate extraction efficiency and to
inform trypsin digestion. Extraction efficiencies were determined from the theoretical
protein content of the sample type (Table 2.7).
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Table 2.7: Quantification of Soluble Protein in Cookie, Dark Chocolate, and PF Extracts
Average Measured
Protein
Concentration
(ug protein/uL)

Theoretical
Protein
Concentration
(ug protein/uL)

Extraction
Efficiency
(%)

Cookie Dough (5,185.96 ppm
peanut protein)

0.868

2.617

33.18

Baked Cookie (6,206.93 ppm
peanut protein)

0.665

3.132

21.25

Dark Chocolate (5,000 ppm
peanut protein)

0.544

2.55

21.34

PF (15 mg/ 30 mL buffer)*

0.296

0.249

119.00

PF (60 mg/ 30 mL buffer)

0.762

1.00

76.16

(N=6, *N=8).

The results of the protein quantification confirmed some degree of protein
extraction for all matrices and samples evaluated. A higher extraction efficiency was
observed for the incurred cookie dough (33.18%) when compared to the incurred baked
cookie (21.25%). This result indicated proteins may have endured structural changes or
aggregation during the baking process which impacted their ability to be extracted.
Others have shown a general decrease in protein extractability in wheat matrices after
baking32, 37. Both incurred matrices had similar extraction efficiencies, at approximately
only 20% of the theoretical protein in the matrices, which suggested an effect of either
matrix components or processing of the matrix on the extractability of proteins. It also
indicated the poor solubility of gluten proteins in aqueous conditions.
d. Peptide Identification
Results from the data analysis of the untargeted MS runs against the peanut
database, as genereated for the PEAKS Summary Report, are shown in Table 2.8.
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Table 2.8: Untargeted MS Results, PEAKS Summary Report for Cookie and Dark Chocolate
Analyses Against Peanut Protein Database
Cookie Matrix

Dark Chocolate Matrix

# of MS Scans

296,235

231,201

# of MS/MS Scans

300,614

109,479

2,898

2,453

Peptide Sequences

115

217

Proteins

27

26

FDR (PSM)

1.0%

1.4%

FDR (Peptide Sequences)

10.4%

10.6%

FDR (Protein)

17.4%

18.2%

de novo Only Spectra

25,932

11,090

PSMs

PSM: peptide spectrum match
FDR: false discovery rate

e. Quantification of Peptides
LFQ was completed for the cookie and dark chocolate datasets separately as a
semi-quantitative analysis of peptides within each dataset. In the cookie dataset, the most
apparent difference in relative allergen abundances was between the PF samples (no
matrix) and the cookie dough and baked cookie matrices (Figure 2.3). The matrix
samples had a decrease in relative peanut protein detected by the instrument compared to
the peanut protein detected in the no matrix PF samples. This indicated an effect of the
matrix on the detection of peanut protein using MS methodologies. There are a number of
effects that could contribute to this decrease in recovery of peanut protein. One
explanation is the change in protein structure or aggregation of protein in the matrix and
the thermal processing of the matrix. These changes in protein structure may impact the
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ability of the buffer to effectively extract these proteins from the matrix samples.

Figure 2.3: Relative Abundance of Major Peanut Allergens in the Incurred Cookie Matrix as
Determined by LFQ
Quantification of peanut proteins based on LFQ results for cookie dough and baked cookie
(5,185.96 and 6,206.03 ppm peanut protein), as well as PF (5,000 ppm peanut protein matrix
equivalence). Average relative allergen abundances determined using the peak areas of the top
three most abundant peptides from each protein. N= 9 ± SEM.

Next, the overall abundance of proteins in the baked cookie appeared to be greater
than that in the cookie dough. It is important to note that the peanut protein that is
contributing greatly to the relative allergen abundance graph is the multiple isoform
groups of Ara h 3, primarily Ara h 3.04/05/10/13/17/20 and Ara h 3.07/16. This observed
effect may be an effect of the matrix or its processing but may also be an effect of the
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varying peanut concentrations between the dough (5,185.96 ppm peanut protein) and the
baked cookie (6,206.93 ppm peanut protein) due to water loss. Additionally, the observed
effect in the LFQ may be due to both the concentration change, as well as the matrix and
processing effects. With respect to the processing effects, one factor that may be
contributing to this observed effect is the change in protein structure after baking reduced
the extraction of other non-Ara h 3 proteins and thus, promoted the preferential extraction
of Ara h 3 isoforms. Peptides from Ara h 1, 2, 6, and 7 were also detected and the
quantification of these proteins was completed. However, their relative abundance is
much less in comparison to Ara h 3. This was an expected result, as Ara h 3 makes up
over 70% of the protein in a peanut seed38. Additionally, it can be observed that the Ara h
2 quantity decreased in its detection between the cookie dough and baked cookie.
Because Ara h 2 is known to be heat stable, the decrease suggested chemical
modifications during baking or a change in its extractability after baking, highlighting the
possibility of its change in structure or possible aggregation after thermal processing39.
For the dark chocolate matrix, a similar trend between non-matrix PF samples and
the incurred matrix material can be observed as was noted for the cookie matrix (Figure
2.4). The dark chocolate matrix also had a decreased relative quantity of proteins
compared to the PF. Again, this suggested an effect of the matrix on the detection of
peanut proteins by MS. An additional similarity between the dark chocolate and the
cookie matrix is the dominance of Ara h 3 and its isoform groups in the relative allergen
quantitation. The majority of peanut protein detected in each the dark chocolate, cookie,
and PF samples originated from Ara h 3 isoforms. Ara h 1 appears to differ in its
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abundance between the dark chocolate samples and the PF samples. Ara h 1 recorded a
greater abundance in the dark chocolate material, compared to the PF alone, which is
unexpected due to the heat lability of Ara h 1 and the moderate thermal processing of
dark chocolate production40. However, this could have been an artifact of the relative
quantification approach or a result of the decrease of Ara h 3 in the dark chocolate,
allowing for greater Ara h 1 detection by the instrument.

Figure 2.4: Relative Abundance of Major Peanut Allergens in the Incurred Dark Chocolate
Matrix as Determined by LFQ
Quantification of peanut proteins based on LFQ results for cookie dough and baked cookie
(5,000 ppm peanut protein), as well as PF (5,000 ppm peanut protein matrix equivalence).
Average relative allergen abundances determined using the peak areas of the top three most
abundant peptides from each protein. N= 9 ± SEM.
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vi.

Selection of Candidate Target Peptides in Incurred Cookie
The goal of exclusion and selection steps was to identify a subset of the peanut

peptides identified in untargeted MS which indicated the potential to be quality targets in
a targeted MS method. A summary of peptide exclusion for peptides in the cookie matrix
is shown in Table 2.9.
Table 2.9: Candidate Target Peptide Tracking Through Selection Criteria: Cookie Matrix
# of Target Peptides
# of Target Peptides
Elimination Criteria:
Eliminated
Remaining
Initial LFQ Data
88
Detections in Blank Matrix

13

75

Variable PTMs

7

68

28

40

32

36

7 (dough)
3 (baked)

33

10% Recovery in Dough vs. PF and Top
60% Overall Abundance (Dough)
10% Recovery in Dough vs. PF and Top
60% Overall Abundance (Baked)
Qualification in Dough and Baked Matrices
Other Elimination
Peptides Deemed “Candidate Target
Peptides”
LFQ: label-free quantification
PTM: post-translational modification

3

30
30 peptides
32 targets

The removal of any peptides that had positive detections in more than one
replicate of the blank cookie dough or baked cookie samples (0 ppm peanut protein) was
completed because the mass events may have been wheat peptides mis-detected as peanut
peptides or peanut peptides that possess too similar of mass-to-charge ratios (m/z) to
wheat peptides to have high specificity to peanut in matrix. Peptides with the variable
modifications outlined (hydroxyprolination and oxidation of methionine) were removed
for the purposes of sensitivity and precision. If a peptide contains a variable modification,
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a certain proportion of its abundance is modified while the inverse proportion does not
contain the modification. This cuts the overall abundance of that target peptide and
creates, in theory, a less sensitive target. If the modification occurs inconsistently, the
quantitative precision will also be impacted.
Next, peptides were subjected to the two selection criteria outlined to determine
candidate target peptides (recovery ratio > 0.1 and top 60% abundance), examples shown
in Figure 2.5. This figure displays peptides from Ara h 2 and Ara h 3, though all peptides
which persisted through exclusion steps were subjected to the selection criteria.

Figure 2.5: Selection Criteria for Abundance and Recovery in Matrix Applied to Peanut
Peptides Identified in the Cookie Matrix
Abundance (top 60%) and ratio (>0.1) selection criteria applied to peptides from a) Ara h 2 or
b) Ara h 3 for both the baked cookie and cookie dough incurred matrices (5,185.96 and
6,206.93 ppm peanut protein). Peptides meeting both criteria fell in the upper right hand
quadrant created by the dotted lines representing selection criteria. N= 9 ± SEM.

Peptides from Ara h 2 (a 2S albumin) in the incurred cookie dough appeared to
have greater abundances and were less affected by the matrix than the baked cookie, as
indicated by the higher recovery ratios observed. This suggested Ara h 2 extraction from
the baked cookie is decreased due to the thermal processing of the matrix. For peptides
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form Ara h 3, a cupin, it appeared that the relative abundances and ratios of peptides were
slightly greater in the baked cookie than the same measures for the cookie dough. This
may be that due to the structural and aggregation changes of proteins induced by thermal
processing, thus cupins are preferentially extracted and/or digested compared to other
proteins after processing, which caused the greater abundance observed.
Of the 32 targets that were deemed candidate target peptides, 21 of the candidates
originate from Ara h 3. This is an expected result, as Ara h 3 is the most abundant protein
in a peanut seed38. Three candidate targets were selected from Ara h 1, the next most
abundant protein in peanut38. From Ara h 2, four candidate targets were selected and from
Ara h 6, only one target peptide was selected. Additionally, three candidate targets were
selected that originate from Ara h 7, a very minor peanut protein with respect to
abundance at approximately 0.04 -0.015% of peanut protein41. There were more factors
than simply abundance that affect the abundance and recovery of these candidate target
peptides in the incurred matrices, as selection does not solely follow abundance trends.
This suggests an effect of the matrix or of matrix processing in the accessibility and
extractability of peanut proteins.
vii.

Selection of Candidate Target Peptides in Incurred Dark Chocolate
The strategy for the selection of candidate target peptides in the incurred dark

chocolate mirrored that of the cookie matrix and is summarized in Table 2.10.
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Table 2.10: Candidate Target Peptide Tracking Through Selection Criteria: Dark Chocolate
Matrix
# of
# of unique
unique
Elimination Criteria:
peptides
peptides
remaining
eliminated
Initial LFQ Data
145
Detections in Blank Matrix

16

129

Variable PTMs

20
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10% Recovery in Dough vs. PF and Top 60% Overall Abundance

50

59

Other Elimination

0

59

Peptides Deemed “Candidate Target Peptides”

59 peptides
67 targets

LFQ: label-free quantification
PTM: post-translational modification

Two examples of selection criteria applied to peptides from the untargeted MS
dataset for the dark chocolate are shown in Figure 2.6. Though all peptides were
subjected to selection criteria, the figure displays peptides from Ara h 2 and Ara h 3 as
examples.

Figure 2.6: Selection Criteria for Abundance and Recovery in Matrix Applied to Peanut
Peptides identified in the Dark Chocolate Matrix.
Abundance (top 60%) and ratio (>0.1) selection criteria applied to peptides from a) Ara h 2 or
b) Ara h 3 for the incurred dark chocolate matrix (5,000 ppm peanut protein). Peptides
meeting both criteria fell in the upper right hand quadrant created by the dotted lines
representing selection criteria. N= 9 ± SEM.
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Of the 67 candidate targets, a similar proportion of the targets are from Ara h 3 as
were selected in the incurred cookie matrix. For the incurred dark chocolate, 49 of the 67
candidates were selected from Ara h 3 (for cookie, 21 of the 32 candidates were from Ara
h 3). The large number of targets selected from Ara h 3 was presumably an effect of the
sheer abundance of this protein in peanut. The next greatest number of candidates, 12,
were from Ara h 1. Ara h 2 and Ara h 6 each contributed three candidate targets in this
selection step. While three candidate targets were selected from Ara h 7 for the cookie
matrix, zero targets from this protein qualified as candidate target peptides in the dark
chocolate matrix. Therefore, there may be some effect of the dark chocolate matrix on the
accessibility and extractability of Ara h 7 in the matrix.
viii.

Targeted MS Filtration of Candidate Target Peptides in Cookie
a. Round 1

In the first run of Round 1 for filtration of candidate target peptides by targeted
MS, the number of target peptides included in the PRM method was 32, all selected
candidate target peptides. After analysis of the 5,000 ppm peanut protein sample of PF,
the selection of the most abundant charge state for two peptide sequences was completed,
thus removing two targets. Additionally, seven target peptides were not detected in these
PRM rounds. These target peptides were not eliminated, but a broad scheduling window
of either five or six minutes was used in the subsequent PRM run. For all other target
peptides, the retention time as observed in the first iteration of Round 1 was used to
create a two minute scheduling window for the second iteration of Round 1. In the second
run of Round 1, there were 29 target peptides detected of the 30 included. The peptide
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that was not detected was eliminated because the lack of detection at such a high
concentration of PF indicated that this target peptide would not be a sensitive target
peptide in the final method.
b. Round 2
Round 2 of PRM filtration was completed with 29 target peptides in the method’s
inclusion list. Filtration criteria for this round of PRM required that target peptides have
at least three product ions, manually determined in Skyline, detected at a concentration
lower than 5,000 ppm PF and chromatograms with appropriate peak shape. This caused
the elimination of five target peptides inclusion list.
c. Round 3
In Round 3, 24 target peptides were analyzed. Four peptides were eliminated due
to non-linear dilution curves. An example of a non-linear dilution curve compared to an
ideal linear dilution curve is shown in Figure 2.7. A disproportionate change in the sum
of the peak area with respect to the concentration of peanut or PF in a sample indicated
that these peptides would be poor quality targets if included in a quantitative MS method.
A quality target for a quantitative method has a linear response to the amount of peanut
present in the analyzed sample. Therefore, peptides with non-linear dilution curves were
not considered for inclusion in the method due to their lack of quantitative robustness.
Additionally, six peptides were removed due to their lack of sensitivity in detection in the
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analyzed samples. In total, Round 3 of PRM filtration resulted in the elimination of 10
target peptides.

Figure 2.7: Representative Examples of Nonlinear and Linear Dilution Curves from Round 3
of PRM Filtration in the Cookie Matrix.
Dilution curves for a) NAMFVPHYTLNAHTIVVALNGR, a peptide from Ara h 3 (3.7/16)
and b) ELMNLPQQCNFR, a peptide from Ara h 6 (6.1/2) constructed from Round 3 of PRM
filtration of targets for the cookie matrix. Analyzed concentrations include 10,000, 5,000,
2,500, 1,000, 500, 100, 50, and 10 ppm PF in matrix. N=2, ± SD.

d. Round 4
Of the 15 target peptides analyzed in this round of PRM filtration, five were
eliminated following data analysis. Four peptides had dilution curves with non-linear
responses to the change in peanut concentration of the sample and lacked sensitivity. One
peptide had a linear dilution curve but did not have ample sensitivity for inclusion in the
quantitative method.
e. Round 5
In this round of PRM filtration, there were 10 target peptides in the inclusion list.
Two peptides were removed due to their lack of sensitivity in both the PF and baked
cookie sample types. One peptide (WLGLSAEYGNLYR) was eliminated from the
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method due the ratio of its peak area in the baked cookie compared to the PF. The
difference between the sum of the peak area in the baked cookie and in the PF was so
large that this peptide would not be a quality peptide in the final method considering
calibration to PF. For a representative peptide in Round 5 of PRM filtration, the ratio of
peak area in the baked cookie to PF was between 1.0 and 2.0. Whereas the ratios for
WLGLSAEYGNLYR ranged from 3.4-17.4. The large discrepancy between the response
in the baked cookie and the response in the PF indicated that calibration to PF for this
peptide would lead to inaccurate quantification in the final method. As a result, this
peptide was eliminated from the list of potential target peptides.
f. Round 6
Seven target peptides were analyzed in Round 6 of PRM filtration. Additionally,
the blank cookie dough and baked cookie (0 ppm peanut protein) were evaluated using
the method to verify that the peptides in the method were specific to peanut and confirm
no issue of cross reactivity or misdetection of the method’s peptides in a cookie matrix.
Results indicated that the remaining peptides were specific to peanut as they did not have
any detections that would meet final method detection criteria for the forthcoming
quantitative MS method in the blank matrices.
Second, the peanut-containing samples (PF and baked cookie) were analyzed for
each of the seven target peptides. The sensitivity of these peptides was evaluated, and it
was determined that one peptide was less sensitive than the other six target peptides. The
lowest concentration of detection for ADFYNPAAGR was 25 ppm PF in the baked
cookie sample. The other six peptides were detected at 10 ppm PF in the baked cookie
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and therefore were more sensitive. Thus, the ADFYNPAAGR peptide was removed from
the list. The result was six target peptides that demonstrated sensitivity and robustness in
the cookie matrix. Dilution curves for all seven peptides evaluated in Round 6 of PRM
filtration are shown in Figure 2.8.

Figure 2.8: Dilution Curves for the Seven Peptides Analyzed in Round 6 of PRM Filtration in
the Cookie Matrix.
Dilution curves for a) NLPQQCGLR (Ara h 2.1/2) b) SSNPDIYNPQAGSLR (Ara h 3.7/16)
c) RPFYSNAPQEIFIQQGR (Ara h 3.4/5/10/13/17/20) d) QQPEENACQFQR (Ara h
3.4/5/10/13/17/20)e) FNLAGNHEQEFLR (Ara h 3.4/5/10/13/17/20) f) TANDLNLLILR (Ara
h 3.4/5/10) g) ADFYNPAAGR (Ara h 3.1/11) from Round 6 of PRM filtration. Analyzed
concentrations include 100, 50, 25, 10, and 1 ppm PF in matrix. N=2, ± SD.
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The dilution curves, shown in Figure 2.7, from Round 6 of PRM filtration
presented a unique increase in the sum of the peak area for the cookie matrix sample
compared to the PF sample. This observed trend was only true for peptides from the Ara
h 3 protein in peanut. The peptide from Ara h 2 (NLPQQCGLR) did not show this trend.
This indicated that this effect may be a result of the behavior of the protein prior to or
during the digestion of the protein into peptides. Perhaps the extraction of certain proteins
is decreased in the cookie matrix, which preferentially extracts the proteins of Ara h 3.
This may explain why there was an observed increase in the peak are of all peptides from
Ara h 3 in the cookie matrix compared to the PF alone. Additionally, dilution curves
indicated that six of the seven peptides perform both sensitively and linearly in the PF
and baked cookie matrix.
g. Filtration Results
After six rounds of iterative PRM experiments, six target peptides demonstrated
ample sensitivity and robustness in the PF samples and in the baked cookie matrix. Table
2.11 shows the narrowing of the candidate target peptide list over the course of PRM
filtration. Peptides that persisted through all rounds of PRM filtration were deemed final
target peptides.
Of the six final target peptides, only one is from a protein that is not Ara h 3. One
peptide, NLPQQCGLR is from Ara h 2 (Ara h 2.1/2). Five peptides are from isoforms of
the Ara h 3 protein: SSNPDIYNPQAGSLR (Ara h 3.7/16), RPFYSNAPQEIFIQQGR
(Ara h 3.4/5/10/13/17/20), QQPEENACQFQR (Ara h 3.4/5/10/13/17/20),
FNLAGNHEQEFLR (Ara h 3.4/5/10/13/17/20), and TANDLNLLILR (Ara h 3.4/5/10).
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It was expected to obtain final target peptides that were from Ara h 3, due to the
abundance of this protein in peanut. However, the experimental approach to filtration by
PRM confirmed, empirically, the efficacy of these final target peptides in the cookie
matrix.
Table 2.11: Lowest Concentration of Detection and Elimination of Target Peptides by PRM
Round for the Cookie Matrix
Round Round Round Round Round Round
Peptide Sequence
1
2
3
4
5
6
(PF) (Cookie) (Cookie) (Cookie) (Cookie) (Cookie)
C(+57.02)QSQLER

5000

X

X

X

X

X

YQQQQGSRPHYR

5000

5000

500

250

X

X

AHVQVVDSNGNR

5000

X

X

X

X

X

AHVQVVDSDGNR

5000

X

X

X

X

X

QFQNLQNHR

10000

5000

1000

750

X

X

QGGEENEC(+57.02)QFQR

5000

5000

1000

X

X

X

X

X

X

X

X

X

QQPEENAC(+57.02)QFQR

1000

500

100

50

50

10

NLPQQC(+57.02)GLR

5000

5000

500

250

10

10

WGPAEPR

5000

5000

2500

X

X

X

ANLRPC(+57.02)EQHLMQK

10000

5000

1000

500

X

X

NLPQNC(+57.02)GFR

5000

5000

1000

X

X

X

ADFYNPAAGR

5000

5000

500

500

50

25

C(+57.02)C(+57.02)NELNEFENNQR

5000

5000

500

500

100

X

SSNPDIYNPQAGSLR

500

10

10

10

10

10

FYLAGNPEEEHPETQQQQPQTR

5000

5000

500

750

X

X

FNLAGNHEQEFLR

100

500

50

50

10

10

ELMNLPQQC(+57.02)NFR

5000

5000

500

750

X

X

RPFYSNAPQEIFIQQGR

100

100

10

50

1

10

WLGLSAEYGNLYR

100

500

10

50

50

X

TVNELDLPILNR

5000

5000

500

250

100

X

NAMFVPHYTLNAHTIVVALNGR

5000

5000

500

X

X

X

GIPADVLINAFGLR [+2]

5000

5000

2500

X

X

X

ANLRPC(+57.02)EEHIR
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GIPADVLINAFGLR [+3]

X

X

X

X

X

X

TANDLNLLILR

100

500

50

100

10

10

C(+57.02)MC(+57.02)QALQQILQNQSFR

5000

5000

500

X

X

X

X

X

X

X

X

X

5000

5000

500

X

X

X

IPSGFISYILNR

100

5000

1000

X

X

X

TDSRPSIANLAGENSFIDNLPEEVVANS
YGLPR

100

10000

X

X

X

X

SVNELDLPILGWLGLSAQHGTLYR

100

5000

10

X

X

X

QGHLLAIPAGVPYWSFNYGNEPIVAITL
LDTSNLDNQLDPSPR

5000

X

X

X

X

X

GYFGLIFPGC(+57.02)PSTYEEPAQQGR
[+2]
GYFGLIFPGC(+57.02)PSTYEEPAQQGR
[+3]

X = peptide not detected or eliminated from method

ix.

Targeted MS Filtration of Candidate Target Peptides in Dark Chocolate

a. Round 1
All 67 candidate target peptides included in the targeted MS method for dark
chocolate were detected in the 10,000 ppm PF sample analyzed for Round 1. In the
inclusion lists used for this round, there were eight peptides which had more than one
charge state. The most abundant charge state for six of the eight peptides were discerned.
This resulted in the removal of six potential target peptides from the list. For all peptides
remaining in the method, a four minute scheduling window was created and added to the
method based on the retention time observed in this round. The scheduling of the
peptides was used in subsequent rounds of PRM and refined to a two minute window in
subsequent work.
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b. Round 2
Round 2 of PRM filtration assessed 61 peptides in PF and the dark chocolate
matrix. In the inclusion list used for this round, there were two peptides that had two
different charge states analyzed. The least abundant charge states for each of these two
peptides were removed. Six potential target peptides were eliminated for lack of detection
at the high peanut concentration level. After Round 2, there remained 53 potential target
peptides.
c. Round 3
Batching of target peptides into two inclusion lists was used for Round 3 for the
purpose of reducing the possibility of co-eluting targets. In Round 3 of PRM, 21 target
peptides were eliminated from the list either due to poor sensitivity or nonlinear
calibration curves, which left 32 target peptides for consideration.
d. Round 4
Round 4 prompted the elimination of 17 total target peptides from the method.
Based on dilution curves, three peptides were eliminated from the method due to their
nonlinear response to the amount of peanut protein present in the sample. An example of
a peptide with a nonlinear dilution curve compared to a peptide with a linear dilution
curve is shown in Figure 2.9.
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Figure 2.9: Representative Examples of Nonlinear and Linear Dilution Curves from Round 4
of PRM Filtration in the Dark Chocolate Matrix.
Dilution curves for a) SQSENFEYVAFK, a peptide from Ara h 3 (3.10/13/17/18/20) and b)
FFVPPSEQSLR, a peptide from Ara h 3 (3.17/20) constructed from Round 4 of PRM
filtration of targets for the dark chocolate matrix. Analyzed concentrations included 500, 250,
100, 50, 10, and 1 ppm PF in matrix. N=2, ± SD.

The dilution curve for SQSENFEYVAFK suggests a nonlinear relationship
between the concentration of peanut in the PF sample and the detection of the peptide by
MS, therefore this target was of poor quality. Second, 14 potential target peptides were
removed from the method based on their lowest detected concentration in this round of
filtration and indication of a lack of ample sensitivity.
e. Round 5
15 potential target peptides were analyzed in Round 5. Evaluation of the 0 ppm
peanut protein dark chocolate by the method indicated appropriate specificity of the
peptides to peanut. From analysis of the incurred dark chocolate and the PF samples,
eight total peptides were eliminated, one for lack of a linear dilution curve. For this
peptide (DQSSYLQGFSR), a nonlinear response at lower concentrations of PF was
observed. This effect indicated this target would be of poor quality in the final method, as
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the decrease in peanut protein does not produce a proportionate decrease in the sum of
the peak area for the peptide. Additionally, seven peptides were eliminated because they
had poor sensitivity in the PF and dark chocolate. The result was seven target peptides
deemed to be the most robust and sensitive in the dark chocolate matrix per the iterative
PRM approach used to filter candidate target peptides (Figure 2.10).

Figure 2.10: Dilution Curves for the Seven Peptides Analyzed in Round 5 of PRM Filtration
in the Dark Chocolate Matrix.
Dilution curves for a) NNPFYFPSR (Ara h 1.1/2) b) NLPQQCGLR (Ara h 2.1/2) c)
TANDLNLLILR (Ara h 3.4/5/10) d) TANELNLLILR (Ara h 3.13/17/20) e)
RPFYSNAPQEIFIQQGR (Ara h 3.4/5/10/13/17/20) f) SPDIYNPQAGSLK (Ara h
3.4/5/10/13/17/20) and g) SSNPDIYNPQAGSLR (Ara h 3.7/16) from Round 5 of PRM
filtration. Analyzed concentrations include , 250, 100, 50, 10, 5, and 1 ppm PF in matrix.
N=2, ± SD.

120
For most of the peptides, the dilution curves showed a similar response between
the dark chocolate matrix and the PF samples. However, for some peptides,
NLPQQCGLR, SSNPDIYNPQAGSLR, and to some extent RPFYSNAPQEIFIQQGR,
the dark chocolate samples have reduced peak area compared to the PF samples. For
NLPQQCGLR (Ara h 2.1/2), there is greater detection in the PF sample than the dark
chocolate. This may be due to the effect of the dark chocolate matrix in that the
extractability of Ara h 2 proteins is impaired by the matrix, suggesting an influence of the
matrix affect, not necessarily thermal processing as Ara h 2 is relatively heat stable39.
SSNPDIYNPQAGSLR, from the variable isoforms of Ara h 3 (Ara h 3.7/16) shows a
similar trend, though to a lesser extent than the NLPQQCGLR peptide.
f. Filtration Results
After five rounds of iterative PRM filtration, seven target peptides were
experimentally determined to be the most robust and sensitive target peptides of those
identified in untargeted MS and selected as candidate target peptides. Table 2.12 shows
the narrowing of the candidate target peptide list over the course of filtration. Peptides
which persisted through all rounds of PRM filtration were deemed final target peptides.
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Table 2.12: Lowest Concentration of Detection and Elimination of Target Peptides by PRM
Round for the Dark Chocolate Matrix
Round Round
Round
Round
Round
1
2
3
4
5
Peptide (m/z)
(PF) (Chocolate) (Chocolate) (Chocolate) (Chocolate)
AGFLTALNTPNLPVLQYVQLGVDR
5000
10000
X
X
X
AGQEEENEGGNIFSGFTPEFLAQAFQV
5000
2500
10000
X
X
DDR
AGQEEENEGGNIFSGFTPEFLEQAFQV
5000
10000
X
X
X
DDR
AGQEQENEGGNIFSGFTPEFLAQAFQ
5000
2500
10000
X
X
VDDR
AGQEQENEGGNIFSGFTSEFLAQAFQ
5000
10000
X
X
X
VDDR
AHVQVVDSDGNR
X
10000
X
X
X
AHVQVVDSNGNR

10000

1000

1000

X

X

AQSENYEYLAFK
C(+57.02)C(+57.02)NELNEFENNQR
[+2]
C(+57.02)C(+57.02)NELNEFENNQR
[+3]
C(+57.02)DLDVSGGR

10000

1000

500

250

X

10000

1000

500

250

X

10000

1000

X

X

X

10000

1000

1000

X

X

DQSSYLQGFSR

10000

1000

50

50

50

EGALMLPHFNSK

10000

1000

500

X

X

EGEQEWGTPGSEVR

10000

5000

500

X

X

EGEQEWGTPGSHVR

10000

1000

100

250

X

FFVPPFQQSPR

10000

1000

100

50

50

FFVPPSEQSLR

10000

1000

100

50

100

FFVPPSQQSLR

10000

1000

50

50

50

FFVPPSQQSPR

10000

1000

50

100

100

FHLAGNQEQEFLR

10000

1000

50

100

250

FNLAGNHEQEFLR

10000

1000

50

50

100

GENESDEQGAIVTVR

10000

1000

500

500

X

GENESEEEGAIVTVR [+2]

10000

1000

500

X

X

GENESEEEGAIVTVR [+3]

10000

X

X

X

X

GIPADVLINAFGLR [+2]

10000

5000

1000

X

X

GIPADVLINAFGLR [+3]

10000

X

X

X

X
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GTGNLELVAVR

10000

1000

50

100

100

10000

5000

2500

X

X

10000

1000

500

250

X

IMGEQEQYDSYDIR

10000

5000

500

X

X

IPSGFISYILNR

10000

1000

500

X

X

IQVVNSQGNAVFNGVLR [+2]

10000

X

X

X

X

IQVVNSQGNAVFNGVLR [+3]

10000

5000

1000

X

X

ISMPVNTPGQFEDFFPASSR

10000

5000

1000

X

X

ISSANSLTFPILR

10000

1000

500

250

X

IVQIEAKPNTLVLPK

10000

1000

500

X

X

LNAQRPDNR

10000

X

X

X

X

NAMFVPHYTLNAHTIVVALNGR [+3]

10000

X

X

X

X

NAMFVPHYTLNAHTIVVALNGR [+4]

10000

5000

2500

X

X

NLPQQC(+57.02)GLR

10000

1000

50

50

50

NNPFYFPSR

1000

1000

10

50

10

QIVQNLR

1000

5000

500

X

X

QMVQQFK

1000

1000

X

X

X

RPFYSNAPQEIFIQQGR

1000

1000

500

50

50

SFNLDEGHALR

1000

1000

50

250

X

SPDIYNPQAGSLK

1000

1000

10

10

10

SQSDNFEYVAFK

1000

1000

100

100

X

SQSENFEYVAFK

1000

1000

100

250

X

SSNPDIYNPQAGSLR
SVNELDLPILGWLGLSAQHGTLYR
[+3]
SVNELDLPILGWLGLSAQHGTLYR
[+4]

1000

1000

50

100

50

1000

1000

500

X

X

1000

X

X

X

X

TANDLNLLILR

1000

1000

10

10

10

TANELNLLILR
TDSRPSIANLAGENSFIDNLPEEVVAN
SYGLPR [+3]
TDSRPSIANLAGENSFIDNLPEEVVAN
SYGLPR [+4]

1000

1000

50

50

50

1000

5000

2500

X

X

1000

5000

X

X

X

IESEGGYIETWNPNNQEFQC(+57.02)A
GVALSR
ILNPDEEDESSR
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TDSRPSIANLAGENSIIDNLPEEVVANS
YGLPR [+3]
TDSRPSIANLAGENSIIDNLPEEVVANS
YGLPR [+4]
TDSRPSIANLAGENSIIDNLPEEVVANS
YR
TDSRPSIANLAGENSVIDNLPEEVVAN
SYGLPR
TVNELDLPILNR

1000

5000

2500

X

X

1000

X

X

X

X

1000

5000

2500

X

X

1000

5000

2500

X

X

1000

1000

500

500

X

VFDEELQEGHVLVVPQNFAVAGK

1000

X

X

X

X

VLLEENAGGEQEER

1000

5000

500

250

X

VYDEELQEGHVLVVPQNFAVAAK

1000

1000

1000

X

X

VYDEELQEGHVLVVPQNFAVAGK

1000

5000

500

X

X

WFQLSAEHVLLYR

1000

5000

1000

X

X

WGPAEPR

1000

1000

100

250

X

1000

100

250

X

WLGLSAEYGNLYR

1000
X = Peptide not detected or eliminated from method.

There were seven final target peptides determined for the dark chocolate matrix.
Five of the seven peptides are from isoforms of the Ara h 3 protein: TANDLNLLILR
(3.4/5/10), TANELNLLILR (3.13/17/20), RPFYSNAPQEIFIQQGR (3.4/5/10/13/17/20),
SPDIYNPQAGSLK (3.4/5/10/13/17/20), and SSNPDIYNPQAGSLR (3.7/16). There was
one final target peptide from each, Ara h 1 and Ara h 2. These final target peptides were
NNPFYFPSR from Ara h 1 (1.1/2) and NLPQQCGLR Ara h 2 (2.1/2). It was expected to
observe a large number of target peptides from the most abundant protein in peanut, Ara
h 3. Additionally, the peptides not from Ara h 3 were from the second and third most
abundant protein in peanut (Ara h 1 and Ara h 2). However, abundance was likely not the
only factor contributing to the efficacy of target peptides since final peptides originated
from multiple proteins and many peptides from Ara h 3 were filtered out during the
iterative PRM approach. Secondly, the complex matrix and possible matrix interactions
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appeared to have affected peptide recovery in analyzing the dark chocolate material
compared to PF, as the lowest detected concentration for a peptide varied across sample
types which indicated some effect of matrix components or matrix processing.
x.

Comparison of Filtered Targets for Cookie and Dark Chocolate
The final peptides determined after PRM filtration in the cookie matrix (six) were

compared to the final peptides determined for the dark chocolate matrix (seven). For the
two matrices, there were four peptides which were determined to be sensitive and robust
in both the cookie and the dark chocolate (NLPQQCGLR, SSNPDIYNPQAGSL,
RPFSNAPQEIFIQQGR, and TANDLNLLILR). This result indicated potential
extensibility of the subsequent MS method as the target selection approach was applied to
two compositionally different matrices and four peptides were determined as quality
targets in both. There were two final peptides that were unique to the cookie matrix (both
from Ara h 3) and three peptides that were unique to the dark chocolate matrix (one from
Ara h 1 and two from Ara h 3). Though selected through a specific matrix filtration
approach, all final target peptides were combined into one for the subsequent MS
method. The result was a list of nine unique peanut target peptides. The final nine target
peptides and the lowest detected peanut concentration for each sample type in the final
round of PRM filtration are shown in Table 2.13.
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Table 2.13: Lowest Detected Concentration for Filtered Peptides Matrix in ppm PF
Cookie
Peptide

Cookie
and Dark
Chocolate

Unique to
Cookie

Unique to
Dark
Chocolate

Protein and
Isoforms

PF

Dark Chocolate

Cookie
Matrix

PF

Dark
Chocolate
Matrix

NLPQQCGLR

Ara h 2.1/2

10

10

5

50

SSNPDIYNPQAGSLR

Ara h 3.7/16

10

10

50

50

RPFYSNAPQEIFIQQGR

Ara h 3.4/5/10
/13/17/20

1

10

50

50

TANDLNLLILR

Ara h 3.4/5/10

10

10

50

10

QQPEENACQFQR

Ara h 3.4/5/10
/13/17/20

25

10

FNLAGNHEQEFLR

Ara h 3.4/5/10
/13/17/20

25

10

NNPFYFPSR

Ara h 1.1/2

10

10

TANELNLLILR

Ara h 3.13/17
/20

50

50

SPDIYNPQAGSLK

Ara h 3.4/5/10
/13/17/20

10

10

The final nine target peptides that resulted from this work’s target selection and
filtration approach originate from three different peanut proteins (Ara h 1, Ara h 2, and
Ara h 3). Ara h 1 and Ara h 2 are each targeted by one target peptide. The remaining
seven target peptides target Ara h 3 and its many isoforms. The variable isoforms of Ara
h 3 (Ara h 3.7/13/16) are covered by one target peptide included in the final list35. For all
six peptides selected for the cookie matrix, sensitivity in the matrix was promising with
detections at 10 ppm PF in post-digestion dilutions of the incurred cookie. In the dark
chocolate, the three of the seven final target peptides indicated comparable sensitivity at
10 ppm PF, while the other four have recorded lowest levels of concentration at 50 ppm
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PF in matrix. As the final target peptides indicated robustness in the matrix and moderate
sensitivity in their detection, it appeared that the target selection and filtration was
preliminarily successful.
The majority of these final target peptides have been frequently included in other
published MS peanut detection methods. Many of these target peptides have been
selected for inclusion in MS methods from both in silico trypsin digestion approaches and
discovery-based target selection approaches. NNPFYFPSR (Ara h 1.1/2) has been
identified as a target peptide in several methods that targeted incurred or spiked
matrices12, 28, 42-45. Other peptides that are commonly used to target Ara h 1 are
DLAFPGSGEQVEK and IFLAGDKDNVIDQIEK, though these peptides were not
selected as candidate target peptides after untargeted MS for this method44, 46-50.
NLPQQCGLR (Ara h 2.1/2) is a commonly used target peptide for the 2S albumin, Ara h
2, in incurred and complex matrices18, 19, 21, 43, 47, 51, 52.
With respect to Ara h 3 peptides, there are three peptides determined as final
target peptides for this method that are commonly targeted in other MS peanuts. These
three peptides RPFYSNAPQEIFIQQGR (Ara h 3.4/5/10/13/17/20), FNLAGNHEQEFLR
(Ara h 3.4/5/10/13/17/20), and SPDIYNPQAGSLK (Ara h 3.4/5/10/13/17/20) are
frequently used in peanut protein detection methods12, 18, 20, 21, 42, 43, 48, 51-59. Two peptides
with similar sequences that originate from different isoforms of Ara h 3
(TANDLNLLILR and TANELNLLILR) have been included in some targeted MS peanut
detection methods. TANDLNLLILR (Ara h 3.4/5/10) has been referenced in peanut
detection methods in various matrices55, 60, 61. TANELNLLILR (Ara h 3.13/17/20) has
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been included in some methods used to analyze incurred or spiked chocolate and other
spiked matrices like jam and mayonnaise18, 61.
The QQPEENACQFQR (Ara h 3.4/5/10/13/17/20) peptide was found less
commonly in the literature but was included in a method that investigated incurred
chocolate desserts and chocolate bars47. Last, SSNPDIYNPQAGSLR (Ara h 3.7/16) is a
peptide not often included in quantitative MS peanut detection methods. Though not
generally used quantitatively for targeted peanut MS methods, probably due to its
variability across cultivars, it has been detected and reported by untargeted MS35, 61, 62.
One study reports using it for quantitation in an untargeted MS analysis35. This peptide
was not found using Allergen Peptide Browser, a resource that reports target peptides
included in published SRM/MRM methods26.
V. SUMMARY
PF-incurred cookie and dark chocolate matrices were generated for analysis by
proteomic techniques for the development of an MS-based quantitative peanut protein
detection method. Peanut-incurred cookie matrices were generated at 0, 0.63, 1.24, 6.21,
62.08, and 6,206.93 ppm peanut protein after water loss calculations and protein content
of the PF was considered. The peanut-incurred dark chocolate matrix was manufactured
in the pilot plant of a prominent chocolate manufacturer at levels including 0, 2, 20, 100,
5,000 ppm peanut protein in dark chocolate.
Untargeted proteomics techniques were used to analyze the incurred materials for
the selection of candidate peanut peptides for a targeted MS method. Selection criteria
allowed for the determination of 32 candidate target peptides in the cookie matrix and 67
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in the dark chocolate matrix. Iterative rounds of PRM were used to empirically filter the
candidate target peptides down to a number of robust and sensitive target peptides in each
matrix. This resulted in six final target peptides for the cookie and seven in the dark
chocolate. Combination of the final target peptides list indicated nine unique peanut
peptides which have all demonstrated sensitivity and robustness in the complex,
processed matrices analyzed. Many of these identified peptides have been utilized in
other published MS-based peanut detection methods.
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CHAPTER III: QUANTITATIVE MS METHOD DEVELOPMENT,
OPTIMIZATION, AND EVALUATION OF PEANUT-INCURRED COOKIE AND
DARK CHOCOLATE MATRICES
I. ABSTRACT
Peanut allergy, an IgE-mediated hypersensitivity to peanut protein, is estimated to
effect approximately 2% of individuals in the United States (US)1, 2. Peanut-allergic
individuals can react to as little as 0.2 mg of peanut protein, and the elicited reaction is
associated with particularly severe reactions3, 4. To protect allergic consumers, US
mandates plain-language labeling of food products to which commonly allergenic foods,
including peanut, have been intentionally added5. Thus, for the food industry, the ability
to detect peanut protein in food products is imperative to comply with labeling
requirements and to monitor the unintentional presence of peanuts in food products.
Often, this detection is based on immunochemical means, though these methods have
demonstrated poor recovery and quantification of peanut in processed and complex food
matrices, such as cookie and dark chocolate6, 7. Mass spectrometry (MS) has been used to
overcome the deficits of immunoassays for the detection of peanut in these matrices, but
these methods struggle with incurred matrices or sufficiently sensitive detection to
protect peanut-allergic individuals8-10.
In previous work, nine target peptides were identified as sensitive and robust in
their detection in peanut-incurred cookie and dark chocolate matrices using targeted MS.
A quantitative strategy was developed using stable isotope labeled (SIL) target peptides
and an external calibration with peanut flour (PF) materials to report sample
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concentration in ppm peanut protein. Method sensitivity was improved through a number
of optimizations including extraction, calibrant preparation, large-scale digestion,
chromatography, and instrument parameters. To protect the most sensitive peanut-allergic
individuals, the method sought to detect peanut at concentrations less than 2 ppm peanut
protein in the cookie and 4 ppm peanut protein in the dark chocolate4, 11. After
optimization, the method was successful in detecting incurred matrices at 1.24 ppm
peanut protein in cookie and 2 ppm peanut protein in dark chocolate. Recovery of peanut
protein was generally high for the low concentration of peanut in cookie matrix (1.24
ppm peanut protein, 270.62 - 456.81%), but reasonable for the higher incurred level (6.21
ppm peanut protein, 42.43 - 117.81% recovery). For the dark chocolate incurred matrices,
recoveries were generally acceptable for the 2 ppm peanut protein level (124.08 -2
88.02% recovery) and the 20 ppm peanut protein level (44.40 - 103.07% recovery). The
method, however, reported high variability in the value for the quantification of peanut
protein. In this work, a quantitative LC-MS/MS method for peanut was developed using
nine target peptides to achieve a method performance which is both highly sensitive and
generally robust in its detection and quantification of peanut in cookie and dark chocolate
matrices.
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II. INTRODUCTION
Food allergy has been increasing in prevalence over recent decades and has
become a prominent food safety concern for many stakeholders12, 13. The prevalence of
specifically IgE-mediated peanut allergy has also increased over recent decades and is
considered to affect approximately 2% of individuals in the US1, 2, 14. To protect allergic
consumers, the US has regulated the labeling of the presence of commonly allergenic
foods, known as the “Big Eight,” which includes peanut5, 15. In order to comply with
regulation and to protect consumers, the food industry utilizes a number of food allergen
detection methods to detect the unintended presence of food allergens in food products, to
inform labeling decisions, and to advise risk management. Enzyme-linked
immunosorbent assays (ELISA) are the most commonly used detection method but have
demonstrated deficiencies in recovery of target proteins when analyzing processed food
matrices16. Further, undeclared peanut in commercially available cookie and dark
products has been observed and the inaccuracy of ELISA detection methods in
quantifying the contamination of peanut has been demonstrated6, 7, 16. This is likely the
result of matrix components or processing effects on the target analyte. Mass
spectrometry (MS) is emerging as an alternative or orthogonal detection method as it
detects mass-to-charge (m/z) values of peptides to indicate the presence of an allergenic
food source and therefore does not need to preserve the conformation of the protein as
with ELISAs17. MS methods for peanut detection in cookie and dark chocolate matrices
have been developed, but a greater sensitivity for detection and quantification is needed
to protect allergic consumers8-10.
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A vital component of a quantitative MS method is the peptides targeted by the
method. In the previous chapter, nine target peptides that were empirically determined to
be robust and sensitive for MS detection of peanut in incurred food matrices were
identified. These nine target peptides originated from three major peanut allergens
including, Ara h 1, Ara h 2, and Ara h 3. Target peptides were determined using
untargeted MS analysis of incurred matrices, followed by selection of candidate target
peptides that were then iteratively filtered to a number of robust and sensitive peptides
using targeted MS.
After identification of these nine target peptides, the quantitative aspects of the
method can be established. Further, optimization of the quantitative method can be
pursued in order to increase the method sensitivity to achieve the desired method
performance. Lastly, the developed and optimized MS method can be evaluated against
the incurred cookie and incurred dark chocolate matrices, as described in Chapter 2,
containing various concentrations of peanut.
The development of a quantitative MS method relies on the quantification
strategy, as it must consider how the peak areas of a target peptides are translated into
concentrations of the analyte in the tested sample. There are several quantification
strategies utilized by MS methods for allergen quantification. One approach achieves
absolute quantification using a known amount of stable isotope labeled (SIL) peptides in
the sample and then utilizes the ratio of the signal for the analyte peptide to the SIL
peptide’s signal (light-to-heavy ratio) to determine a molar amount of the target peptide18.
SIL peptides act as an internal standard. This quantification can be very specific and
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sensitive, however often requires optimization of many steps and is not applicable when
the allergenic source is unknown18. An external calibration strategy is another approach
to quantification that can be utilized for MS methods and even for other detection
methods19. In this approach, standard samples containing the analyte or the analyte itself
can be analyzed at various concentrations to create a calibration standard curve19. Using
the calibration curve, interpolation of the analyte signal can be used to determine analyte
concentration20.
For the method presented in this work, the approach to quantification is based on
both internal standards using SIL peptides and a calibration to the allergen source
material, peanut flour (PF). The strategy of using both standards and SIL peptides has
been used for other MS methods such as that by Planque et.al20. SIL peptides for each of
the nine target peptides were added to samples (both matrix samples and PF calibrant
samples) at known concentrations and the light-to-heavy ratio was determined. Using the
light-to-heavy ratio and a calibration curve formed from the PF calibrant samples, a
concentration of peanut contamination in a test sample was determined.
The desired method performance for the targeted MS method that this work
sought to develop was established using risk assessment principles. Ideally, the MS
method would be able to detect and quantify the presence of peanut protein at 2 ppm
peanut protein in cookie and 4 ppm peanut protein in dark chocolate. This needed method
performance is based on the Voluntary Incidental Trace Allergen Labeling (VITAL)
reference dose for peanut, 0.2 mg peanut protein, which is the amount of peanut that
would elicit a reaction in the most sensitive 1% of peanut-allergic individuals if
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consumed in one eating occasion4. This determination utilizes an overestimation of the
median intake amount of a cookie in the US at one eating occasion which is 36.0 g, by
using a 100 g intake of cookie amount to maximize food safety11. For an individual to
receive 0.2 mg of peanut protein in 100 g of cookie, the concentration of peanut protein
would have to be 2 ppm peanut protein. The same calculation can be completed for dark
chocolate, of which the median intake is 31.2 g11. Using an overestimation of the intake
amount of 50 g dark chocolate, the concentration of peanut protein equated to 4 ppm
peanut protein in order for an individual to consume the reference dose of peanut protein
in one eating occasion. Thus, to protect the majority (99%) of peanut-allergic consumers,
the needed method performance is detection and quantification of peanut protein at or
below the 2 and 4 ppm peanut protein concentrations in cookie and dark chocolate,
respectively.
To achieve the desired method sensitivity, several optimization strategies were
evaluated for their impact on the concentration of peanut which the method could detect.
A number of optimization approaches were employed, including chromatographical
refinements, instrument parameter improvements, sample preparation additions,
increased peptide concentrations, and optimized extraction concentrations.
III. MATERIALS AND METHODS
A targeted MS method for the detection and quantification of peanut protein in
processed food matrices was developed based on nine target peptides that were
determined to be sensitive and robust in Chapter 2. Sample preparation for MS analysis
mirrored that used in the experiments used in Chapter 2 to select and filter candidate
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target peptides. All materials and solvents used were identical to those listed in Chapter 2,
unless otherwise noted. A summary of the materials and protocols used to prepare
samples for MS is provided in Table 3.1.
Table 3.1: Overview of Methods Used for Sample Preparation for MS Analysis
Sample
Procedural Description
Procedure Details
Preparation
Cookie matrices were ground using a food
processor prior to extraction. Dark chocolate
Approximately 100 g of
Grinding
matrices were ground manually using a spatula.
each matrix ground and
PF materials were fine in particle size and were
stored at -20 °C.
not ground.
Extractions at 1:20 w/v were completed using a
6M Urea, 2M Thiourea, 20 mM DL-dithiothreitol 0.500 g of matrix/ 10 mL
Extraction (DTT), and 50 mM Tris-hydrochloride (Tris-HCl)
buffer
buffer. Extraction utilized 60 °C shaking water
0.060 g of PF/ 30 mL buffer
bath incubation, sonication, and centrifugation.
Protein digestion was completed using trypsin
protease and ABC for buffering. DTT was used to 105 µL of sample extracts
reduce disulfide bonds at 95 °C for five minutes. digested with 150 µL of 50
Alkylation was completed using IAA and a 20mM ABC, 15 µL of 100 mM
Digestion
minute dark incubation. Trypsin digestion was
DTT, alkylated with 30 µL
completed for one hour at 37 °C, followed by
IAA, and digested with 20
additional trypsin and overnight incubation at 30
µL of 100 ng/uL trypsin
°C.
Desalting was completed using large capacity
Desalting
columns (Strata™-X 33 um Polymeric Reversed 320 µL of samples desalted
Phase (10 mg/1 mL).
Desalted samples were lyophilized in a vacuum
100 µL resuspension volume
Lyophilization concentrator. Resuspension of peptides was
for matrices
and
completed using 5% ACN/0.1% FA and SIL
400 µL resuspension volume
Resuspension peptides. SIL peptides were included at a
for PF
concentration to accomplish a 100 fmol load.
Peptide separation was completed using a Dionex
UltiMate 3000 UHPLC+ system for liquid
chromatography and a Hypersil GOLD™ Dim.
LC
15 µL injection volume
(mm) 20x2.1 (Part No 25002-101030) column at
35 °C (Thermo Scientific). Method shown in
Figure 3.1.
Thermo Scientific™ Q Exactive™ Plus hybrid
quadrapole-Orbitrap™ mass spectrometer was
15 µL of sample analyzed
MS/MS
used with instrument parameters described
with 100 fmol SIL peptide
previously, set for PRM.
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The chromatography used for this targeted method was developed and optimized
for the nine target peptides selected for the method, shown in Figure 3.1.

Figure 3.1: Chromatography Gradient Used for Peptide Separation Prior to Targeted MS
The %ACN gradient used to elute target peptides before analysis by MS/MS. The
chromatography method was developed after determination of the nine target peptides that
were included in the method. The elution gradient occurs between 10 - 35% ACN. Further
optimization of this chromatography occurred in later method optimization stages.

The targeted MS method developed was a total of 22 minutes in duration,
including LC separation. This method had a parallel reaction monitoring (PRM) run time
from 1 to 10 minutes in the method, with the remainder of the gradient used for column
washing and re-equilibration. The instrument was set in positive ion mode and utilized a
resolution of 35,000, an automatic gain control (AGC) target of 1e6, and a maximum
injection time of 500 ms. A loop count of 1 was utilized to accommodate using an
inclusion list for PRM. The inclusion list contained m/z values for the nine target
peptides and the nine stable isotope labeled (SIL) target peptides. A scan window within
the inclusion list was used to schedule the PRM scan and the window was 2 minutes
wide. An isolation window of 0.8 m/z was used and no isolation no offset was utilized. A
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normalized collision energy (NCE) of 27 was used. Peptide details used for the inclusion
list for this targeted MS method are shown in Table 3.2. This method for targeted MS
was used for the duration of method optimization experiments, except when method
parameters or sample preparation procedures were changed for improvement of the
method, as noted for individual experiments.
Table 3.2: Light and Heavy Peptide Inclusion Lists for PRM
Target
Type

Mass (m/z)

Charge
(z)

Start
(min)

End (min)

NLPQQ[C]GL[R]

Heavy

548.2838

2

3.30

5.30

NLPQQ[C]GLR

Light

543.2797

2

3.30

5.30

SSNPDIYNPQAGSL[R]

Heavy

814.8988

2

4.40

6.40

SSNPDIYNPQAGSLR

Light

809.8946

2

4.40

6.40

RPFYSNAPQEIFIQQG[R]

Heavy

687.6895

3

6.00

8.00

RPFYSNAPQEIFIQQGR

Light

684.3534

3

6.00

8.00

TANDLNLLIL[R]

Heavy

633.3762

2

7.90

9.90

TANDLNLLILR

Light

628.3721

2

6.00

8.00

QQPEENA[C]QFQ[R]

Heavy

772.8429

2

2.90

4.90

QQPEENA[C]QFQR

Light

767.8388

2

2.90

4.90

FNLAGNHEQEFL[R]

Heavy

528.9313

3

5.50

7.50

FNLAGNHEQEFLR

Light

525.5952

3

5.50

7.50

NNPFYFPS[R]

Heavy

576.2790

2

6.10

8.10

NNPFYFPSR

Light

571.2749

2

6.10

8.10

TANELNLLIL[R]

Heavy

640.3840

2

8.10

10.10

TANELNLLILR

Light

635.3799

2

8.10

10.10

SPDIYNPQAGSL[K]

Heavy

699.3612

2

4.40

6.40

SPDIYNPQAGSLK

Light

695.3541

2

4.40

6.40

Peptide
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Spectra obtained from PRM experiments were imported into Skyline Software
from the University of Washington, MacCoss Lab for data analysis21. The sum of the
peak area for the top three product ions for each peptide was taken manually, until
product ions were permanently established for the quantitative method. The sum of the
peak areas was used to determine the light-to-heavy ratio, which was used as the primary
quantitative value for samples until the final quantification strategy was adopted in the
quantitative method evaluation. The final quantification strategy utilized calibration
techniques within Skyline software22.
i.

Method Development: Stable Isotope Labeled Peptides
HeavyPeptide™ AQUA Basic stable isotope labeled (SIL) versions of the nine

target peptides were obtained from Thermo Scientific™. The SIL target peptide
sequences and molecular weights (MW) provided by the manufacturer are shown in
Table 3.3. The three SIL peptides (QQPEENA[C]QFQ[R], FNLAGNHEQEFL[R], and
TANELNLLIL[R]), which had not previously been utilized in the group’s methods, were
evaluated for any light peptide contamination using direct infusion MS.
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Table 3.3: Calculated and Experimental MW of SIL Peptides as Provided by Manufacturer
Calculated
Experimental
Peptide
Protein
Isoforms
MW (Da)
MW (Da)
NLPQQ[C]GL[R]

Ara h 2

2.1/2

1094.55

1095.17

SSNPDIYNPQAGSL[R]

Ara h 3

3.7/16

1627.78

1628.65

RPFYSNAPQEIFIQQG[R]

Ara h 3

3.4/5/10/13/17/20

2060.05

2061.21

TANDLNLLIL[R]

Ara h 3

3.4/5/10

1264.74

1265.4

QQPEENA[C]QFQ[R]

Ara h 3

3.4/5/10/13/17/20

1544.65

1545.5

FNLAGNHEQEFL[R]

Ara h 3

3.4/5/10/13/17/20

1584.73

1585.38

NNPFYFPS[R]

Ara h 1

1.1/2

1150.54

1151.17

TANELNLLIL[R]

Ara h 3

3.13/17/20

1279.52

1279.43

SPDIYNPQAGSL[K]

Ara h 3

3.4/5/10/13/17/20

1396.71

1397.46

Lyophilized SIL peptides were resuspended using 50% ACN to achieve a
concentration of 10 pmol SIL peptide/uL. An equimolar mix of the nine SIL peptides was
created to obtain a solution of 500 fmol of each SIL peptide/ µL in 50% ACN. The
equimolar mix of SIL peptides was stored at -20 °C prior to use. Prior to analysis by MS,
the equimolar mix was diluted to an appropriate SIL concentration in 5% ACN and 0.1%
FA that would yield the desired molar amount for each SIL peptide per LC-MS/MS
injection of 15 µL.
The optimal molar amount of SIL peptide for each injection was determined
empirically. Six loading amounts including, 50, 100, 150, 200, 250, and 500 fmol of each
SIL peptide in a 15 µL injection were evaluated for their signal quality and variation
across injections. One loading amount was selected for continued use throughout the
method development and method optimization stages.
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ii.

Method Optimization of Instrument Parameters: Automatic Gain
Control (AGC) and Injection Time (IT)

Initial evaluation of SIL peptides by the method indicated issues with variability,
as observed through large %CVs of peak areas, between injections and samples. In
attempt to mitigate the large variation of SIL peptide responses observed, two instrument
parameters were optimized. The parameters optimized were the AGC target value and the
maximum IT value. The original AGC target was set at 1e6, and the maximum IT was set
at 500 ms. An AGC target of 5e5 and an IT of 50 ms were tested in these analyses. Five
injections (15 µL) from an equimolar mix at 6.667 fmol SIL/ µL in 5% ACN/0.1 % FA
were analyzed (100 fmol on column) for each combination of these two instrument
parameters (AGC = 1e6 with IT = 500 ms, AGC = 1e6 with IT = 50 ms, AGC = 5e5 with
IT = 500 ms, and AGC = 5e5 with IT = 50 ms). The sum of the peak area for the top
three product ions was evaluated for each injection and the average peak area, standard
deviation, and %CV were determined for each combination of instrument parameters.
The variability between injection replicates was considered through a weighted ranking
system to select the least variable combination of instrument parameters to use for further
optimization of the method.

iii.

Method Evaluation: Stability of SIL Equimolar Mix

The stability of the equimolar mix of SIL peptides over time was evaluated. An
equimolar mix that had been stored at -20 °C for two weeks was compared to an
equimolar mix which was prepared on the same day of analysis by LC-MS/MS. Both
equimolar mixes were prepared according to identical protocols to achieve an SIL
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concentration of 500 fmol/uL in 50% ACN and then were further diluted to various SIL
concentrations to yield 1, 10, 25, and 50 fmol SIL on column with a 15 µL injection in
5% ACN/0.1% FA. Triplicate injections of each equimolar mix at each SIL concentration
were evaluated by LC-MS/MS. The method used to analyze these sample sets utilized an
AGC target of 1e6 and an IT of 50 ms, as previously optimized. For each peptide, the
sum of the peak area for the top three product ions was compared across the two
equimolar mixes, the stored equimolar mix and the freshly prepared equimolar mix, to
determine if there were any effects of the storage over time on the signal intensity or
signal variability of the peptides. The %CV was also evaluated across injection replicates.
iv.

Preliminary Evaluation of Method on Incurred Matrices
To investigate the efficacy of the targeted MS method in its detection of peanut

protein in processed food matrices, the method was used to analyze the peanut-incurred
cookie and peanut-incurred dark chocolate matrices, as described in Chapter 2. The PF
used was light roast (12% fat) from the Golden Peanut and Tree Nuts Company. Incurred
cookie, dark chocolate, and PF samples were prepared for MS analysis according to the
protocol outlined previously, with two extraction replicates (Table 3. 1). Following
resuspension, samples were diluted to various PF concentrations using a solution of 5%
ACN/0.1% FA with 6.667 SIL peptide/uL to yield 100 fmol SIL peptide on column with
a 15 µL injection. The concentrations analyzed included 0.5, 1, 5, 10, 20, 50, 100, 500,
and 1,000 ppm PF. These samples were evaluated in triplicate against the targeted MS
method to gauge the sensitivity of the method through detection limits of target peptides.
Detection criteria, at this stage in method development, required that three of three pre-
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determined product ions were detected in the sample and appropriate peak shape as
determined using visual assessment of chromatograms. The lowest concentration of PF
detected was compared across sample types to discern the sensitivity of the method at this
stage of optimization.
v.

Optimization of Instrument Parameters: Injection Time (IT)
To address deficits in method sensitivity, the IT was reconsidered with respect to

suggested method parameters for the MS instrument utilized. For the resolution used for
this targeted MS method (35,000), the recommended IT is 110 ms, though previous
optimization attempts for IT informed the decision of setting the IT at 50 ms28. The same
samples as were evaluated in the preliminary evaluation of the targeted method in
incurred matrices with an IT of 50 ms were analyzed for this experiment, but with an IT
of 110 ms. Matrix and PF samples were diluted to various concentrations of PF, including
0.5, 1, 5, 10, 20, 50, 100, 500, and 1,000 ppm PF prior to injection (15 µL). Samples were
resuspended with 5% ACN/ 0.1% FA and 6.667 fmol SIL peptide/uL to yield 100 fmol of
SIL peptide for each injection. The light-to-heavy ratio for each sample was compared
between analyses that utilized the 50 ms and 110 ms for IT. The IT which yielded the
greatest signal response, based on the light-to-heavy ratios, for most peptides and samples
was selected for continued use throughout.
vi.

Method Optimization: Addition of Background Protein
After observation of high variability in both the light and the heavy target

peptides, further method optimization of the sample preparation protocol was pursued.
The principle tested in this analysis was the inclusion of additional non-target protein into

149
the dilutions of samples prior to analysis by MS to reduce non-specific binding of the
analyte to reduce the hypothesized loss of peptide to plasticware.
Single extracts from the incurred cookie and incurred dark chocolate matrix
samples, triplicate extracts of the respective blank matrices, duplicate extracts of PF, and
duplicate extracts of instant non-fat dry milk (NFDM) (Nestle® Carnation) were
completed. Sample preparation for MS analysis was completed as previously described,
except for the generation of the dilution series after peptide resuspension. After samples
were resuspended with the appropriate volume of 5% ACN/0.1% FA with 6.667 fmol
SIL peptide/ µL, the dilutions were created using resuspended blank matrix samples (for
the cookie and the dark chocolate) or with resuspended NFDM samples (for the PF).
Samples were diluted with the background protein samples to levels including 1, 10, 100,
and 1,000 ppm PF prior to analysis by MS. To control this experiment, samples were also
diluted to the respective PF concentrations using the resuspension buffer (5% ACN/ 0.1%
FA with 6.667 fmol SIL peptide/ µL). 15 µL of the sample was injected in triplicate for
LC-MS/MS. After data analysis using Skyline to determine the sum of the peak area for
the top three product ions, dilution curves were constructed to compare the sensitivity of
the samples using the background matrix dilution and samples which were resuspended
with only buffer. The lowest detected concentration for each sample and resuspension
type was recorded and the %CV was evaluated for each peptide, resuspension type, and
concentration of PF. The resuspension strategy which provided the least amount of
variability, as measured by %CV, and greatest sensitivity was selected for the method.
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vii.

Method Optimization: Chromatographic Refinements
Optimization of the chromatography gradient used for LC prior to MS/MS was

completed in order to achieve greater separation of target peptides prior to MS analysis
and to improve peak characteristics, such as points (scans) across the peak. Two
chromatography gradients were designed and evaluated against the chromatography that
had been used for all previous quantitative method development and optimization
included in this chapter. The three tested chromatography gradients each had varying
slopes for the peptide elution gradient, which ranged from 1.09% ACN/min to 3.13%
ACN/min. Reducing the slope of the elution gradient, in principle, was thought to
increase the separation by time of peptides with similar chemical characteristics.
Chromatography gradients, with respect to % ACN, are shown in Figure 3.2.

Figure 3.2: Three Chromatography Gradients as Evaluated for Method Optimization
The three versions (V) of chromatography that were analyzed against two concentrations of
PF to determine any effect on peak area responses or points across the peak. The respective
ACN gradients for the methods are 3.13% ACN/min (V1), 1.92% ACN/ min (V2), and 1.08%
ACN/min (V3).
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Testing of the chromatography gradients was completed on PF samples diluted to
100 and 1,000 ppm PF in solutions containing 5% ACN/ 0.1% FA with 6.667 SIL
peptide/ µL. The sum of the peak area for the top three product ions for each peptide in
each chromatography method was compared. Points across chromatogram peaks were
recorded and an optimal chromatography method was selected for subsequent LCMS/MS analyses. At this point in method optimization, the top three product ions that
would be used to determine the sum of the peak area were permanently established for
each peptide. The product ions selected are shown in Table 3.4. Furthermore, a spectral
library created from an untargeted MS analysis of PF (Chapter 2) was added to Skyline.
The spectral library allowed comparison of collected spectra to reference spectra to
increase detection confidence through library dotp values.
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Table 3.4: Target Peptides, Product Ions Selected for Quantification, and Scheduling Window
for the Final Method
Charge
Product Ions for
Start
End
Peptide (Abbreviation) Mass (m/z)
(z)
Quantification
(min)
(min)
P [y7] - 858.4250+
NLPQQ[C]GLR
543.2797
2
Q [y5] - 633.3137+
3.60
5.60
(NLP)
P [y7] - 429.7162++
Y [y9] - 1005.5112+
SSNPDIYNPQAGSLR
809.8946
2
N [y8] - 842.4479+
6.40
8.40
(SSN)
P [y7] - 728.4050+
F [y6] - 748.4100+
RPFYSNAPQEIFIQQGR
684.3534
3
I [y5] - 601.3416+
11.20
13.20
(RPF)
A [b7] - 836.4050+
N [y9] - 1083.6521+
TANDLNLLILR
628.3721
2
N [y6] - 741.4981+
15.70
17.70
(TAND)
A [b2] - 173.0921+
P [y10] - 1278.5532+
QQPEENA[C]QFQR
767.8388
2
P [y10] - 639.7802++
3.00
5.00
(QQP)
Q [b2] - 257.1244+
A [y10] - 600.7914++
FNLAGNHEQEFLR
525.5952
3
H [y7] - 479.7407
9.50
11.50
(FNL)
N [b2] - 262.1186+
F [y6] - 816.4039+
NNPFYFPSR
571.2749
2
Y [y5] - 669.3355+
10.40
12.40
(NNP)
F [y4] - 506.2722+
N [y9] - 1097.6677+
TANELNLLILR
635.3799
2
L [y7] - 854.5822+
16.30
18.30
(TANE)
N [y6] - 741.4981+
Y [y9] - 977.5051+
SPDIYNPQAGSLK
695.3541
2
P [y7] - 700.3988+
6.40
8.40
(SPD)
D [b3] - 300.1190+

viii.

Method Optimization: Improving Sample Preparation

Further optimization of sample preparation techniques was employed in order to
increase method sensitivity and decrease variation in peptide quantification by the
method. There were three additions to sample preparation which were evaluated against
the control sample preparation (REG). A hexane defatting (HD) of the sample materials
prior to extraction, an acetone precipitation (AP) of extracts, and a filter-aided sample
preparation (FASP) alongside protein digestion were completed. For HD, samples (0.100
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g PF, 0.800 g cookie, and 0.800 g dark chocolate) were defatted with 1.4 mL of hexane
(HPLC Grade, Fisher Chemical) three successive times. Following evaporation of
hexane, samples were weighed to determine the percent fat lost during HD. The
corresponding amount of HD sample was extracted with a mass adjustment to account for
the effect of fat loss on mass. The protocol for AP was based off that used by Chen et. al,
2015, with modifications23. AP was completed through a two-hour precipitation of
extracts using 49.95% acetone/ 49.95% ethanol/ 0.1% FA at -20 °C. Following protein
precipitation, samples were washed using 100% acetone and 75% ethanol. Samples were
dried and subsequently resuspended to the extract volume for digestion. FASP protocol
utilized Amicon® Ultra 0.5 mL centrifugal filters (Millipore Sigma) and a streamlined
protocol, adapted from a method for proteomic use outlined by Wisniewski and utilized
by Ramachandran, et al24, 25. For FASP, reduction and alkylation for digestion was
completed as normal and the sample was transferred to the spin filter for 15 min
centrifugation at 14,0000 x g at RT. 1 mL of 1M urea and 50 mM ABC were added to the
filter, followed by 20 µL of 100 ng/uL trypsin. Spin filters where then covered with
parafilm to reduce evaporation loss and samples were digested overnight at 37 °C. The
control sample preparation (REG) was completed as described previously for this
method. Two extraction replicates of each sample type (cookie, dark chocolate, and PF)
and of each procedural type (HD, AP, FASP, and REG) were completed. Following
resuspension using 5% ACN/ 0.1% FA with 6.667 fmol SIL peptide/ µL, samples were
diluted using the previously optimized dilution with NFDM digest samples, to various
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concentrations of PF, including 1, 10, 50, and 100 ppm PF. Samples were injected (15
µL) in duplicate.
ix.

Method Optimization: Addressing Method Sensitivity
The primary goal of the final method was the detection and quantification of low

levels of peanut contamination in cookie and dark chocolate matrices. Based on observed
lowest concentrations of peanut detected for several peptides in both the matrices and the
PF calibrant, even after selection of AP of extracts prior to digestion, further optimization
of sample preparation parameters was required. One approach to increase the sensitivity
of the method in detecting target peptides at low concentrations is to increase the final
peptide concentration prior to injection for LC-MS/MS. In addition to the volume
changes made in Chapter 2, a large-scale sample preparation protocol was created with
adjustments, primarily at the digestion stage, to increase the peptide amount loaded on
column. Table 3.5 shows the volume adjustments made to increase the final concentration
of peptide in MS samples to, in theory, increase method sensitivity. Additionally, an
extraction of 1.00 g matrix in 20 mL buffer was used (1:20 w/v) as compared to the
previous 0.500 g matrix in 10 mL buffer (1:20 w/v). The scale up factor for the increased
large-scale sample preparation protocol was designed to achieve approximately 9.4 times
the peptide concentration prior to injection. One additional adjustment was made for the
purpose of optimization with respect to samples prepared using AP. In the previous
analysis of samples using AP, the precipitated pellet was dried and then resuspended
using water to the original extract volume. To ensure proper buffering of protein, the
resuspension of the precipitated pellet was completed using the mix of 50 mM ABC and
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100 mM DTT in 50 mM ABC to begin reduction, with volume adjustment for the
original extract volume.
Table 3.5: Scaled Up Sample Preparation Procedures Compared to the Previous Protocol
Previous
Protocol
(uL)

Scaled Up
Protocol
(uL)

Sample Volume Precipitated

105

250

Acetone Precipitated Pellet Resuspended in Water

105

0

50 mM ABC

150

1000

100 mM DTT

15

75

Water

0

0

50 mM IAA

30

150

Trypsin (100 ng/uL)

20

70

Total Digestion Volume

320

1295

Volume Desalted

320

1280

PF: 400
Matrix: 100

PF: 200
Matrix: 50

Sample Preparation Step

Digestion Mix:

Resuspension Volume

Using the increased large-scale sample protocol, duplicate extractions of the matrix
and PF samples were completed and precipitated using acetone, as previously described.
The samples proceeded through sample preparation according to Table 3.5. Resuspension
and dilutions to various PF concentrations (0.5, 1, 10, and 50 ppm PF) were completed
using resuspended NFDM digests in 5% ACN/ 0.1% FA with 6.667 fmol SIL peptide/
µL. Samples were injected (15 µL) in duplicate. Dilution curves of the light-to-heavy
ratio was constructed and the lowest concentrations for detection were evaluated for each
peptide. The expected fold change for the sum of the peak area of the top three product
ions, 9.4x, was compared to the observed fold change. Assessments for method
sensitivity using the increased large-scale sample preparation protocol were completed.
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i.

Method Optimization: Calibrant Extraction
The method sought to be quantitative using a calibration to PF material and thus,

further optimization of PF samples was investigated to minimize variability observed in
the peak area response of calibrant samples. To optimize the calibrant extraction, various
extraction concentrations were evaluated using the targeted MS method. Resuspension
volumes proportional to the sample PF concentration were used to normalize the final
peptide concentration prior to injection for MS.
The method’s PF extraction of 0.060 g PF in 30 mL buffer was included in the
analysis, as well as 0.120 g PF/30 mL buffer, 0.150 g PF/30 mL buffer, and 0.300 g
PF/30 mL buffer. Two extraction replicates were completed for each extraction
concentration. Following resuspension, dilutions of the PF samples were created to
various concentrations of PF using NFDM digests in 5% ACN/ 0.1% FA with 6.667 fmol
SIL peptide/ µL, as previously demonstrated to reduce variability. Each sample was
analyzed with duplicate injects.
x.

Quantitative Method Evaluation
To demonstrate the efficacy of the quantitative method developed in this work,

peanut-incurred cookie and peanut-incurred dark chocolate matrices were evaluated using
all optimized method protocols, instrument parameters, and final quantification strategy.
Triplicate extracts were completed for the cookies incurred with 2 ppm PF (final
concentration after baking of 2.38 ppm PF) and 10 ppm PF (final concentration of 11.91
ppm PF), and dark chocolate incurred with 4 or 40 ppm PF across two days. One set of
triplicate extracts of PF (0.150 g PF/ 30 mL buffer) was completed with each set of
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matrix samples, including cookie and dark chocolate. One day contained extraction for
the cookie matrix and PF and the second day included extractions for the dark chocolate
matrix and the PF. This entire experiment was repeated to obtain additional day-to-day
measures of the PF calibrant and to obtain initial day-to-day measures for the incurred
matrix samples. Resuspension was completed using 5% ACN/ 0.1% FA with 6.667 fmol
SIL peptide/ µL for the matrix samples. Dilutions of resuspended PF was completed
using NFDM digest samples in 5% ACN/ 0.1% FA with 6.667 fmol SIL peptide/ µL.
Triplicate injects (15 µL) of matrix samples and duplicate injects (15 µL) of PF calibrant
samples were evaluated by the instrument to yield 100 fmol of SIL peptide on column for
each sample. The optimized LC-MS/MS method was used for this analysis. The
sequences, product ions, and scheduling windows for target peptides based on optimized
chromatography is shown in Table 3.4.
For the quantitative MS method, it was necessary to formalize criteria that a
signal obtained from this method must meet in order to be objectively determined as a
detection. One inherent detection criterion is that the transition signals must be within the
scheduled retention time window. Only detections with library dotp values ≥ 0.80 were
considered. A 5.0 ppm mass error tolerance for the average mass error of measured
product ions was also used as a detection criterion. Additionally, the peptide peak found
ratio (PFR) must be equal to 1, indicating that all three product ions were observed for
each peptide. Only signals which met all formalized detection criteria were used for
quantification.
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The quantification strategy developed for this method was based on the peak area
of the light peptide divided by the peak area of the SIL peptide, which is referred to as the
light-to-heavy ratio. The peak area was determined using the top three product ions for
each peptide as noted in Table 3.4. Further, the light-to-heavy ratios were calibrated to
the PF calibrant to obtain a ppm PF concentration for the sample. This calibration to the
PF occurred within Skyline. PF samples were denoted as standards in Skyline and their
respective PF concentration was recorded in the software. The multi-point calibration
curve for the PF was constructed from PF samples with concentrations of 0.1, 0.5, 1, 5,
10, 50, and 100 ppm PF. Following the interpolation of the matrix samples to the
calibration curve, Skyline reported a value for PF concentration in ppm PF. Using the
protein content of the PF used as the calibrant material (52.1% protein as determined by
Dumas analysis), the ppm PF value was converted to a ppm peanut protein value.
For the method, there are three reported values in ppm peanut protein for the four
samples analyzed. The first reported value is the average ppm peanut protein value for a
peptide. This is the average of all quantified values for each injection completed, this is
denoted as the peptide average. Next, for each of the four matrix samples analyzed the
maximum of all nine peptide averages is reported (termed the maximum peptide
average). Lastly, to provide a conservative value for risk assessment and food safety
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purposes, the maximum extract average is also reported. An example of the reported
values for the quantitative method is shown in Figure 3.3 using a model peptide.

Maximum
Extract
Average

Peptide
Average

Maximum
Peptide
Average

Figure 3.3: Summary of Reported Values for the Quantitative Method
There are three reported values as a result of the quantification strategy and method. A) Each
quantified value for each injection is plotted (N=18), b) extract averages calculated from three
injection replicates, as shown in a), with the maximum extract average of all peptides reported
(N=3, Mean ± SD), c) the average quantified value for a peptide, a reported value (N=18,
Mean ± SD), and d) of all peptide averages the maximum quantified value is reported as the
maximum peptide average (N=18, Mean ± SD) for each peptide average value as shown in c).

A variation analysis was also completed to quantify the observed variability. For
this analysis, a number of components with possible contribution to variation were
considered, primarily method variation, extraction variation, and injection variation. In
this experiment, there are a total of 18 data points for each matrix and level analyzed.
These values were obtained in experiments across two different days, nine data points for
day one and nine data points for day two. The quantified value, the ppm peanut protein
values, were used as the data points for this variation analysis.
An overall method variation measure was calculated using the %CV of all
reported data points for a sample, including all values from both days (N=18). A within-

160
day method variation was also calculated for each day and was represented by the %CV
(N=9). Day-to-day variation of the method was determined using the %CV of the within
day overall averages (N=2). Extraction variation within each day was calculated using
the average reported values for each extract replicate and determination of the %CV
between these values (N=3). Day-to-day extraction variation was calculated using the
average reported values for each extract across both of the experiments and is displayed
as %CV (N=6). Injection variation was calculated by the %CV of values that were
injection replicates of the same sample (N=3) and a range of the injection variation
values were recorded to show the maximum and minimum %CV per sample.
IV. RESULTS AND DISCUSSION
For results and discussion, a three- or four-letter abbreviation was used to refer to
target peptides. Table 3.4 shows the abbreviation used for each peptide sequence.
i.

Method Development: Stable Isotope Labeled Peptides

The optimal molar amount of SIL peptide for each injection was determined
through analysis of six loading amounts including, 50, 100, 150, 200, 250, and 500 fmol
of each SIL peptide. The purpose of determining the optimal loading amount for SIL
peptides was to establish a molar amount for SIL peptides that is both robust in its
detection and minimally variable, as SIL peptides play a critical role in the quantitative
aspect of the method. From the top three product ions for each peptide, the sum of the
peak area was determined. The %CV of the sum of the peak areas for injection replicates
was determined (Figure 3.4).
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Figure 3.4: The %CV Between Injection Replicates for SIL Peptides at Various Loading
Amounts.
A heatmap displaying the %CV of the sum of the peak area between injections calculated for
each peptide at five SIL loading amounts including 50, 100, 150, 200, 250, and 500 fmol.
N=3.

For a majority of the SIL peptides analyzed (except for NLP and SPD) the %CV
between injection triplicates was much higher than anticipated for a standard material.
The %CV results did not indicate the expected trend, in which increasing the fmol of SIL
peptide analyzed directly decreased the variability between injections. Therefore,
selection of the highest loading amount was not necessary. RPF and FNL peptides had
particularly high %CVs, which suggested some chemical characteristics of the peptides
may be contributing to the variability in the detection of the peptide by the instrument.
One factor that may be contributing to the variable nature of the response of these
peptides is hydrophobicity. These peptides elute later in the ACN gradient, indicating a
greater hydrophobicity relative to other peptides in the method. Hydrophobicity of
peptides was thought to contribute to nonspecific binding and loss of analyte peptide.
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Grand average of hydropathicity indices (GRAVY) values for these two peptides were
found to be -0.929 (RPF) and -0.815 (FNL) using ProtParam (Expasy). GRAVY values
represent the hydrophobicity of a peptide using hydropathy values of amino acids in the
peptide26. Negative GRAVY values indicate hydrophilicity, while positive values predict
hydrophobicity26. While the GRAVY scores for these two peptides are negative
(indicating some hydrophilicity), they are more hydrophobic than some peptides included
in the method, for example QQP = -1.958. Two other variable peptides, TAND and
TANE, appear to have some hydrophobicity as well with GRAVY scores of 0.527 each.
However, hydrophobicity, as indicated by GRAVY scores, does not follow identically the
trend observed or fully explain the variability observed in this experiment.
The 100 fmol loading amount was used for subsequent analyses, except when
noted, as it demonstrated sufficient detection, comparable variability compared to other
loading amounts, and was predicted to be an appropriate level of SIL peptide for most
samples that would be analyzed for the final method. As the 100 fmol loading amount
had similar variability to other loading amounts, as demonstrated by the %CV, it still
indicated an issue in the variability of the response of most SIL peptides.
ii.

Method Optimization of Instrument Parameters: Automatic Gain
Control (AGC) and Injection Time (IT)

As previously observed, the variability of the response of SIL peptides by the
method proved to be an issue as the variability is too large for a robust quantitative
method. In order to reduce the variability observed, two instrument parameters were
investigated (AGC and IT). AGC is an instrument parameter that regulates the number of
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ions present in the Orbitrap to reduce space charge effects27. The IT parameter sets a
maximum amount of time that ions can accumulate in the ion trap before being sent the
mass analyzer. These are not independent parameters, as mass events depend on which
parameter (AGC or IT) is met first27. Since these are not independent parameters,
multiple combinations of these settings were investigated. Optimizing these parameters
was predicted to increase the points (scans) across peptide peaks which could, in theory,
decrease the variability in detection. The %CV for the sum of the peak area of the top
three product ions was determined for each peptide and method parameter combination
(Figure 3.5).

Figure 3.5: The %CV Between Injection Replicates for SIL Peptides Using Various
Instrument Parameters.
A heatmap displaying the %CV of the sum of the peak area between injections calculated for
each peptide at each SIL loading amount in fmol for different instrument parameters. AGC
targets evaluated include 1e6 and 5e5. Maximum IT values evaluated included 50 and 500 ms.
N=5.
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As the goal of this analysis was to determine which instrument settings resulted in
peptide responses with the least variability, the %CV was the primary result considered
for the selection of an optimal AGC target and IT. In observation of %CVs for peptides
and instrument parameters, there is no clear parameter setting combination which results
in the lowest variability for all peptides. There are some peptides (QQP, SSN, and NLP)
which seem to have low %CV regardless of the instrument parameter used. In general, it
seems the IT of 500 ms generally caused a greater %CV for most peptides, though it is
important to note that the two parameters tested are not independent. Overall, the effect
of the AGC target and IT varied by peptide. To objectively discern the least variable
method, a weighted point system was used to determine which parameter combination
was the least variable. The instrument parameters selected, as determined to be the least
variable for the greatest number of peptides, included the AGC target of 1e6 and a
maximum IT of 50 ms. The second least variable combination of settings was 1e6 for
AGC and 500 ms for IT. These settings (AGC = 1e6 and IT = 50 ms) would be used in
subsequent MS analyses using this targeted method, unless otherwise noted. Further
optimization of IT occurred later in method optimization steps.
iii.

Method Evaluation: Stability of SIL Equimolar Mix

An important consideration for the use of SIL peptides through an equimolar mix
is the stability of the SIL peptides over time. If an equimolar mix of SIL peptides is
stored and used in numerous quantitative analyses over time, it is important to determine
the effect of storage on the response expected from the sample. The sum of the peak area
for the top three product ions for the SIL peptide for each equimolar mix type (prepared
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same day and stored for two weeks) was calculated and is shown for three representative
peptides in Figure 3.6.

Figure 3.6: Peak Area Responses at Various SIL Peptide Loading Amounts for Stored and
New Equimolar Mixes.
The average sum of the peak area for the top three product ions for equimolar mixes prepared
on the same day of analysis or prepared and stored for two weeks prior to analysis at -20 ºC.
Dilution curves are shown for three peptides, a) NLP (Ara h 2), b) FNL (Ara h 3), c) NNP
(Ara h 1), and d) SPD (Ara h 3). Product ions used for peak area measures included NLP (y7 868.4333+, y6 - 771.3806+, y5 - 643.3220+), FNL(y6 - 831.4235+, y11 - 662.3376++, y10 605.7956++), NNP (y7 - 923.4649+, y6 - 826.4122+, y5 - 679.3438+) and SPD (y9 985.5193+, y8 - 822.4559+, y7 - 708.4130+). N=3, Mean ± SD.

Dilution curves for SIL peptide equimolar mixes indicated highly comparable
peak area responses for both the equimolar mix was prepared on the same day of analysis
and for the equimolar mix prepared and stored at -20 ºC for two weeks. For one peptide
shown, FNL, there appears to be a greater variability as apparent in the graphed SD. This
is a result which has been observed in previous experiments indicating high variability
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with late-eluting, partially hydrophobic target peptides. Overall, this result showed
relative stability of the equimolar mix at the storage concentration (500 fmol SIL peptide/
µL in 50% ACN). Further, the similar responses in peak area between new and stored
equimolar mixes provided support for the continued use of a stock equimolar mix of SIL
peptides throughout method development and for the SIL peptide dilution strategy used
to achieve the desired SIL loading amount (100 fmol). In the dilution curves, an effect is
observed in which decreasing analyte concentrations did not produce the expected linear
decrease in reported analyte signal, but instead an increase compared to the expected
point. This is observed primarily at the 1 fmol SIL peptide point on the dilution curve.
Though not satisfactory, the level of 1 fmol is only 1% of the SIL peptide loading amount
selected for the quantitative method, and thus, is not considered an issue for the
quantitative aspect of the method.
iv.

Preliminary Evaluation of Method on Incurred Matrices
A desired component of the targeted MS method is the ability to detect peanut

protein at low concentrations in food matrices, namely cookie and dark chocolate.
Therefore, analysis of post-digestion dilutions of the incurred matrices to discern the
current sensitivity of the method and its approximate detection limits for each of the nine
target peptides was completed. A representative dilution curve is shown in Figure 3.7 for
the TAND peptide.
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Figure 3.7: A Representative Dilution Curve from the Preliminary Evaluation of the Method
on Incurred Matrix Samples.
The light-to-heavy ratio for the TAND peptide (Ara h 3) in all three sample types, PF, cookie,
and dark chocolate. Analyzed concentrations included 0.5, 1, 5, 10, 20, 50, 100, 500, and
1,000 ppm PF. Product ions used for the sum of the peak area for TAND include (y9 1083.6521+, y7 - 854.5822+, y6 - 741.4981+). N= 6, Mean ± SD.

The dilution curve for the TAND peptide (Ara h 3) indicated one general trend
observed in the preliminary evaluation of the method on incurred matrices. The dilution
curve displayed comparable light-to-heavy ratio values for the PF and dark chocolate
samples, but a decrease in the light-to-heavy ratios for the cookie samples. This effect
was apparent at each of the concentrations of PF and appeared to intensify at lower
concentrations. The same trend was observed in the Ara h 1 peptide (NNP) and two Ara h
3 peptides (TANE and SPD). This suggested the cookie matrix obtained lower recoveries
of certain proteins or peptides compared to the other food matrix (dark chocolate) or no
matrix (PF). This could be attributed to the effect of the matrix components or an effect
of the processing of matrix components causing a reduction in extractability, digestibility,
or other factors for certain proteins. Three peptides (SSN, FNL, RPF) recorded very
similar light-to-heavy ratios across the three sample types, while the NLP peptide
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indicated similar matrix responses (cookie and dark chocolate) but a greater recovery in
the no matrix samples (PF). This suggested that the recovery of NLP peptide, or likely
the Ara h 2 protein, is impacted by interactions of the matrix components or its
processing.
The dilution curve in Figure 3.7 also displayed the lowest detected concentration
of PF in the three sample types to be 50 ppm PF, which was not considered sufficiently
sensitive for the needed method performance. This lowest detected concentration is one
of the most common limits for the other target peptides as well. Of analyzed
concentrations, including 0.5, 1, 5, 10, 20, 50, 100, 500, and 1,000 ppm PF, the lowest
detected PF concentration for each peptide and sample type is shown in Table 3.6.
Table 3.6: Lowest Concentrations of Detection by Peptide and Matrix (ppm PF in matrix)
from the Preliminary Evaluation of the Method on Incurred Matrices
Target Peptide

PF

Cookie

Dark Chocolate

NLPQQ[C]GLR

50

100

100

SSNPDIYNPQAGSLR

50

50

50

TANDLNLLILR

50

50

50

NNPFYFPSR

50

50

50

TANELNLLILR

50

100

50

SPDIYNPQAGSLK

100

100

50

QQPEENA[C]QFQR

500

500

1000

FNLAGNHEQEFLR

50

50

100

RPFYSNAPQEIFIQQGR

20

50

50

The lowest detected concentrations for the nine target peptides indicated a further
need for method optimization to improve the sensitivity of the method. One peptide, QQP
(Ara h 3), indicated a particular lack of sensitivity compared to the other eight peptides.
In this evaluation, the RPF peptide (Ara h 3) was the most sensitive. All peptides
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recorded lower or identical levels of detection in the PF (no matrix) compared to the
matrices (cookie and dark chocolate). This suggested, again, the effect of matrix
components or the processing of the matrix on proteins and resulting peptides targeted by
the method. Additionally, large %CVs were observed in these samples, particularly for
the SIL peptide. This issue was later addressed in method optimization through the
addition of background protein to resuspended and diluted MS samples.
Generally, most peptides reported lowest concentrations of detection at 50 or 100
ppm PF. This necessitated further method optimization to improve sensitivity because
these concentrations were not low enough to achieve the needed method performance for
this detection method. The desired method performance for this method was in the low
ppm PF range for the cookie (4 ppm PF or 2 ppm peanut protein) and dark chocolate
samples (8 ppm PF or 4 ppm peanut protein) based on calculated risk assessment
principles using the VITAL reference dose for peanut and US consumption data4, 11.
v.

Optimization of Instrument Parameters: Injection Time (IT)
Further optimization of the IT setting was pursued based on the continued

observation of high variability in target peptide responses across injection replicates.
Additionally, for the resolution utilized in this method (35,000), the recommended IT is
110 ms28. Though previous work suggested an optimal IT of 50 ms compared to 500 ms,
this investigation displayed superior peak area response in samples analyzed with an IT
of 110 ms compared to an IT of 50 ms (Figure 3.8).
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Figure 3.8: Dilution Curves of PF, Cookie, and Dark Chocolate Samples Analyzed with
an IT 110 ms vs 50 ms.
The mean light-to-heavy ratio for three representative target peptides a) NNP (Ara h 1),
b) SPD (Ara h 3), and c) RPF (Ara h 3). Product ions used for determination of the lightto-heavy ratio include NNP (y6 - 816.4039+, y5 - 669.3355+, y4 - 506.2722+), SPD (b2 185.0921+ , b3 - 300.1190+, b4 - 413.2031+), and RPF (y6 - 748.4100+, y5 - 601.3416+,
b6 - 765.3678+). N=6. Mean.

The effect of IT (110 ms or 50 ms) for NNP, SPD, and RPF peptides is
representative of the effect observed for a majority of the nine target peptides. The results
indicated an increase in the light-to-heavy ratio for samples using the longer IT time for
all sample types, including cookie, dark chocolate, and PF samples. The IT time of 110
ms likely allowed a greater number of ions to accumulate in the ion trap prior to being
sent to the mass analyzed compared to the IT time of 50 ms. This obvious effect of the IT
time indicated that IT may be providing greater control of the flow of ions than the AGC
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target which would suggest that the AGC target may not have been met prior to the IT
setting for most previously analyzed samples. The increase in the light-to-heavy ratio for
the 110 ms IT informed its use as an instrument parameter setting for subsequent analyses
using the method because it improved the detection of target peptides compared to a 50
ms IT, as was previously used.
vi.

Method Optimization: Addition of Background Protein
One observation from the preliminary evaluation of the method in analyzing

incurred matrices that prompted this method optimization procedure was the variability
of the SIL peptide and its relationship to sample (light) protein concentration. This trend
was observed for several of the SIL peptides but was considered to have a predominant
effect on five of the nine target peptides (TAND, NNP, TANE, FNL, and RPF). Two
examples of peptides which displayed the observed trend (FNL and RPF), alongside two
peptides that did not have the same effect (SPD and QQP) are shown in Figure 3.9.
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Figure 3.9: The %CV of SIL Peptides with Respect to the Light Peptide Concentration of
Samples.
The %CV for the respective SIL peptide, a) FNL, b) RPF, c) SPD, and d) QQP, plotted
against the concentration of the light sample through ppm PF in matrix. N=6.

In Figure 3.9, it can be observed that there were two main trends in the effect of
the light sample concentration on the %CV of the SIL peptide. The expected trend, as
seen in the plots for SPD and QQP, is no correlation between the light peptide
concentration the variation calculated for the SIL peptide. In a simple linear regression of
the data points in SPD and QQP plots, the slopes were considered not to be significantly
different from zero. In principle, this should occur when an SIL peptide is used as an
internal standard because its response should not be affected by different concentrations
of the target analyte. The reverse, observed with the FNL and RPF peptides, was an
apparent trend of the effect of the light concentration of the sample analyzed on the %CV
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of the SIL peptide, specifically that as the light concentration decreases, the variability of
the response of the SIL peptide increases. This trend was also observed for other lateeluting, partially hydrophobic peptides in the method. A simple linear regression for the
data sets for FNL and RPF indicated many slopes that were significantly different than
zero. The slopes for the PF (-0.04844) and dark chocolate (-0.03808) were significantly
different from zero for the FNL peptide, however the slope for the cookie (-0.03805) was
not significantly different from zero. For the RPF peptide, all slopes (PF = -0.9757,
cookie = -0.08422, and dark chocolate = -0.08880) were considered significantly
different from zero. This observed trend is not ideal for a quantitative method, as the
quantification of the target peptides is dependent on the response of the SIL peptide. It
would not be a robust method if the internal standards were impacted by the
concentration of the target analyte. Thus, further optimization was pursued in order to
address this deficit in the robustness of the method.
To combat the problematic effect of the light concentration on the variation of the
SIL peptide response, an optimization strategy of diluting samples with background
protein was employed. This approach was selected because it was hypothesized that
increasing the concentration of background peptides in the sample would allow for a
decrease in the variation of the SIL peptide, as had been previously observed. It is
important to note that the background peptide in the samples did not contain analyte or
peanut peptides. For PF, NFDM digests were used as background peptide to dilute
samples for MS. For the cookie and dark chocolate, digests of the blank matrices (0 ppm
PF) were used as background material to create the dilution series for MS.
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The results indicated that the background matrix dilutions did accomplish a
moderate decrease in the variability of the SIL peptide. This was observed especially for
partially hydrophobic peptides, like FNL (Figure 3.10).

Figure 3.10: The %CV of SIL Peptides for Samples Diluted with Buffer or With Background
Protein.
The %CV for the FNL peptide for a) PF, b) cookie, and c) dark chocolate samples diluted
with buffer (5% ACN/0.1% FA/ 6.667 fmol SIL peptide) or with blank matrix dilutions
(NFDM, blank cookie, or blank dark chocolate resuspended in 5% ACN/0.1% FA/ 6.667 fmol
SIL peptide). N=3.

The background protein dilution strategy appeared to reduce the %CV of the SIL
peptides in general, as well as address the trend of increasing %CV with decreasing light
peptide concentration. The strategy also increased the sensitivity of the method for some
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light peptides, especially those that are partially hydrophobic, such as FNL,TANE, and
RPF (Table 3.7).
Table 3.7: Lowest Levels of Detection for All Sample Types Using Buffer Dilution (BD) or
Background Protein Dilutions (BPD) Prior to MS Analysis
Matrix Type
Dilution Type

PF

C

DC

BD

BPD

BD

BPD

BD

BPD

FNLAGNHEQEFLR

100

100

10

10

100

10

TANELNLLILR

100

10

100

10

100

10

RPFYSNAPQEIFIQQGR

100

10

1

1

10

1

This increase in detection and thus, sensitivity, for some peptides suggested that
the background protein dilution benefited the stability of the analyte peptides, not just the
SIL peptides. This may be due to the partially hydrophobic nature of the light peptides
being lost due to nonspecific binding to plasticware during sample preparation following
digestion or in MS vials prior to injection for LC-MS/MS. The background protein
dilution strategy was adopted for the remainder of the method optimization analyses.
However, to simplify the sample preparation and to reduce the number of samples
necessary to create enough digest material for the dilution series, the background protein
dilutions were modified to utilize NFDM digests for all sample types (PF, cookie, and
dark chocolate). Furthermore, it is important to note that the background protein dilution
was only necessary when creating dilutions of incurred materials, which only occurred
when diluting high concentrations of incurred materials (10,000 ppm PF cookie or dark
chocolate) to create lower concentrations for analysis or for the PF calibrant. When low
levels of incurred matrices were evaluated for the quantitative method evaluation (2 and
10 ppm PF cookie and 4 and 40 ppm PF dark chocolate) no background protein dilution
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was necessary as these samples were not diluted prior to analysis for MS, simply
resuspended.
vii.

Method Optimization: Chromatographic Refinements
Optimization of the chromatography used for this method was pursued because

further separation of target peptides was hypothesized to increase points across the peak
and peak width, thus increasing the sensitivity of the method. An increase in sensitivity
was desired for method optimization based on the previous lowest concentrations of PF
that were observed to be in the range of 1-100 ppm PF. These levels are not sufficient for
the method and thus chromatographic refinements were analyzed. In addition to the
previously used chromatography gradients for this work (Version 1 = V1), two additional
chromatography gradients were evaluated (Version 2 = V2 and Version 3 = V3) (Figure
3.2).
After analyzing each of the three chromatography gradients against PF samples
diluted to 100 and 1,000 ppm PF, it was clear that the peak area responses of all target
peptides were not generally different between chromatography gradients. However, the
points across the peak were notably different between V1, V2, and V3 of the
chromatography. As hypothesized, decreasing the slope of the ACN gradient increased
peptide separation and thus, increased points across the peak. This was directly observed
with respect to V3, the shallowest of ACN gradients, as it recorded the greatest number
of points across the peak for a majority of the light peptides. While this chromatography
method (V3) extended the method duration to 35 minutes, it was decided that the possible
increase in sensitivity that the shallow gradient and increased points across the peak
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would cause at lower levels of peanut contamination outweighed the increase in method
time. As a result, the V3 chromatography was selected and used in all subsequent
analyses using this LC-MS/MS method.
viii.

Method Optimization: Improving Sample Preparation

Further method optimization through different sample preparation additions was
explored in order to improve the sensitivity of the method to reach the desired method
performance. Hexane defatting (HD) was analyzed because it was hypothesized that the
fat in the samples, particularly the PF and dark chocolate, was impacting some
component of the sample preparation. HD has been used in other MS methods for the
detection of peanut29, 30. Acetone precipitation (AP) has been demonstrated to improve
recovery of peptides by MS and was therefore tested in this analysis31, 32. Filter-aided
sample preparation (FASP) is another sample preparation addition which has been
commonly employed in the field of food allergen proteomics30, 33. The effect of FASP,
AP, HD, and REG sample preparation protocols on light-to-heavy ratios and variability
of target peptides was analyzed. Three representative peptides and the dilution curves for
each sample type are shown in Figure 3.11.

178

Figure 3.11: Dilution Curves for Three Target Peptides with FASP, AP, HD, or REG Sample
Preparation.
Dilution curves for three representative target peptides prepared by four sample preparation
strategies including FASP, AP, HD, and REG sample preparation. Peptides shown include a)
SPD (Ara h 3), b) NNP (Ara h 1), and c) NLP (Ara h 2). Product ions used for the light to
heavy ratio determinations were SPD (y9 - 977.5051+, y7 - 700.3988+, b3 - 300.1190+), NNP
(y7 - 913.4567+, y5 - 669.3355+, y4 - 506.2722+), and NLP (y7 - 858.4250+, y5 - 633.3137+,
y7 - 429.7162++). N=4. Mean ± SD.

The evaluation of different sample preparation procedures indicated an apparent
effect of the procedure used on the light-to-heavy ratio recorded for peptides, as well as
the overall sensitivity for some peptides. The three peptides shown in Figure 3.10
originated from each of the three peanut proteins targeted by the method, Ara h 1, Ara h
2, and Ara h 3. The protein to which a peptide is from appeared to have affected which
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sample preparation procedure provided the most optimal response by MS. For SPD (Ara
h 3) and NNP (Ara h 1), AP recorded the greatest peak area at most PF concentrations
evaluated and for all sample types (PF, cookie, and dark chocolate). The other six
peptides from Ara h 3 mirrored the result of AP outperforming the other sample
preparation procedures. On the other hand, NLP (Ara h 2) did not show the same trend.
For NLP, the REG sample preparation resulted in the greatest light-to-heavy ratio for the
PF and cookie samples, while AP may have been the most effective method for the dark
chocolate samples. The results suggested that AP of the sample extracts is an effective
method for increasing the recovery for a large number of target peptides. This was likely
due to the efficient concentration of protein, by precipitation, immediately after
extraction, though it did have differing affects based on the type of protein. For all
peptides, FASP protocols appeared to result in the smallest light-to-heavy ratios in all
sample types, though only slightly compared to HD and REG protocols. With respect to
variability, AP also appeared to be the superior sample preparation method as the SD for
AP samples was generally less than that for the other sample preparation procedures. AP
also resulted in the most sensitive levels of detection in ppm PF, as shown in Table 3.8.
Additionally, HD and REG had better sensitivity of the target peptides compared to
FASP. Based on the results of the improved sensitivity and increase in light-to-heavy
ratio, plus the decrease in variability, AP was utilized in subsequent analyses using the
targeted MS method.
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Table 3.8: Lowest Detected Concentration for FASP, AP, HD, and REG Preparation
Protocols in PF, Cookie, and Dark Chocolate Samples in ppm PF
Peptide and Matrix

NLPQQ[C]GLR

SSNPDIYNPQAGSLR

TANDLNLLILR

NNPFYFPSR

TANELNLLILR

SPDIYNPQAGSLK

QQPEENA[C]QFQR

FNLAGNHEQEFLR

RPFYSNAPQEIFIQQGR

FASP

AP

HD

REG

PF

50

1

10

10

C

50

50

10

50

DC

50

10

10

10

PF

10

1

10

10

C

50

10

10

10

DC

10

10

10

10

PF

10

1

10

10

C

50

10

10

10

DC

10

10

10

10

PF

50

1

10

10

C

50

10

50

50

DC

10

10

10

10

PF

10

1

10

10

C

50

10

10

10

DC

10

10

10

10

PF

10

1

10

10

C

50

10

50

50

DC

10

10

10

10

PF

50

50

50

50

C

100

50

50

50

DC

100

100

50

100

PF

10

1

10

10

C

10

1

10

10

DC

10

10

10

10

PF

10

1

1

1

C

10

1

1

1

DC

10

1

1

1
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ix.

Method Optimization: Addressing Method Sensitivity

The scaled-up sample preparation procedure was completed with the intention of
improving method sensitivity to achieve the desired method performance. The
approximate factor that the concentration of peptide was increased between the previous
protocol and the scaled-up protocol was 9.4. Results indicated a large increase in method
sensitivity, however, the fold changes observed for some peptides were unexpectedly
greater than 9.4. Fold changes were calculated by taking the light-to-heavy ratio as
determined for the scaled-up protocol and dividing it by the light-to-heavy ratio
determined in the previous experiment. The fold changes calculated based on the 50 ppm
PF in matrix sample concentration, for each target peptide and sample type are shown in
Table 3.9.
Table 3.9: Fold Changes Between Scaled Up and Previous Sample Preparation Protocol
Based on 50 ppm PF in Matrix Sample
Peptide

PF

C

DC

NLPQQ[C]GLR

6.63

3.86

11.54

SSNPDIYNPQAGSLR

4.85

6.32

5.13

TANDLNLLILR

8.19

9.15

8.38

NNPFYFPSR

5.95

7.11

7.58

TANELNLLILR

9.68

9.77

9.59

SPDIYNPQAGSLK

4.96

5.05

5.53

QQPEENA[C]QFQR

6.23

4.79

nd*

FNLAGNHEQEFLR

17.30

17.97

19.50

RPFYSNAPQEIFIQQGR

15.23

18.98

25.17

*not detected

The fold changes for a majority (seven) of the target peptides were within the
expected range for the scaled up protocol. However, two peptides (FNL and RPF)
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recorded unexpectedly high fold changes, greater than the theoretical 9.4x increase in
peptide concentration of the sample. This suggested some impact of their physiochemical
properties on their detection by MS. These peptides had been demonstrated to be variable
in previous experiments, perhaps due to their hydrophobic characteristics. However, the
unexpected fold change indicated a greater recovery than expected which points to
resuspension or behavior of these peptides in the instrument. One possible explanation is
that a greater solvation of these two peptides at resuspension compared to the other seven
peptides occurred, perhaps due to buffer capacity. Another possibility was the effect of
the chemical nature of these peptides at high concentrations either in LC or MS/MS. One
peptide, QQP, was not detected in the dark chocolate sample at 50 ppm PF in matrix
which suggested the peptide is not as sensitive as the other eight peptides and may not
achieve the desired method performance in dark chocolate. The lowest levels of PF in
matrix which were detected in this experiment are shown in Table 3.10.
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Table 3.10: Lowest Levels of Detection for Each Peptide and Sample Type Using the Scaled Up
Protocol to Address Method Sensitivity in ppm PF
Peptide

PF

C

DC

NLPQQ[C]GLR

10

10

1

SSNPDIYNPQAGSLR

10

0.5

1

TANDLNLLILR

0.5

10

0.5

NNPFYFPSR

0.5

10

10

TANELNLLILR

0.5

10

0.5

SPDIYNPQAGSLK

1

10

0.5

QQPEENA[C]QFQR

10

10

50

FNLAGNHEQEFLR

1

1

1

RPFYSNAPQEIFIQQGR

1

1

1

x.

Method Optimization: Calibrant Extraction
In the previous experiment with the scaled up sample preparation protocol, large

%CVs were observed between PF extracts. The extraction %CV for PF samples ranged
from 42.98-68.94%. As the PF samples will be used to create a calibration curve for the
quantification strategy of this method, further optimization of the PF calibrant extraction
was pursued. Greater extraction concentrations for PF in buffer were analyzed based on
the hypothesis that some of the extraction variability observed was due to issues in
accurate weighing of the PF material or the small sample size of the PF itself. After the
various extraction concentrations, the resuspension buffer volume was proportionally
changed to result in the same theoretical peptide concentrations prior to injection for MS.
Though four different extraction concentrations were evaluated (0.060 g PF/30
mL buffer, 0.120 g PF/30 mL buffer, 0.150 g PF/30 mL buffer, and 0.300 g PF/30 mL
buffer), there was no observable trend for the %CV of the light-to-heavy ratio for each of
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these different sample types (data not shown). No extraction concentration appeared
better than another with respect to the %CV between extract replicates. Based on the
principle that a higher weighing volume should, in theory, reduce weighing inaccuracies
and gather a large sample size of the PF material, the 0.150 g PF/30 mL buffer was
selected for the extraction concentration for the PF calibrant samples. It is important to
consider that only two extract replicates were taken to evaluate each of these extraction
concentrations. More extraction replicates may have provided a better understanding of
the %CV between extractions at various concentrations.
xi.

Quantitative Method Evaluation
The quantitative method, which had been developed and optimized throughout the

previously described work, was evaluated for its efficacy in analyzing incurred cookie
and incurred dark chocolate matrices. The purpose of evaluating the quantitative method
was to determine its ability to detect and accurately quantify peanut protein at low levels
in processed food matrices. Prior to this analysis, the method had been challenged only
on post-digestion dilutions of the incurred matrices at high peanut concentrations (10,000
ppm PF). This evaluation investigated the method against matrices that had been incurred
with PF at 2.38 ppm in cookie, 11.91 ppm in cookie, 4 ppm in dark chocolate, and 40
ppm in dark chocolate. With respect to peanut protein, the cookie samples were 1.24 and
6.21 ppm peanut because the PF used to incur this matrix was 52.1% protein (as
determined experimentally by the Dumas method). The manufacture of the dark
chocolate was designed in ppm peanut protein and therefore these samples were 2 and 20
ppm peanut protein in matrix.
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Overall, the method achieved the needed method performance with respect to
sensitivity and detection limits to ensure the safety of food products for peanut-allergic
consumers. This is because the method was able to robustly detect peanut-incurred
matrices, even at very low levels of peanut contamination (1.24 ppm peanut protein in
cookie and 2 ppm peanut protein in dark chocolate). Eight of the nine target peptides
detected these low concentrations of peanut protein in 100% of samples analyzed (N=18
for each matrix). The QQP peptide detected the 1.24 ppm peanut protein cookie in 100%
of analyzed samples (N=18), but only detected the 2 ppm peanut protein dark chocolate
in 77.78% of replicates (N=14). Representative calibration curves are shown from the
second experiment and both days of analyses for three peptides (Figure 3.12).
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Figure 3.12: Calibration Curves for Incurred Cookie and Incurred Dark Chocolate Samples
for Quantitative Method Evaluation.
Representative calibration curves for analyzed incurred cookie and incurred dark chocolate
shown for three peptides. Peptides shown include a) FNL (Ara h 3), b) NLP (Ara h 2), and c)
RPF (Ara h 3). Quantification of these peptides continued with the outlined quantification
strategy for this method to determine peanut concentration in ppm peanut protein and the
reported value shown is the peptide average within one experimental day. N=9, Mean ± SD.

As shown in Figure 3.12, the light-to-heavy ratio of the analyzed incurred
matrices samples were relatively linear in their response compared to the same-day PF
calibration curve. It can be visually observed that the incurred matrices, both cookie and
dark chocolate, have greater variability in the lower incurred levels than with the samples
of greater peanut concentrations. Further, the lower levels appeared to have light-toheavy ratios greater than the PF calibrant in the cookie matrix and to some degree for the
NLP peptide dark chocolate matrix. However, overall, the robustness of this method was
demonstrated through the effective detection of peanut protein at low levels in incurred
matrices and in the relatively accurate ability of the PF calibrant to quantify the presence
of peanut.
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The quantification of peanut protein in the analyzed matrices was completed
based on the light-to-heavy signal ratio and the interpolation of the ratio to the PF
calibration curve, as generated by Skyline. A summary of the three quantitative reported
values for the method is shown in Figure 3.3. The results for the average peptide reported
value for measured peanut protein in the analyzed incurred cookie matrix is shown in
Table 3.11.
Table 3.11: Quantification, Variation, and Recovery of Peanut in Two Incurred Cookie Levels in
ppm peanut protein
1.24 ppm peanut protein
6.21 ppm peanut protein
Cookie
Cookie
Average ppm
Average ppm
peanut protein
%CV
% Recovery peanut protein
%CV
% Recovery
N=18
N=18
FNL
5.67*
121.03%
456.81%
7.01
37.89%
112.95%
NLP
3.54
86.04%
285.40%
2.63
20.59%
42.43%
NNP
3.36
108.55%
270.62%
3.94
37.34%
63.51%
QQP
4.50
105.76%
362.39%
5.80
50.66%
93.38%
RPF
4.07
108.77%
327.79%
5.48
35.00%
88.20%
SPD
3.85
122.53%
310.34%
3.09
34.57%
49.77%
SSN
5.19
116.81%
418.47%
7.32*
41.11%
117.88%
TAND
3.90
116.64%
314.62%
3.59
37.11%
57.81%
TANE
3.71
119.93%
298.96%
3.11
37.64%
50.15%
* maximum peptide average value for each analyzed matrix concentration

The method detected peanut with all nine target peptides and at both
concentrations of peanut contamination, even at the level which surpasses the needed
method performance outlined for this method (2 ppm peanut protein in cookie). The third
reported value, the maximum extract average for any peptide, was 20.60 ppm peanut
protein in the 1.24 ppm peanut protein cookie (FNL) and 12.80 for the 6.21 ppm peanut
protein cookie (SSN). The maximum reporting peptides for all of these samples were
either SSN or FNL, both Ara h 3 peptides. This exceptional recovery of Ara h 3 peptides
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was congruent with both untargeted MS results and with targeted MS results during
target filtration. The maximum reported peanut protein concentration is considered based
on a food safety perspective. By assuming the maximum reported concentration to be the
contamination level, any resulting risk assessment and risk management decisions will be
as conservative as possible and will increase food safety for allergic consumers.
These results indicated great variability of the method, as observed by the high
%CVs shown. Particularly for the 1.24 ppm peanut protein sample, the method seems to
be over-recovering and quantifying a concentration much higher than the known
concentration. With an in depth view of the data, there are particular extraction replicates
which appear to be contributing greatly to the high average ppm peanut protein values
observed. This may be due to hot spots of peanut contamination within the cookie matrix
itself. Furthermore, this variability and over-recovery or quantification effect was
amplified at the lower peanut protein concentration, even reporting maximum
contamination values greater than that of the 6.21 ppm peanut protein cookie.
The results for the quantification of peanut protein in the analyzed incurred dark
chocolate matrix is shown in Table 3.12.
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Table 3.12: Quantification, Variation, and Recovery of Peanut in Two Incurred Dark Chocolate
Levels in ppm peanut protein
2 ppm peanut protein
20 ppm peanut protein
Dark Chocolate
Dark Chocolate
Average ppm
Average ppm
peanut protein
%CV
% Recovery peanut protein
%CV
% Recovery
N=18**
N=18
FNL
2.59
51.80%
124.08%
10.83
17.13%
51.95%
NLP
6.00*
37.03%
288.02%
21.49*
25.73%
103.07%
NNP
3.53
57.13%
169.12%
16.03
22.55%
76.91%
QQP
2.73
46.42%
131.17%
9.26
19.48%
44.40%
RPF
4.60
54.52%
220.51%
19.60
19.53%
94.02%
SPD
2.99
47.42%
143.44%
13.52
20.68%
64.83%
SSN
4.37
52.62%
209.51%
17.55
22.14%
84.19%
TAND
3.24
42.59%
155.26%
14.58
21.08%
69.95%
TANE
3.27
44.85%
156.73%
15.14
19.14%
72.62%
* maximum peptide average value for each analyzed matrix concentration
**QQP, N=14

The method was able to effectively detect low ppm peanut protein values in a
complex incurred dark chocolate matrix. All but one target peptide was detected 18 of 18
times in the 2 ppm peanut protein dark chocolate. The QQP peptide was observed in only
14 of 18 replicates which analyzed the low level of peanut-incurred dark chocolate. The
third reported value, the maximum extract average for any peptide, was 9.98 ppm peanut
protein in the 2 ppm peanut protein dark chocolate (RPF) and 29.79 for the 20 ppm
peanut protein dark chocolate (NLP). Commonly, the highest reporting peptide was NLP
(Ara h 2), which was expected to be such in the dark chocolate as this peptide was
observed to be highly sensitive throughout method development stages.
As previously mentioned, the variability observed in the quantification of peanut
protein in the analyzed incurred matrices was higher than desired for a quantitative food
allergen detection method. Variation analysis was completed to quantify several factors
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with possible contribution to the observed variation, including method variation,
extraction variation, and injection variation. The variation analysis for one representative
peptide is recorded in Table 3.13 and the approach to estimating these values is described
in the table caption.
Table 3.13: Quantification of the Method, Extraction, and Injection Variation in %CV for
TANELNLLILR
Cookie
Dark Chocolate
6.21 ppm
1.24 ppm
20 ppm
TANELNLLILR
2 ppm
peanut
peanut
peanut
peanut protein
protein
protein
protein
Method Variation: Overall

37.64%

119.93%

19.14%

44.85%

Method Variation: Within Day
(Day 1)

40.57%

16.06%

11.46%

31.23%

Method Variation: Within Day
(Day 2)

33.21%

79.40%

9.77%

42.80%

Method Variation: Day to Day

8.95%

71.46%

15.99%

27.15%

Extraction Variation: Within Day
(Day 1)

40.48%

14.88%

11.34%

31.20%

Extraction Variation: Within Day
(Day 2)

33.06%

79.38%

9.70%

42.75%

Extraction Variation: Day to Day

37.52%

119.91%

19.09%

44.82%

0.20-4.81%

0.77-9.32%

0.55-2.26%

0.40-4.21%

Injection Variation

Method variation = %CV of quantified values from all data points collected for the analyzed
concentration and matrix overall, (N=18) or within day (N=9). Day-to-day method variation
equated to the %CV between the average values for each day (N=2).
Extraction variation = %CV between three extract averages (N=3) per sample, calculated for
each day. Day-to-day method variation the %CV between the extraction values of any day
(N=6).
Injection variation = %CV of quantified values from injection replicates (N=3). A range is
shown to indicate the minimum and maximum injection variation calculated.

The variation quantified for the TANE peptide is comparable to that of the
majority of the method’s target peptides. The overall variation is generally acceptable for
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the incurred matrices, except for the 1.24 ppm peanut protein, which generally recorded a
very high method variation for most peptides. Further, the extraction variation seemed to
play a particular role in the variation observed in the quantitative output of the method.
Extraction variation within day and between day is somewhat high. Extraction may be a
highly variable procedure in sample preparation, as indicated for TANE and for other
peptides. This may suggest a need for improved extraction procedures to reduce the
variability observed between extracts. Injection variation did not impact the overall
variation to a large extent, as the observed injection variations were minute compared to
other variation measures. Overall, further optimization of the method, including
extraction procedures, may be necessary to decrease the variability observed with the
final reported peanut protein concentration.
Overall, evaluation of the quantitative method on the incurred cookie and incurred
dark chocolate provided support for the efficacy of the developed MS method. The
method appeared to be highly sensitive and robust in its detection of low-level peanut
contamination. The method was able to robustly detect and to reasonably quantify levels
of peanut contamination that were lower than the needed method performance. In order to
protect the most sensitive 1% of peanut-allergic individuals, calculated method sensitivity
desired was 2 ppm peanut protein in cookie and 4 ppm peanut protein in dark chocolate.
This quantitative MS method achieved detections and quantifications of peanut protein in
incurred cookie at 1.24 ppm peanut protein, a level more sensitive than the desired 2 ppm
peanut protein level. For the dark chocolate, the MS method was able to detect and
quantify an incurred matrix of 2 ppm peanut protein, which is more sensitive than the
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desired 4 ppm peanut protein concentration. Though the method is highly sensitive to
detect peanut protein in cookie and dark chocolate matrices, the variability of the method
indicated a need for further optimization to increase the repeatability and quantitative
accuracy.
V. SUMMARY
A quantitative LC-MS/MS method for the detection and quantification of peanut
protein in cookie and dark chocolate matrices was developed based on nine target
peptides identified as sensitive and robust in these matrices in previous work. Method
optimization was completed for several components of the method including extraction,
calibrant preparation, chromatography, and MS instrument parameters. Method
sensitivity was improved through method optimization procedures, as well as inclusion of
an acetone precipitation of extract protein and an increase in protein digested and
subsequent peptide loaded on column. The quantification strategy used for this method
relied on SIL peptides and signal light-to-heavy ratios, plus an external calibration curve
using PF material. The maximum quantification value in ppm peanut protein was
considered as the final reported value for the method to maximize food safety.
The developed and optimized MS method achieved the desired method
performance with respect to sensitivity. The method robustly detected low levels of
peanut contamination in incurred food matrices, including 1.24 ppm peanut protein in
cookie and 2 ppm peanut protein in dark chocolate. Based on risk assessment principles,
the method sensitivity is sufficient to detect levels of peanut protein which would be
relevant for the most sensitive peanut-allergic individuals.

193
For the incurred cookie matrix, the 1.24 ppm peanut protein level was quantified
by target peptides with averaged quantified values ranging from 3.36 - 5.67 ppm peanut
protein (270.62 - 456.81% recovery) and for the 6.21 ppm peanut protein level the
reported quantification ranged from 2.63 - 7.32 ppm peanut protein (42.43 - 117.81%
recovery). For the dark chocolate matrix, the 2 ppm peanut protein level, as quantified by
target peptides, averages ranged from 2.59 - 6.00 ppm peanut protein (124.08 - 288.02%
recovery). The 20 ppm peanut protein level reported quantification averages that ranged
from 9.26 - 21.49 ppm peanut protein (44.40 - 103.07% recovery). Though the method
indicated high variability, the developed MS method is highly sensitive and is generally
robust in its detection of low levels of peanut protein in incurred cookie and dark
chocolate matrices.
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CHAPTER IV: SUMMARY AND FUTURE WORK
I. SUMMARY
Because of the prevalence of peanut allergy and the severity of elicited allergic
reactions, the United States (US) requires the labeling of peanut and ingredients derived
from peanut on food products. To comply with labeling regulations and to monitor the
unintended presence of peanut in food products, the food industry utilizes a number of
allergen detection methods, such as immunoassays, to detect peanut protein. However,
antibody-based detection methods may struggle to detect or accurately quantify peanut
protein in complex or processed food matrices. Mass spectrometry (MS) provides the
opportunity for an alternative, orthogonal peanut detection method that does not maintain
the same deficits when analyzing food matrices. Thus, a quantitative mass spectrometry
method for the detection and quantification of peanut protein in processed food matrices,
namely cookie and dark chocolate, was developed.
Peanut-incurred cookie and peanut-incurred dark chocolate matrices were
generated at various concentrations of peanut protein for target selection, method
development, and method evaluation strategies. Untargeted MS analysis of incurred
matrices, blank matrices, and peanut flour (PF) was completed for target selection
purposes, followed by the identification and quantification of peanut peptides. Based on
criteria established to select peptides which were both abundant and minimally affected
by the matrix, a subset of the identified peptides was selected as candidates for inclusion
in the final method. Selected candidate target peptides for the cookie and dark chocolate
matrices numbered 32 and 67, respectively.
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Peptides that were selected as candidate target peptides were subsequently filtered
using iterative rounds of targeted MS analysis, specifically parallel reaction monitoring
(PRM). PRM was used to analyze post-digestion dilutions of incurred matrices to
empirically determine the best performing peptides for each matrix. A number of target
peptides were determined to be robust and sensitive in the cookie (six peptides) and in the
dark chocolate (seven peptides). The final target peptides were combined, and nine target
peptides were identified for the detection and quantification of peanut protein in these
matrices. Of the nine target peptides, seven were from Ara h 3, one was from Ara h 1,
and one originated from Ara h 2. Four of the nine target peptides were determined as
final target peptides in both matrices. The discovery-based target selection approach
appeared to be successful in its identification of peptides that are sensitive in their
detection and robustly detected in the incurred matrices, on which the untargeted MS was
completed.
Using the nine target peptides determined to be sensitive and robust in the
analyzed food matrices, a quantitative LC-MS/MS method was developed (PRM).
Peptide detection criteria for were formalized and included the following: detection of
three of the three pre-established product ions, library dotp value ≥ 0.80, a 5.0 ppm mass
error tolerance for the average mass error of measured product ions, and peak found ratio
(PFR) equal to one. Detected peptides were quantified using their ratio to a constant
amount of stable isotope labeled (SIL) peptides, with an external calibration to PF. A
maximum value for the quantification of peanut protein by the nine peptides in the
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analyzed sample was reported based on food safety principles and conservative estimates
for food allergen risk assessment.
The sensitivity and variability of the quantitative method was optimized through a
number of strategies. Method parameters, such as the automatic gain control (AGC) and
injection time (IT) were tested to determine optimal settings of 1e6 and 110 ms,
respectively. The addition of non-analyte background protein to dilutions of samples
prior to injection decreased the variability observed for SIL and analyte peptides for
calibrant samples. Chromatography was optimized by decreasing the slope of the
acetonitrile (ACN) gradient. This provided the expected increase in analyte separation
and improved points across the peak for peptides in the method. An acetone precipitation
(AP) of sample extracts was shown to increase the response and decrease the variability
of peptide peak areas. The final peptide concentration of samples was increased through
scaled up sample preparation, primarily at the digestion stage. This resulted in improved
method sensitivity. The variability of the PF calibrant was addressed through
optimization of the PF extraction concentration.
The developed and optimized method was evaluated with the peanut-incurred
cookie (1.24 and 6.21 ppm peanut protein) and peanut-incurred dark chocolate matrices
(2 and 20 ppm peanut protein) to assess the sensitivity, quantitative accuracy, and
precision of the method. The method detected peanut protein in the analyzed matrices,
even the lowest levels of peanut contamination (1.24 ppm peanut protein in cookie and 2
ppm peanut protein in dark chocolate). This sensitivity surpassed the needed method
performance based on the reference dose for peanut and typical consumption of the food
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product, which was calculated at 2 ppm peanut protein in the cookie and 4 ppm peanut
protein in the dark chocolate.
The method achieved quantification of peanut protein in the incurred food
matrices using the nine target peptides. Reported values for the quantification included
peptide averages, the maximum of peptide averages, and the maximum extract average
across any peptide.
Of all nine peptide averages (N=18), the average with the maximum quantified
value was reported for each analyzed matrix sample and concentration. The peptide
maximums were determined to be as follows: 5.67 ppm peanut protein (1.24 ppm peanut
protein cookie), 7.32 ppm peanut protein (6.21 ppm peanut protein cookie), 6.00 ppm
peanut protein (2 ppm peanut protein dark chocolate), and 21.49 ppm peanut protein (20
ppm peanut protein dark chocolate).
Next, the maximum for an extract average was included to provide a conservative
estimate of the peanut contamination to inform risk assessment and increase food safety
for allergic consumers. The maximum for any extract average was reported as follows:
20.60 ppm peanut protein (.24 ppm peanut protein cookie), 12.80 ppm peanut protein
(6.21 ppm peanut protein cookie), 9.98 ppm peanut protein (2 ppm peanut protein dark
chocolate), and 29.79 ppm peanut protein (20 ppm peanut protein dark chocolate).
It is recommended that the maximum of any extract average be used to inform
risk assessment as it provides the most conservative quantification of the peanut
contamination in the matrices. When carried through risk assessment principles, this
value will provide increased food safety for peanut-allergic consumers.
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The method demonstrated considerable variability in the quantified values for the
concentration of peanut in the incurred matrices. This is an issue which will need to be
addressed in future work. Additionally, the method reported values which are considered
over recovery of peanut protein based on the known concentration of peanut protein in
the analyzed matrices. Thus, future work regarding the recovery of peanut protein in the
incurred food matrices may be needed to improve the quantitative accuracy of the
method.
II. FUTURE WORK
The primary aspects of the developed quantitative LC-MS/MS method for the
detection of peanut protein in cookie and dark chocolate that need to be addressed in
future work include further determination of method recovery, consideration for
quantitative variability, evaluation of method extensibility, and transfer of the method to
additional MS instrumentation.
One area in which future work regarding this method may be necessary is the
additional determinations of the recovery of the method compared to the known
concentrations of analyzed samples. First, additional replication of the method in its
analysis of the incurred matrices is important to determine more accurately the average or
expected method recovery. This is because the over-recoveries observed may be an
artifact of the small number of replications completed for this work. A greater number of
recovery data points for each matrix and level may confirm whether recovery of this
method is consistently higher than expected for such a method. Second, spike and
recovery experiments will help to better understand the recovery of the method by

202
determining the role that the matrix components and the processing of the matrix play in
the recovery of peanut protein by the method. To complete this analysis, blank cookie
and blank dark chocolate matrices spiked with PF should be analyzed using the method in
tandem with the true, incurred matrices (at the same PF concentration as the spiked
materials) as generated for this work. Third, comparison against commercially available
ELISA kits will provide perspective on the recovery of peanut protein observed for this
method. ELISA kits that target different peanut proteins should be included so that the
recovery comparison is not biased based on matrix or processing effects. Suggested
ELISA kits for this comparison are the Veratox® for peanut allergen (Neogen®) kit,
Peanut Protein ELISA Kit II (Morinaga Inc.), and the BioFront MonoTrace Peanut
ELISA kit. Comparison will indicate whether there is support for the use of MS over
ELISA when evaluating these matrix types for the presence of peanut.
The next step in future work regarding the method would be to address the high
variability of the method observed in the quantitative evaluation of incurred matrices. As
with method recovery, an increased number of replicates analyzed by this method would
allow for a better understanding of the variation measure observed. More replication of
samples extracted and digested on the same and different days would provide a greater
understanding of the sources of variation in the method. It may also be necessary to
monitor the variation across an extended period of time. The reason additional
replications may be advisable is because the high variability observed in this work may
be due to hotspots of peanut contamination within the generated incurred matrices. A
greater number of samples analyzed from the incurred matrices would allow for the
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determination of whether the variability is a result of heterogenous contamination of
peanut in the matrices. One way to improve the variability may be to target the digestion
variability. To complete this, digestion standards can be added to samples prior to
digestion and by including target peptides from the standard proteins in the method,
normalization of the other peptide responses can be completed to control for digestion
variability. Additionally, extraction variability should be addressed as it appears to
contribute greatly to method variation.
An additional component of future work would be to analyze the extensibility of
the method in its evaluation of other food matrices. One acknowledged limitation of this
method is that it was developed specifically for two matrices, cookie and dark chocolate.
Therefore, until evaluated, it has uncertain efficacy for analysis of peanut protein in
matrices other than cookie and dark chocolate. Thus, to extend the application of the
method, it should be tested on other food matrices. Further, other matrices that have the
potential to be contaminated by peanut due to allergen cross-contact should be evaluated.
These may include pie crusts, muffin, milk chocolate, ice cream, or other complex and
processed food matrices. The rationale behind evaluating the extensibility of the
developed method is primarily based on the four target peptides (NLPQQCGLR,
SSNPDIYNPQAGSLR, RPFYSNAPQEIFIQQGR, TANDLNLLILR) that were
determined to be robust and sensitive in both matrices during PRM filtration. There were
four target peptides that performed well in two very different matrices, one of which
contains a gluten network that is extensively thermally processed, while the other is high
in fats and polyphenols and endures multiple thermally processed steps. If four targets
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succeed in these dissimilar matrices, perhaps they may perform sensitively and robustly
in other matrices. Thus, this potential should be explored. This evaluation will also give
insight to the contribution of the effect of the matrix on the recovery of target peptides
included in the method.
Additionally, the method could be transferred to other MS instrumentation. As the
method was developed using one specific MS instrument (Thermo Scientific™ Q
Exactive™ Plus hybrid quadrupole-Orbitrap™ mass spectrometer), transferring the
method to another instrument will allow for more expanded application of the method.
After transferring the method to an additional instrument, the quantification, recovery,
and variation of the method should be determined and compared to the same measures for
this method. One reason this work would be important is to evaluate whether instruments
with lower resolution can effectively utilize this method to detect and quantify peanut
protein in incurred food matrices, as a decrease in resolution may increase the observed
matrix interference.
Overall, future work concerning this method should be centered around further
determination of both method recovery and variability, followed by strategies to improve
these measures. Additionally, the extensibility of the method to evaluate other food
matrices should be explored, as well as transferring of the method to other MS
instrumentation to increase future application and use of the method in the food industry.

